[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f392dvzrxVINH1S7RqMgZM-RcGpRhvKUonI1GD5rV5Oc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Asan Medical Center",[4],573,false,80,50,1810058,56,269,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Hepatocellular Carcinoma",15,{"name":18,"count":19},"Gastrointestinal Stromal Tumors",13,{"name":21,"count":22},"Gastric Cancer",11,{"name":24,"count":25},"Prostate Cancer",10,{"name":27,"count":28},"Breast Cancer",9,{"name":30,"count":28},"Healthy",{"name":32,"count":28},"Cervical Cancer",{"name":34,"count":35},"Leukemia",8,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04308174","Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer","2023-06-30","Durvalumab + Gem\u002FCis",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04782375","Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B","2024-08-19","Stop group",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04986930","mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma","2025-01-23","mFOLFIRINOX",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06438913","Tezepelumab Treatment in Korean Severe Asthma Patients","2025-05-12","Tezepelumab",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT04010955","Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)","2025-06-27","Edoxaban Monotherapy",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT03695952","A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors","2025-07-30","Nivolumab or pembrolizumab",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT05222971","Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","2025-12-30","Durvalumab",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05992220","Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion","2026-03","Atezolizumab plus bevacizumab",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06051253","TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease","2026-06-30","TDM-based infliximab intravenous therapy",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT01917552","Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS","2026-08-01","capecitabine",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,174,213,262,316,338,366,384,407,433,451,472,499,517,564,608,633,663,681,699,725,743,769,787,805,832,889,1001,1051,1107,1142,1170,1192,1225,1248,1266,1289,1315,1338,1356,1379,1401,1425,1449,1473,1496,1514,1541,1580,1601,1625,1653,1680,1698,1718,1741,1764,1838,1900,1958,1994,2031,2053,2085,2107,2129,2157,2179,2216,2238,2264,2288,2315,2333,2358,2384,2402,2426,2444,2469,2496,2514,2532,2550,2576,2594,2619,2637,2664,2682,2709,2732,2750,2772,2796,2814,2832,2859,2883,2909,2927,2952,2979,2997,3019,3044,3062,3080,3104,3133,3151,3176,3200,3224,3242,3265,3283,3308,3332,3378,3416,3442,3474,3508,3542,3573,3595,3619,3644,3668,3686,3710,3734,3752,3774,3800,3818,3836,3854,3877,3895,3913,3938,3963,3987,4005,4030,4048,4072,4095,4113,4139,4162,4180,4205,4223,4247,4271,4293,4321,4360,4406,4436,4475,4516,4552,4587,4617,4646,4680,4707,4733,4755,4785,4812,4835,4858,4881,4899,4925,4943,4965,4988,5006,5029,5053,5071,5094,5117,5141,5163,5188,5206,5224,5246,5271,5289,5312,5337,5360,5378,5406,5424,5442,5467,5485,5503,5521,5542,5564,5591,5615,5640,5663,5686,5707,5732,5758,5781,5799,5817,5835,5853,5871,5889,5914,5932,5954,5977,5999,6021,6044,6066,6092,6110,6135,6153,6171,6195,6217,6242,6260,6278,6296,6319,6340,6358,6380,6398,6424,6442,6466,6484,6509,6527,6545,6571,6589,6612,6635,6653,6677,6699,6717,6742,6764,6788,6813,6834,6868,6897,6919,6945,6966,6989,7010,7031,7053,7071,7092,7113,7134,7155,7177,7198,7220,7241,7265,7283,7301,7324,7346,7367,7394,7441,7471,7497,7523,7554,7593,7615,7645,7668,7691,7716,7738,7762,7780,7804,7822,7844,7866,7884,7907,7932,7953,7975,7998,8023,8045,8068,8090,8108,8134,8159,8177,8195,8220,8238,8262,8286,8308,8332,8355,8377,8398,8420,8442,8465,8483,8505,8530,8548,8570,8594,8620],{"intervention":96,"totalTrials":97,"cells":98},"Aspirin",5,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":172},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[],{"trials":109,"activeCount":171,"soonestReadout":143},[110,124,139,151,164],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":121},"NCT06757764","The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis","RECRUITING",[92],"2028-03-31","2025-07-10",2340,[119,120],"Cerebral Infarction","Stenosis Artery",[96,122,123],"Clopidogrel","Cilostazol",{"nctId":125,"briefTitle":126,"status":127,"phases":128,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":136},"NCT02483169","PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study","UNKNOWN",[92],"2016-09","2016-12","2009-06",800,[134,135],"Brain Ischemia","Intracranial Hemorrhages",[137,138,96],"cilostazol","Probucol",{"nctId":140,"briefTitle":141,"status":113,"phases":142,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":149},"NCT05418556","Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent",[92],"2027-08-30","2028-12-31","2022-10-21",3944,[148],"Coronary Artery Disease",[150],"aspirin",{"nctId":152,"briefTitle":153,"status":154,"phases":155,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":162},"NCT07431762","Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Heart Valve Replacement","NOT_YET_RECRUITING",[92],"2030-10-31","2031-03-31","2026-02-01",1058,[161],"Valve Replacement Surgery",[96,163],"Vitamin K antagonist",{"nctId":165,"briefTitle":166,"status":127,"phases":167,"primaryCompletion":129,"completion":130,"start":131,"enrollment":168,"conditions":169,"interventions":170},"NCT01013532","PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage",[92],1600,[134,135],[123,138,96],3,{"trials":173,"activeCount":101},[],{"intervention":175,"totalTrials":176,"cells":177},"Treatment",2,{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":211},{"trials":179,"activeCount":101},[],{"trials":181,"activeCount":101},[],{"trials":183,"activeCount":101},[],{"trials":185,"activeCount":101},[],{"trials":187,"activeCount":176,"soonestReadout":204},[188,200],{"nctId":189,"briefTitle":190,"status":191,"phases":192,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":199},"NCT04780204","Effectiveness of Antiviral Treatment in Cirrhotic Patients with Low-level Hepatitis B Virus DNA Levels","ACTIVE_NOT_RECRUITING",[92],"2027-01","2027-12","2021-08-23",600,[198],"Hepatitis B, Chronic",[175],{"nctId":201,"briefTitle":202,"status":113,"phases":203,"primaryCompletion":204,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":210},"NCT05148286","Albumin and Crystalloid Administration in Septic Shock",[92],"2026-09-30","2026-12-31","2022-01-17",2426,[209],"Septic Shock",[175],{"trials":212,"activeCount":101},[],{"intervention":123,"totalTrials":97,"cells":214},{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":221,"PHASE4":223,"NA":260},{"trials":216,"activeCount":101},[],{"trials":218,"activeCount":101},[],{"trials":220,"activeCount":101},[],{"trials":222,"activeCount":101},[],{"trials":224,"activeCount":259,"soonestReadout":115},[225,229,240,244,255],{"nctId":111,"briefTitle":112,"status":113,"phases":226,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":227,"interventions":228},[92],[119,120],[96,122,123],{"nctId":230,"briefTitle":231,"status":232,"phases":233,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":239},"NCT00446641","Overcome Biochemical Aspirin Resistance Through Cilostazol Combination","COMPLETED",[92],"2008-06","2008-07","2007-03",244,[119],[123],{"nctId":125,"briefTitle":126,"status":127,"phases":241,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":242,"interventions":243},[92],[134,135],[137,138,96],{"nctId":245,"briefTitle":246,"status":232,"phases":247,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":253},"NCT00130039","Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II",[92],"2009-01","2005-08",457,[119,252],"Atherosclerosis",[254,123],"clopidogrel",{"nctId":165,"briefTitle":166,"status":127,"phases":256,"primaryCompletion":129,"completion":130,"start":131,"enrollment":168,"conditions":257,"interventions":258},[92],[134,135],[123,138,96],1,{"trials":261,"activeCount":101},[],{"intervention":263,"totalTrials":171,"cells":264},"Warfarin",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":283,"PHASE4":285,"NA":314},{"trials":266,"activeCount":101},[],{"trials":268,"activeCount":101},[],{"trials":270,"activeCount":101},[271],{"nctId":272,"briefTitle":273,"status":232,"phases":274,"primaryCompletion":275,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":281},"NCT02042534","Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation",[90],"2015-12","2014-01",195,[279,280],"Ischemic Stroke","Transient Ischemic Attack",[282,263],"Rivaroxaban",{"trials":284,"activeCount":101},[],{"trials":286,"activeCount":259,"soonestReadout":303},[287,299],{"nctId":288,"briefTitle":289,"status":232,"phases":290,"primaryCompletion":291,"completion":291,"start":130,"enrollment":292,"conditions":293,"interventions":296},"NCT02982850","Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease",[92],"2020-10",120,[294,295],"Atrial Fibrillation","Valve Heart Disease",[297,298,263],"Dabigatran","Acetylsalicylic acid",{"nctId":300,"briefTitle":301,"status":154,"phases":302,"primaryCompletion":303,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":313},"NCT07081035","Trial of Low-intensity Anticoagulation to Reduce GI or Other Bleeding Complications With Equivalent Therapeutic Efficacy in HeartMate 3 LVAD Patients",[92],"2028-10","2029-01","2025-10",94,[308,309,310,311,312],"Advanced Heart Failure","Left Ventricular Assist Devices","Anticoagulation Treatment","Bleeding Complications","Thrombotic Complications",[263,263],{"trials":315,"activeCount":101},[],{"intervention":122,"totalTrials":176,"cells":317},{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":324,"PHASE4":326,"NA":336},{"trials":319,"activeCount":101},[],{"trials":321,"activeCount":101},[],{"trials":323,"activeCount":101},[],{"trials":325,"activeCount":101},[],{"trials":327,"activeCount":259,"soonestReadout":115},[328,332],{"nctId":111,"briefTitle":112,"status":113,"phases":329,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":330,"interventions":331},[92],[119,120],[96,122,123],{"nctId":245,"briefTitle":246,"status":232,"phases":333,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":334,"interventions":335},[92],[119,252],[254,123],{"trials":337,"activeCount":101},[],{"intervention":339,"totalTrials":259,"cells":340},"Pitavastatin 4mg and ezetimibe 10mg, taken once daily",{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":349,"NA":364},{"trials":342,"activeCount":101},[],{"trials":344,"activeCount":101},[],{"trials":346,"activeCount":101},[],{"trials":348,"activeCount":101},[],{"trials":350,"activeCount":259,"soonestReadout":355},[351],{"nctId":352,"briefTitle":353,"status":113,"phases":354,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":362},"NCT06722521","GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification",[92],"2032-06-30","2032-10-31","2025-07-09",7435,[360,361],"Primary Prevention","Vascular Calcification",[339,363],"Pitavastatin 2 mg with aspirin 100 mg, taken once daily.",{"trials":365,"activeCount":101},[],{"intervention":363,"totalTrials":259,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":376,"NA":382},{"trials":369,"activeCount":101},[],{"trials":371,"activeCount":101},[],{"trials":373,"activeCount":101},[],{"trials":375,"activeCount":101},[],{"trials":377,"activeCount":259,"soonestReadout":355},[378],{"nctId":352,"briefTitle":353,"status":113,"phases":379,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":380,"interventions":381},[92],[360,361],[339,363],{"trials":383,"activeCount":101},[],{"intervention":385,"totalTrials":259,"cells":386},"BPaL(M) regimen",{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":393,"PHASE4":395,"NA":405},{"trials":388,"activeCount":101},[],{"trials":390,"activeCount":101},[],{"trials":392,"activeCount":101},[],{"trials":394,"activeCount":101},[],{"trials":396,"activeCount":259,"soonestReadout":194},[397],{"nctId":398,"briefTitle":399,"status":113,"phases":400,"primaryCompletion":194,"completion":194,"start":401,"enrollment":8,"conditions":402,"interventions":404},"NCT05381194","BPaL(M) Regimen for the Treatment of MDR\u002FRR-TB",[92],"2022-12-13",[403],"Multidrug- and Rifampicin-resistant Tuberculosis",[385],{"trials":406,"activeCount":101},[],{"intervention":408,"totalTrials":259,"cells":409},"Inhaled Nitric Oxide",{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":431},{"trials":411,"activeCount":101},[],{"trials":413,"activeCount":101},[],{"trials":415,"activeCount":101},[],{"trials":417,"activeCount":101},[],{"trials":419,"activeCount":259,"soonestReadout":424},[420],{"nctId":421,"briefTitle":422,"status":154,"phases":423,"primaryCompletion":424,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":430},"NCT07247240","Efficacy of Inhaled Nitric Oxide in Congenital Diaphragmatic Hernia",[92],"2028-12","2025-11",40,[428,429],"Congenital Diaphragmatic Hernia","Pulmonary Hypertension",[408],{"trials":432,"activeCount":101},[],{"intervention":163,"totalTrials":259,"cells":434},{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":441,"PHASE4":443,"NA":449},{"trials":436,"activeCount":101},[],{"trials":438,"activeCount":101},[],{"trials":440,"activeCount":101},[],{"trials":442,"activeCount":101},[],{"trials":444,"activeCount":259,"soonestReadout":156},[445],{"nctId":152,"briefTitle":153,"status":154,"phases":446,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":447,"interventions":448},[92],[161],[96,163],{"trials":450,"activeCount":101},[],{"intervention":46,"totalTrials":259,"cells":452},{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":459,"PHASE4":461,"NA":470},{"trials":454,"activeCount":101},[],{"trials":456,"activeCount":101},[],{"trials":458,"activeCount":101},[],{"trials":460,"activeCount":101},[],{"trials":462,"activeCount":259,"soonestReadout":45},[463],{"nctId":43,"briefTitle":44,"status":191,"phases":464,"primaryCompletion":45,"completion":465,"start":466,"enrollment":467,"conditions":468,"interventions":469},[92],"2026-01-31","2021-09-01",140,[198],[46],{"trials":471,"activeCount":101},[],{"intervention":81,"totalTrials":259,"cells":473},{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":482,"NA":497},{"trials":475,"activeCount":101},[],{"trials":477,"activeCount":101},[],{"trials":479,"activeCount":101},[],{"trials":481,"activeCount":101},[],{"trials":483,"activeCount":259,"soonestReadout":80},[484],{"nctId":78,"briefTitle":79,"status":113,"phases":485,"primaryCompletion":80,"completion":486,"start":487,"enrollment":488,"conditions":489,"interventions":495},[92],"2027-06-30","2023-11-01",86,[490,491,492,493,494],"Crohn Disease","Infliximab","Perianal Fistula Due to Crohn's Disease","Therapeutic Drug Monitoring","Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease Score",[81,496],"Standard infliximab intravenous therapy",{"trials":498,"activeCount":101},[],{"intervention":496,"totalTrials":259,"cells":500},{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":515},{"trials":502,"activeCount":101},[],{"trials":504,"activeCount":101},[],{"trials":506,"activeCount":101},[],{"trials":508,"activeCount":101},[],{"trials":510,"activeCount":259,"soonestReadout":80},[511],{"nctId":78,"briefTitle":79,"status":113,"phases":512,"primaryCompletion":80,"completion":486,"start":487,"enrollment":488,"conditions":513,"interventions":514},[92],[490,491,492,493,494],[81,496],{"trials":516,"activeCount":101},[],{"intervention":518,"totalTrials":171,"cells":519},"Capecitabine",{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":552,"PHASE4":560,"NA":562},{"trials":521,"activeCount":101},[],{"trials":523,"activeCount":101},[],{"trials":525,"activeCount":101},[526,536],{"nctId":527,"briefTitle":528,"status":232,"phases":529,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":534},"NCT00278863","Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial",[90],"2007-01","2004-11",96,[21],[535,518],"S-1",{"nctId":537,"briefTitle":538,"status":232,"phases":539,"primaryCompletion":540,"completion":541,"start":542,"enrollment":543,"conditions":544,"interventions":550},"NCT03079427","Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma",[90],"2021-12-15","2022-11-15","2017-05-15",101,[545,546,547,518,548,549],"Cholangiocarcinoma","Biliary Tract Cancer","Adjuvant Chemotherapy","Gemcitabine","Cisplatin",[551,518],"Gemcitabine plus cisplatin",{"trials":553,"activeCount":259,"soonestReadout":85},[554],{"nctId":83,"briefTitle":84,"status":113,"phases":555,"primaryCompletion":85,"completion":85,"start":556,"enrollment":557,"conditions":558,"interventions":559},[91],"2013-08-19",870,[21],[86],{"trials":561,"activeCount":101},[],{"trials":563,"activeCount":101},[],{"intervention":565,"totalTrials":176,"cells":566},"cytarabine",{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":589,"PHASE4":604,"NA":606},{"trials":568,"activeCount":101},[],{"trials":570,"activeCount":101},[],{"trials":572,"activeCount":101},[573],{"nctId":574,"briefTitle":575,"status":232,"phases":576,"primaryCompletion":577,"completion":248,"start":578,"enrollment":9,"conditions":579,"interventions":580},"NCT00618501","Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",[90],"2008-12","2005-10",[34],[565,581,582,583,584,585,586,587,588],"daunorubicin hydrochloride","etoposide","imatinib mesylate","leucovorin calcium","methotrexate","prednisolone","therapeutic hydrocortisone","vincristine sulfate",{"trials":590,"activeCount":259,"soonestReadout":144},[591],{"nctId":592,"briefTitle":593,"status":594,"phases":595,"primaryCompletion":144,"completion":144,"start":596,"enrollment":597,"conditions":598,"interventions":600},"NCT03507842","A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.","ENROLLING_BY_INVITATION",[91],"2018-03-01",380,[599],"Acute Myeloid Leukemia",[601,602,603],"High dose Cytarabine","Cytarabine","Hign dose Daunorubicin",{"trials":605,"activeCount":101},[],{"trials":607,"activeCount":101},[],{"intervention":609,"totalTrials":259,"cells":610},"Ferinject",{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":617,"PHASE4":629,"NA":631},{"trials":612,"activeCount":101},[],{"trials":614,"activeCount":101},[],{"trials":616,"activeCount":101},[],{"trials":618,"activeCount":259,"soonestReadout":623},[619],{"nctId":620,"briefTitle":621,"status":113,"phases":622,"primaryCompletion":623,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":628},"NCT05226169","Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)",[91],"2026-11-30","2022-04-29",330,[627],"Advanced Gastric Carcinoma",[609],{"trials":630,"activeCount":101},[],{"trials":632,"activeCount":101},[],{"intervention":634,"totalTrials":259,"cells":635},"High-dose trivalent inactivated influenza vaccine",{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":642,"PHASE4":659,"NA":661},{"trials":637,"activeCount":101},[],{"trials":639,"activeCount":101},[],{"trials":641,"activeCount":101},[],{"trials":643,"activeCount":259,"soonestReadout":648},[644],{"nctId":645,"briefTitle":646,"status":113,"phases":647,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":652,"interventions":656},"NCT07485855","Influenza Vaccination Strategy for Patients With Hematologic Malignancy",[91],"2027-04-30","2028-04-30","2025-12-04",60,[653,654,655],"Hematologic Neoplasms","Influenza","Immunogenicity",[634,657,658],"MF59-adjuvanted quadrivalent inactivated influenza vaccine","Standard-dose trivalent inactivated influenza vaccine",{"trials":660,"activeCount":101},[],{"trials":662,"activeCount":101},[],{"intervention":657,"totalTrials":259,"cells":664},{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":671,"PHASE4":677,"NA":679},{"trials":666,"activeCount":101},[],{"trials":668,"activeCount":101},[],{"trials":670,"activeCount":101},[],{"trials":672,"activeCount":259,"soonestReadout":648},[673],{"nctId":645,"briefTitle":646,"status":113,"phases":674,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":675,"interventions":676},[91],[653,654,655],[634,657,658],{"trials":678,"activeCount":101},[],{"trials":680,"activeCount":101},[],{"intervention":658,"totalTrials":259,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":689,"PHASE4":695,"NA":697},{"trials":684,"activeCount":101},[],{"trials":686,"activeCount":101},[],{"trials":688,"activeCount":101},[],{"trials":690,"activeCount":259,"soonestReadout":648},[691],{"nctId":645,"briefTitle":646,"status":113,"phases":692,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":693,"interventions":694},[91],[653,654,655],[634,657,658],{"trials":696,"activeCount":101},[],{"trials":698,"activeCount":101},[],{"intervention":700,"totalTrials":259,"cells":701},"Docetaxel and capecitabine and oxaliplatin",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":721,"NA":723},{"trials":703,"activeCount":101},[],{"trials":705,"activeCount":101},[],{"trials":707,"activeCount":101},[],{"trials":709,"activeCount":259,"soonestReadout":714},[710],{"nctId":711,"briefTitle":712,"status":113,"phases":713,"primaryCompletion":714,"completion":714,"start":715,"enrollment":716,"conditions":717,"interventions":719},"NCT01935778","Compare Adjuvant Chemotherapy of Docetaxel\u002FCapecitabine\u002FOxliplatin Versus Capecitabine\u002FOxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH",[91],"2028-06-30","2013-10-02",286,[718],"Gastric Cancer, Adjuvant Chemotherapy, XO",[700,720],"capecitabine and oxaliplatin",{"trials":722,"activeCount":101},[],{"trials":724,"activeCount":101},[],{"intervention":720,"totalTrials":259,"cells":726},{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":733,"PHASE4":739,"NA":741},{"trials":728,"activeCount":101},[],{"trials":730,"activeCount":101},[],{"trials":732,"activeCount":101},[],{"trials":734,"activeCount":259,"soonestReadout":714},[735],{"nctId":711,"briefTitle":712,"status":113,"phases":736,"primaryCompletion":714,"completion":714,"start":715,"enrollment":716,"conditions":737,"interventions":738},[91],[718],[700,720],{"trials":740,"activeCount":101},[],{"trials":742,"activeCount":101},[],{"intervention":744,"totalTrials":259,"cells":745},"Tislelizumab",{"EARLY_PHASE1":746,"PHASE1":748,"PHASE2":750,"PHASE3":752,"PHASE4":765,"NA":767},{"trials":747,"activeCount":101},[],{"trials":749,"activeCount":101},[],{"trials":751,"activeCount":101},[],{"trials":753,"activeCount":259,"soonestReadout":758},[754],{"nctId":755,"briefTitle":756,"status":154,"phases":757,"primaryCompletion":758,"completion":759,"start":760,"enrollment":761,"conditions":762,"interventions":764},"NCT06914011","Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma",[91],"2031-06-28","2034-05-30","2026-05-06",172,[763],"Esophageal Cancer",[744],{"trials":766,"activeCount":101},[],{"trials":768,"activeCount":101},[],{"intervention":601,"totalTrials":259,"cells":770},{"EARLY_PHASE1":771,"PHASE1":773,"PHASE2":775,"PHASE3":777,"PHASE4":783,"NA":785},{"trials":772,"activeCount":101},[],{"trials":774,"activeCount":101},[],{"trials":776,"activeCount":101},[],{"trials":778,"activeCount":259,"soonestReadout":144},[779],{"nctId":592,"briefTitle":593,"status":594,"phases":780,"primaryCompletion":144,"completion":144,"start":596,"enrollment":597,"conditions":781,"interventions":782},[91],[599],[601,602,603],{"trials":784,"activeCount":101},[],{"trials":786,"activeCount":101},[],{"intervention":603,"totalTrials":259,"cells":788},{"EARLY_PHASE1":789,"PHASE1":791,"PHASE2":793,"PHASE3":795,"PHASE4":801,"NA":803},{"trials":790,"activeCount":101},[],{"trials":792,"activeCount":101},[],{"trials":794,"activeCount":101},[],{"trials":796,"activeCount":259,"soonestReadout":144},[797],{"nctId":592,"briefTitle":593,"status":594,"phases":798,"primaryCompletion":144,"completion":144,"start":596,"enrollment":597,"conditions":799,"interventions":800},[91],[599],[601,602,603],{"trials":802,"activeCount":101},[],{"trials":804,"activeCount":101},[],{"intervention":806,"totalTrials":259,"cells":807},"Enavogliflozin",{"EARLY_PHASE1":808,"PHASE1":810,"PHASE2":812,"PHASE3":814,"PHASE4":828,"NA":830},{"trials":809,"activeCount":101},[],{"trials":811,"activeCount":101},[],{"trials":813,"activeCount":101},[],{"trials":815,"activeCount":259,"soonestReadout":820},[816],{"nctId":817,"briefTitle":818,"status":191,"phases":819,"primaryCompletion":820,"completion":821,"start":822,"enrollment":823,"conditions":824,"interventions":827},"NCT06027307","Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation",[91],"2027-06","2027-08","2023-10-25",541,[825,826],"Tricuspid Regurgitation","Heart Failure With Preserved Ejection Fraction",[806],{"trials":829,"activeCount":101},[],{"trials":831,"activeCount":101},[],{"intervention":833,"totalTrials":834,"cells":835},"Lenvatinib",4,{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":883,"PHASE4":885,"NA":887},{"trials":837,"activeCount":101},[],{"trials":839,"activeCount":101},[],{"trials":841,"activeCount":834,"soonestReadout":857},[842,853,862,873],{"nctId":843,"briefTitle":844,"status":113,"phases":845,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":849,"interventions":852},"NCT07149090","Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites",[89,90],"2027-07-30","2025-11-11",61,[850,21,851],"STOMACH NEOPLASM","Gastric Cancer Adenocarcinoma Metastatic",[833],{"nctId":854,"briefTitle":855,"status":191,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":9,"conditions":860,"interventions":861},"NCT06138769","Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma",[90],"2026-11-01","2027-11-01","2023-07-20",[15],[833],{"nctId":863,"briefTitle":864,"status":154,"phases":865,"primaryCompletion":866,"completion":424,"start":867,"enrollment":868,"conditions":869,"interventions":871},"NCT07495579","Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)",[90],"2028-04","2026-04",146,[870],"Hepatocellular Carcinoma (HCC)",[833,872],"regorafenib",{"nctId":874,"briefTitle":875,"status":113,"phases":876,"primaryCompletion":877,"completion":877,"start":878,"enrollment":879,"conditions":880,"interventions":882},"NCT07096609","Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients",[89,90],"2027-12-31","2025-10-29",48,[881],"GIST",[833],{"trials":884,"activeCount":101},[],{"trials":886,"activeCount":101},[],{"trials":888,"activeCount":101},[],{"intervention":890,"totalTrials":35,"cells":891},"Cyclophosphamide",{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":893,"activeCount":101},[],{"trials":895,"activeCount":101},[],{"trials":897,"activeCount":259,"soonestReadout":959},[898,911,927,939,955,965,974,983],{"nctId":899,"briefTitle":900,"status":232,"phases":901,"primaryCompletion":902,"completion":902,"start":903,"enrollment":904,"conditions":905,"interventions":907},"NCT01105273","Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia",[89,90],"2012-07","2009-07",12,[906],"Aplastic Anemia",[908,909,910,890],"anti-thymocyte globulin","filgrastim","Fludarabine",{"nctId":912,"briefTitle":913,"status":127,"phases":914,"primaryCompletion":915,"completion":916,"start":917,"enrollment":25,"conditions":918,"interventions":922},"NCT01509300","HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors",[89,90],"2013-12","2014-03","2012-01",[919,920,921],"Acute Leukemia","Myelodysplastic Syndrome","Solid Tumors",[908,909,910,923,924,925,926],"cyclophosphamide","Tacrolimus","Mycophenolate mofetil","Rituximab",{"nctId":928,"briefTitle":929,"status":127,"phases":930,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":934,"interventions":938},"NCT02014506","Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents",[89,90],"2018-12","2017-01",30,[935,936,937],"Haploidentical Hematopoietic Stem Cell Transplantation","Malignant Disease","Non-malignant Disease",[910,890,908,909],{"nctId":940,"briefTitle":941,"status":232,"phases":942,"primaryCompletion":943,"completion":943,"start":944,"enrollment":945,"conditions":946,"interventions":949},"NCT00379574","Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL",[89,90],"2011-01","2006-09",49,[947,948],"Lymphoma, Large-Cell, Diffuse","Lymphoma, B-Cell",[950,890,951,952,953,954],"Bortezomib","Doxorubicin","Vincristine","Prednisolone","Lenograstim",{"nctId":956,"briefTitle":957,"status":191,"phases":958,"primaryCompletion":959,"completion":959,"start":960,"enrollment":961,"conditions":962,"interventions":964},"NCT06098313","HCT With PTCy in Higher-risk MDS",[90],"2027-05-31","2020-07-01",113,[963],"Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)",[890],{"nctId":966,"briefTitle":967,"status":232,"phases":968,"primaryCompletion":969,"completion":969,"start":970,"enrollment":933,"conditions":971,"interventions":973},"NCT02969980","Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS",[90],"2021-12-16","2016-11",[972],"Myelodysplastic Syndromes",[890],{"nctId":975,"briefTitle":976,"status":127,"phases":977,"primaryCompletion":978,"completion":275,"start":979,"enrollment":25,"conditions":980,"interventions":982},"NCT01759732","Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia",[90],"2014-12","2012-09",[981],"Acquired Aplastic Anemia",[910,890,908,909],{"nctId":984,"briefTitle":985,"status":232,"phases":986,"primaryCompletion":987,"completion":987,"start":988,"enrollment":989,"conditions":990,"interventions":991},"NCT01020734","Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission",[90],"2015-07","2011-05",263,[34],[908,992,923,993,994,585],"busulfan","cyclosporine","fludarabine phosphate",{"trials":996,"activeCount":101},[],{"trials":998,"activeCount":101},[],{"trials":1000,"activeCount":101},[],{"intervention":1002,"totalTrials":834,"cells":1003},"Imatinib Mesylate",{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1045,"PHASE4":1047,"NA":1049},{"trials":1005,"activeCount":101},[],{"trials":1007,"activeCount":101},[],{"trials":1009,"activeCount":259,"soonestReadout":1014},[1010,1019,1023,1033],{"nctId":1011,"briefTitle":1012,"status":113,"phases":1013,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":1016,"conditions":1017,"interventions":1018},"NCT05385549","5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk",[90],"2030-04-30","2022-09-07",35,[18],[1002],{"nctId":574,"briefTitle":575,"status":232,"phases":1020,"primaryCompletion":577,"completion":248,"start":578,"enrollment":9,"conditions":1021,"interventions":1022},[90],[34],[565,581,582,583,584,585,586,587,588],{"nctId":1024,"briefTitle":1025,"status":232,"phases":1026,"primaryCompletion":1027,"completion":1027,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1032},"NCT02712112","A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs",[90],"2019-06-15","2016-03-16",51,[1031],"Gastrointestinal Stromal Tumors (GISTs)",[1002],{"nctId":1034,"briefTitle":1035,"status":232,"phases":1036,"primaryCompletion":1037,"completion":1038,"start":1039,"enrollment":1040,"conditions":1041,"interventions":1043},"NCT00278876","Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation",[90],"2007-08","2011-03","2005-04",47,[1042,18],"Sarcoma",[1044],"Imatinib mesylate",{"trials":1046,"activeCount":101},[],{"trials":1048,"activeCount":101},[],{"trials":1050,"activeCount":101},[],{"intervention":1052,"totalTrials":171,"cells":1053},"Oxaliplatin",{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1058,"PHASE3":1101,"PHASE4":1103,"NA":1105},{"trials":1055,"activeCount":101},[],{"trials":1057,"activeCount":101},[],{"trials":1059,"activeCount":259,"soonestReadout":877},[1060,1072,1090],{"nctId":1061,"briefTitle":1062,"status":113,"phases":1063,"primaryCompletion":877,"completion":877,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1069},"NCT06732856","A Phase Ib\u002FII Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer",[89,90],"2025-04-04",57,[1067,1068],"Stomach Neoplasm","Gastric (Stomach) Cancer",[1070,1052,1071,535],"zolbetuximab","Docetaxel",{"nctId":1073,"briefTitle":1074,"status":232,"phases":1075,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":1079,"conditions":1080,"interventions":1085},"NCT03698461","Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab",[90],"2021-12-22","2023-10-24","2019-05-15",20,[1081,1082,1083,1084],"Colorectal Neoplasms","Neoplasm Metastasis","Colonic Neoplasms","Rectal Neoplasms",[1086,1087,1052,1088,1089],"Atezolizumab","Bevacizumab","Levoleucovorin","5-FU",{"nctId":1091,"briefTitle":1092,"status":232,"phases":1093,"primaryCompletion":1094,"completion":1095,"start":1096,"enrollment":1097,"conditions":1098,"interventions":1100},"NCT00336583","Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)",[90],"2006-12","2008-01","2006-06",27,[1099],"Non-Hodgkin's Lymphoma",[1052],{"trials":1102,"activeCount":101},[],{"trials":1104,"activeCount":101},[],{"trials":1106,"activeCount":101},[],{"intervention":1108,"totalTrials":176,"cells":1109},"Temozolomide",{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1125,"PHASE3":1136,"PHASE4":1138,"NA":1140},{"trials":1111,"activeCount":101},[],{"trials":1113,"activeCount":101},[1114],{"nctId":1115,"briefTitle":1116,"status":232,"phases":1117,"primaryCompletion":1118,"completion":1119,"start":1120,"enrollment":1121,"conditions":1122,"interventions":1124},"NCT01781403","Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer",[89],"2014-09-03","2016-05-04","2013-05-10",22,[1123],"Rectal Cancer",[1108],{"trials":1126,"activeCount":259,"soonestReadout":1131},[1127],{"nctId":1128,"briefTitle":1129,"status":113,"phases":1130,"primaryCompletion":1131,"completion":877,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1135},"NCT05661643","The Efficacy and Safety of Temozolomide in SDH-deficient GIST",[90],"2026-12-01","2023-06-28",29,[18],[1108],{"trials":1137,"activeCount":101},[],{"trials":1139,"activeCount":101},[],{"trials":1141,"activeCount":101},[],{"intervention":1071,"totalTrials":176,"cells":1143},{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1164,"PHASE4":1166,"NA":1168},{"trials":1145,"activeCount":101},[],{"trials":1147,"activeCount":101},[],{"trials":1149,"activeCount":259,"soonestReadout":877},[1150,1154],{"nctId":1061,"briefTitle":1062,"status":113,"phases":1151,"primaryCompletion":877,"completion":877,"start":1064,"enrollment":1065,"conditions":1152,"interventions":1153},[89,90],[1067,1068],[1070,1052,1071,535],{"nctId":1155,"briefTitle":1156,"status":127,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":1161,"interventions":1163},"NCT01461746","Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer",[90],"2017-12","2011-10",67,[1162],"Endometrial Cancer",[1071,549],{"trials":1165,"activeCount":101},[],{"trials":1167,"activeCount":101},[],{"trials":1169,"activeCount":101},[],{"intervention":535,"totalTrials":176,"cells":1171},{"EARLY_PHASE1":1172,"PHASE1":1174,"PHASE2":1176,"PHASE3":1186,"PHASE4":1188,"NA":1190},{"trials":1173,"activeCount":101},[],{"trials":1175,"activeCount":101},[],{"trials":1177,"activeCount":259,"soonestReadout":877},[1178,1182],{"nctId":1061,"briefTitle":1062,"status":113,"phases":1179,"primaryCompletion":877,"completion":877,"start":1064,"enrollment":1065,"conditions":1180,"interventions":1181},[89,90],[1067,1068],[1070,1052,1071,535],{"nctId":527,"briefTitle":528,"status":232,"phases":1183,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":1184,"interventions":1185},[90],[21],[535,518],{"trials":1187,"activeCount":101},[],{"trials":1189,"activeCount":101},[],{"trials":1191,"activeCount":101},[],{"intervention":71,"totalTrials":176,"cells":1193},{"EARLY_PHASE1":1194,"PHASE1":1196,"PHASE2":1198,"PHASE3":1219,"PHASE4":1221,"NA":1223},{"trials":1195,"activeCount":101},[],{"trials":1197,"activeCount":101},[],{"trials":1199,"activeCount":259,"soonestReadout":70},[1200,1210],{"nctId":1201,"briefTitle":1202,"status":232,"phases":1203,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":1207,"interventions":1209},"NCT03435107","Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer",[90],"2023-04-26","2018-04-12",33,[1208],"Metastatic Colorectal Cancer",[71],{"nctId":68,"briefTitle":69,"status":113,"phases":1211,"primaryCompletion":70,"completion":1212,"start":1213,"enrollment":1214,"conditions":1215,"interventions":1217},[90],"2026-12-30","2022-04-01",62,[546,1216],"DNA Damage Repair Deficiency",[71,1218],"Olaparib",{"trials":1220,"activeCount":101},[],{"trials":1222,"activeCount":101},[],{"trials":1224,"activeCount":101},[],{"intervention":41,"totalTrials":259,"cells":1226},{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1242,"PHASE4":1244,"NA":1246},{"trials":1228,"activeCount":101},[],{"trials":1230,"activeCount":101},[],{"trials":1232,"activeCount":259,"soonestReadout":40},[1233],{"nctId":38,"briefTitle":39,"status":191,"phases":1234,"primaryCompletion":40,"completion":70,"start":1235,"enrollment":1236,"conditions":1237,"interventions":1240},[90],"2020-05-20",45,[1238,1239,545],"Biliary Tract Neoplasms","Gallbladder Cancer",[41,1241],"Gem\u002FCis",{"trials":1243,"activeCount":101},[],{"trials":1245,"activeCount":101},[],{"trials":1247,"activeCount":101},[],{"intervention":1241,"totalTrials":259,"cells":1249},{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1260,"PHASE4":1262,"NA":1264},{"trials":1251,"activeCount":101},[],{"trials":1253,"activeCount":101},[],{"trials":1255,"activeCount":259,"soonestReadout":40},[1256],{"nctId":38,"briefTitle":39,"status":191,"phases":1257,"primaryCompletion":40,"completion":70,"start":1235,"enrollment":1236,"conditions":1258,"interventions":1259},[90],[1238,1239,545],[41,1241],{"trials":1261,"activeCount":101},[],{"trials":1263,"activeCount":101},[],{"trials":1265,"activeCount":101},[],{"intervention":1267,"totalTrials":259,"cells":1268},"INCMGA00012",{"EARLY_PHASE1":1269,"PHASE1":1271,"PHASE2":1273,"PHASE3":1283,"PHASE4":1285,"NA":1287},{"trials":1270,"activeCount":101},[],{"trials":1272,"activeCount":101},[],{"trials":1274,"activeCount":259,"soonestReadout":205},[1275],{"nctId":1276,"briefTitle":1277,"status":191,"phases":1278,"primaryCompletion":205,"completion":205,"start":1279,"enrollment":1280,"conditions":1281,"interventions":1282},"NCT04494009","PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy",[90],"2020-09-07",110,[763],[1267],{"trials":1284,"activeCount":101},[],{"trials":1286,"activeCount":101},[],{"trials":1288,"activeCount":101},[],{"intervention":1290,"totalTrials":259,"cells":1291},"Platinum Based Chemotherapy",{"EARLY_PHASE1":1292,"PHASE1":1294,"PHASE2":1296,"PHASE3":1309,"PHASE4":1311,"NA":1313},{"trials":1293,"activeCount":101},[],{"trials":1295,"activeCount":101},[],{"trials":1297,"activeCount":259,"soonestReadout":1302},[1298],{"nctId":1299,"briefTitle":1300,"status":154,"phases":1301,"primaryCompletion":1302,"completion":1302,"start":1303,"enrollment":1304,"conditions":1305,"interventions":1308},"NCT07295132","RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)",[90],"2029-11-15","2025-12-15",160,[1306,1307],"Ovarian Cancer Recurrent","Platinum Sensitive Ovarian Cancer",[1290],{"trials":1310,"activeCount":101},[],{"trials":1312,"activeCount":101},[],{"trials":1314,"activeCount":101},[],{"intervention":1316,"totalTrials":259,"cells":1317},"Docetaxel injection, oxaliplatin, S-1",{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1332,"PHASE4":1334,"NA":1336},{"trials":1319,"activeCount":101},[],{"trials":1321,"activeCount":101},[],{"trials":1323,"activeCount":259,"soonestReadout":486},[1324],{"nctId":1325,"briefTitle":1326,"status":113,"phases":1327,"primaryCompletion":486,"completion":877,"start":1328,"enrollment":1329,"conditions":1330,"interventions":1331},"NCT05184803","A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer",[90],"2022-03-23",63,[1067],[1316],{"trials":1333,"activeCount":101},[],{"trials":1335,"activeCount":101},[],{"trials":1337,"activeCount":101},[],{"intervention":1070,"totalTrials":259,"cells":1339},{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1344,"PHASE3":1350,"PHASE4":1352,"NA":1354},{"trials":1341,"activeCount":101},[],{"trials":1343,"activeCount":101},[],{"trials":1345,"activeCount":259,"soonestReadout":877},[1346],{"nctId":1061,"briefTitle":1062,"status":113,"phases":1347,"primaryCompletion":877,"completion":877,"start":1064,"enrollment":1065,"conditions":1348,"interventions":1349},[89,90],[1067,1068],[1070,1052,1071,535],{"trials":1351,"activeCount":101},[],{"trials":1353,"activeCount":101},[],{"trials":1355,"activeCount":101},[],{"intervention":1357,"totalTrials":259,"cells":1358},"Rivoceranib Mesylate, Paclitaxel",{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1363,"PHASE3":1373,"PHASE4":1375,"NA":1377},{"trials":1360,"activeCount":101},[],{"trials":1362,"activeCount":101},[],{"trials":1364,"activeCount":259,"soonestReadout":1369},[1365],{"nctId":1366,"briefTitle":1367,"status":113,"phases":1368,"primaryCompletion":1369,"completion":877,"start":1370,"enrollment":879,"conditions":1371,"interventions":1372},"NCT05905887","Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor",[90],"2027-08-31","2023-09-06",[18],[1357],{"trials":1374,"activeCount":101},[],{"trials":1376,"activeCount":101},[],{"trials":1378,"activeCount":101},[],{"intervention":1380,"totalTrials":259,"cells":1381},"cyclophosphamide, fludarabine, and antithymocyte globulin",{"EARLY_PHASE1":1382,"PHASE1":1384,"PHASE2":1386,"PHASE3":1395,"PHASE4":1397,"NA":1399},{"trials":1383,"activeCount":101},[],{"trials":1385,"activeCount":101},[],{"trials":1387,"activeCount":259,"soonestReadout":205},[1388],{"nctId":1389,"briefTitle":1390,"status":191,"phases":1391,"primaryCompletion":205,"completion":205,"start":1392,"enrollment":933,"conditions":1393,"interventions":1394},"NCT06098326","CyFluATG in Lower Risk MDS",[90],"2018-03-06",[972],[1380],{"trials":1396,"activeCount":101},[],{"trials":1398,"activeCount":101},[],{"trials":1400,"activeCount":101},[],{"intervention":1402,"totalTrials":259,"cells":1403},"Liporaxel",{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1419,"PHASE4":1421,"NA":1423},{"trials":1405,"activeCount":101},[],{"trials":1407,"activeCount":101},[],{"trials":1409,"activeCount":259,"soonestReadout":1414},[1410],{"nctId":1411,"briefTitle":1412,"status":113,"phases":1413,"primaryCompletion":1414,"completion":1414,"start":1415,"enrollment":1416,"conditions":1417,"interventions":1418},"NCT06326346","GIST Oral Paclitaxel(Liporaxel)",[90],"2027-03-31","2024-11-20",28,[18],[1402],{"trials":1420,"activeCount":101},[],{"trials":1422,"activeCount":101},[],{"trials":1424,"activeCount":101},[],{"intervention":76,"totalTrials":259,"cells":1426},{"EARLY_PHASE1":1427,"PHASE1":1429,"PHASE2":1431,"PHASE3":1443,"PHASE4":1445,"NA":1447},{"trials":1428,"activeCount":101},[],{"trials":1430,"activeCount":101},[],{"trials":1432,"activeCount":259,"soonestReadout":75},[1433],{"nctId":73,"briefTitle":74,"status":113,"phases":1434,"primaryCompletion":75,"completion":75,"start":1435,"enrollment":1436,"conditions":1437,"interventions":1442},[90],"2022-10-22",138,[15,1438,1439,1440,1441],"Hepatocellular Cancer","Hepatocellular Carcinoma Non-resectable","Hepatocellular Carcinoma Stage IV","Liver Cancer",[76],{"trials":1444,"activeCount":101},[],{"trials":1446,"activeCount":101},[],{"trials":1448,"activeCount":101},[],{"intervention":1450,"totalTrials":259,"cells":1451},"irpagratinib",{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1456,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1453,"activeCount":101},[],{"trials":1455,"activeCount":101},[],{"trials":1457,"activeCount":259,"soonestReadout":1462},[1458],{"nctId":1459,"briefTitle":1460,"status":113,"phases":1461,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1206,"conditions":1464,"interventions":1466},"NCT07010497","A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma",[90],"2029-03-31","2026-03-16",[1465],"Carcinoma, Hepatocellular",[1450],{"trials":1468,"activeCount":101},[],{"trials":1470,"activeCount":101},[],{"trials":1472,"activeCount":101},[],{"intervention":51,"totalTrials":259,"cells":1474},{"EARLY_PHASE1":1475,"PHASE1":1477,"PHASE2":1479,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1476,"activeCount":101},[],{"trials":1478,"activeCount":101},[],{"trials":1480,"activeCount":259,"soonestReadout":50},[1481],{"nctId":48,"briefTitle":49,"status":191,"phases":1482,"primaryCompletion":50,"completion":1483,"start":1484,"enrollment":1485,"conditions":1486,"interventions":1489},[90],"2025-12-14","2021-08-14",92,[1487,1488],"Pancreatic Adenocarcinoma","Pancreatic Cancer Non-resectable",[51],{"trials":1491,"activeCount":101},[],{"trials":1493,"activeCount":101},[],{"trials":1495,"activeCount":101},[],{"intervention":1218,"totalTrials":259,"cells":1497},{"EARLY_PHASE1":1498,"PHASE1":1500,"PHASE2":1502,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1499,"activeCount":101},[],{"trials":1501,"activeCount":101},[],{"trials":1503,"activeCount":259,"soonestReadout":70},[1504],{"nctId":68,"briefTitle":69,"status":113,"phases":1505,"primaryCompletion":70,"completion":1212,"start":1213,"enrollment":1214,"conditions":1506,"interventions":1507},[90],[546,1216],[71,1218],{"trials":1509,"activeCount":101},[],{"trials":1511,"activeCount":101},[],{"trials":1513,"activeCount":101},[],{"intervention":1515,"totalTrials":259,"cells":1516},"IMC-001",{"EARLY_PHASE1":1517,"PHASE1":1519,"PHASE2":1521,"PHASE3":1535,"PHASE4":1537,"NA":1539},{"trials":1518,"activeCount":101},[],{"trials":1520,"activeCount":101},[],{"trials":1522,"activeCount":259,"soonestReadout":1527},[1523],{"nctId":1524,"briefTitle":1525,"status":191,"phases":1526,"primaryCompletion":1527,"completion":1528,"start":1529,"enrollment":879,"conditions":1530,"interventions":1534},"NCT04196465","Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers",[90],"2026-09-09","2026-09-26","2019-09-09",[1531,1532,1533],"Subjects With Resectable and Localized Gastric Cancer","Subjects With Resectable Esophageal Cancer or Liver Cancer","Subjects With Resectable Liver Cancer",[1515],{"trials":1536,"activeCount":101},[],{"trials":1538,"activeCount":101},[],{"trials":1540,"activeCount":101},[],{"intervention":1542,"totalTrials":171,"cells":1543},"Regorafenib",{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1548,"PHASE3":1563,"PHASE4":1565,"NA":1567},{"trials":1545,"activeCount":101},[],{"trials":1547,"activeCount":101},[],{"trials":1549,"activeCount":259,"soonestReadout":866},[1550,1559],{"nctId":1551,"briefTitle":1552,"status":232,"phases":1553,"primaryCompletion":1554,"completion":1555,"start":129,"enrollment":1556,"conditions":1557,"interventions":1558},"NCT02889328","Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs",[90],"2017-08-09","2018-01",25,[1031],[1542],{"nctId":863,"briefTitle":864,"status":154,"phases":1560,"primaryCompletion":866,"completion":424,"start":867,"enrollment":868,"conditions":1561,"interventions":1562},[90],[870],[833,872],{"trials":1564,"activeCount":101},[],{"trials":1566,"activeCount":101},[],{"trials":1568,"activeCount":101},[1569],{"nctId":1570,"briefTitle":1571,"status":232,"phases":1572,"primaryCompletion":1573,"completion":1574,"start":1575,"enrollment":1576,"conditions":1577,"interventions":1579},"NCT02175095","[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib",[93],"2016-08-10","2019-04-30","2014-07-18",68,[1578],"Colorectal Cancer",[1542],{"intervention":66,"totalTrials":259,"cells":1581},{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1586,"PHASE3":1588,"PHASE4":1590,"NA":1592},{"trials":1583,"activeCount":101},[],{"trials":1585,"activeCount":101},[],{"trials":1587,"activeCount":101},[],{"trials":1589,"activeCount":101},[],{"trials":1591,"activeCount":101},[],{"trials":1593,"activeCount":259,"soonestReadout":65},[1594],{"nctId":63,"briefTitle":64,"status":191,"phases":1595,"primaryCompletion":65,"completion":1596,"start":1597,"enrollment":1598,"conditions":1599,"interventions":1600},[],"2026-07-30","2018-07-01",100,[15,546],[66],{"intervention":1602,"totalTrials":259,"cells":1603},"Vedolizumab, Ustekinumab, or Tofacitinib",{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1610,"PHASE4":1612,"NA":1614},{"trials":1605,"activeCount":101},[],{"trials":1607,"activeCount":101},[],{"trials":1609,"activeCount":101},[],{"trials":1611,"activeCount":101},[],{"trials":1613,"activeCount":101},[],{"trials":1615,"activeCount":259,"soonestReadout":205},[1616],{"nctId":1617,"briefTitle":1618,"status":113,"phases":1619,"primaryCompletion":205,"completion":205,"start":1620,"enrollment":1621,"conditions":1622,"interventions":1624},"NCT05186623","Prediction Model for Response to Biologics and Small Molecular Agent for UC",[],"2022-02-05",300,[1623],"Ulcerative Colitis",[1602],{"intervention":61,"totalTrials":259,"cells":1626},{"EARLY_PHASE1":1627,"PHASE1":1629,"PHASE2":1631,"PHASE3":1633,"PHASE4":1635,"NA":1637},{"trials":1628,"activeCount":101},[],{"trials":1630,"activeCount":101},[],{"trials":1632,"activeCount":101},[],{"trials":1634,"activeCount":101},[],{"trials":1636,"activeCount":101},[],{"trials":1638,"activeCount":259,"soonestReadout":60},[1639],{"nctId":58,"briefTitle":59,"status":191,"phases":1640,"primaryCompletion":60,"completion":1641,"start":1642,"enrollment":1643,"conditions":1644,"interventions":1652},[],"2026-06-27","2019-10-08",1200,[1645,294,1646,1647,1648,1649,1650,1651],"Acute Ischemic Stroke","Extracranial Atherosclerosis","Intracranial Atherosclerosis","Coronary Artery Atherosclerosis","Peripheral Artery Stenosis","Anticoagulant","Antiplatelet",[61],{"intervention":1654,"totalTrials":259,"cells":1655},"single dose preoperative antibiotic",{"EARLY_PHASE1":1656,"PHASE1":1658,"PHASE2":1660,"PHASE3":1662,"PHASE4":1664,"NA":1666},{"trials":1657,"activeCount":101},[],{"trials":1659,"activeCount":101},[],{"trials":1661,"activeCount":101},[],{"trials":1663,"activeCount":101},[],{"trials":1665,"activeCount":101},[],{"trials":1667,"activeCount":259,"soonestReadout":303},[1668],{"nctId":1669,"briefTitle":1670,"status":594,"phases":1671,"primaryCompletion":303,"completion":424,"start":1672,"enrollment":1673,"conditions":1674,"interventions":1678},"NCT07043855","Duration of Perioperative Antibiotics in Pancreatoduodenectomy",[93],"2026-05-11",558,[1675,1676,1677],"Pancreatoduodenectomy","PPPD","Infectious Complications",[1654,1679],"Prolonged perioperative antibiotics",{"intervention":1679,"totalTrials":259,"cells":1681},{"EARLY_PHASE1":1682,"PHASE1":1684,"PHASE2":1686,"PHASE3":1688,"PHASE4":1690,"NA":1692},{"trials":1683,"activeCount":101},[],{"trials":1685,"activeCount":101},[],{"trials":1687,"activeCount":101},[],{"trials":1689,"activeCount":101},[],{"trials":1691,"activeCount":101},[],{"trials":1693,"activeCount":259,"soonestReadout":303},[1694],{"nctId":1669,"briefTitle":1670,"status":594,"phases":1695,"primaryCompletion":303,"completion":424,"start":1672,"enrollment":1673,"conditions":1696,"interventions":1697},[93],[1675,1676,1677],[1654,1679],{"intervention":56,"totalTrials":259,"cells":1699},{"EARLY_PHASE1":1700,"PHASE1":1702,"PHASE2":1704,"PHASE3":1706,"PHASE4":1708,"NA":1710},{"trials":1701,"activeCount":101},[],{"trials":1703,"activeCount":101},[],{"trials":1705,"activeCount":101},[],{"trials":1707,"activeCount":101},[],{"trials":1709,"activeCount":101},[],{"trials":1711,"activeCount":259,"soonestReadout":55},[1712],{"nctId":53,"briefTitle":54,"status":154,"phases":1713,"primaryCompletion":55,"completion":205,"start":1714,"enrollment":1598,"conditions":1715,"interventions":1717},[],"2024-06-12",[1716],"Asthma",[56],{"intervention":1719,"totalTrials":259,"cells":1720},"Serial blood collection for MRD testing",{"EARLY_PHASE1":1721,"PHASE1":1723,"PHASE2":1725,"PHASE3":1727,"PHASE4":1729,"NA":1731},{"trials":1722,"activeCount":101},[],{"trials":1724,"activeCount":101},[],{"trials":1726,"activeCount":101},[],{"trials":1728,"activeCount":101},[],{"trials":1730,"activeCount":101},[],{"trials":1732,"activeCount":259,"soonestReadout":486},[1733],{"nctId":1734,"briefTitle":1735,"status":154,"phases":1736,"primaryCompletion":486,"completion":877,"start":1737,"enrollment":196,"conditions":1738,"interventions":1740},"NCT07382505","Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer",[],"2026-02-15",[1739,32],"Uterine Neoplasms",[1719],{"intervention":1742,"totalTrials":259,"cells":1743},"Infliximab-Dyyb",{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1748,"PHASE3":1750,"PHASE4":1752,"NA":1754},{"trials":1745,"activeCount":101},[],{"trials":1747,"activeCount":101},[],{"trials":1749,"activeCount":101},[],{"trials":1751,"activeCount":101},[],{"trials":1753,"activeCount":101},[],{"trials":1755,"activeCount":259,"soonestReadout":205},[1756],{"nctId":1757,"briefTitle":1758,"status":113,"phases":1759,"primaryCompletion":205,"completion":205,"start":1760,"enrollment":1598,"conditions":1761,"interventions":1763},"NCT06064864","Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD",[93],"2023-10-09",[1762],"Crohn's Disease",[1742],{"intervention":1765,"totalTrials":1766,"cells":1767},"Remimazolam",6,{"EARLY_PHASE1":1768,"PHASE1":1770,"PHASE2":1772,"PHASE3":1774,"PHASE4":1776,"NA":1836},{"trials":1769,"activeCount":101},[],{"trials":1771,"activeCount":101},[],{"trials":1773,"activeCount":101},[],{"trials":1775,"activeCount":101},[],{"trials":1777,"activeCount":101},[1778,1787,1800,1808,1817,1825],{"nctId":1779,"briefTitle":1780,"status":232,"phases":1781,"primaryCompletion":1782,"completion":1782,"start":1783,"enrollment":651,"conditions":1784,"interventions":1786},"NCT05468996","Median Effective Dose of Remimazolam for Sedation in Elderly Patients",[92],"2022-10-28","2022-05-10",[1785],"Sedative",[1765],{"nctId":1788,"briefTitle":1789,"status":232,"phases":1790,"primaryCompletion":1791,"completion":1791,"start":1792,"enrollment":1793,"conditions":1794,"interventions":1799},"NCT05651399","Comparison in Frequency of Hypotension Between Remimazolam and Propofol in Hip Surgery",[92],"2023-06-14","2022-12-26",78,[1765,1795,1796,1797,1798],"Propofol","Orthopedic Procedures","Sedatives","Anesthesia, Spinal",[1765,1795],{"nctId":1801,"briefTitle":1802,"status":232,"phases":1803,"primaryCompletion":1804,"completion":1804,"start":1805,"enrollment":9,"conditions":1806,"interventions":1807},"NCT05340335","ED90 of Remimazolam Loading Dose for Sedation in Patients Under Monitored Anesthetic Care",[92],"2022-05-02","2022-04-18",[1765,1796,1797],[1765],{"nctId":1809,"briefTitle":1810,"status":232,"phases":1811,"primaryCompletion":1812,"completion":1812,"start":1813,"enrollment":306,"conditions":1814,"interventions":1816},"NCT05644483","Effect of Remimazolam and Propofol on Hemodynamic Stability in Prone Position",[92],"2023-01-25","2022-03-29",[1815],"Hemodynamic Instability",[1765,1795],{"nctId":1818,"briefTitle":1819,"status":232,"phases":1820,"primaryCompletion":1821,"completion":1821,"start":1822,"enrollment":1029,"conditions":1823,"interventions":1824},"NCT05379777","Effective Dose of Remimazolam for Sedation in Patients Undergoing Lower Extremity Surgery Under Spinal Anesthesia",[92],"2022-08-24","2022-05-11",[1765,1796,1797,1798],[1765],{"nctId":1826,"briefTitle":1827,"status":232,"phases":1828,"primaryCompletion":1829,"completion":1830,"start":1831,"enrollment":292,"conditions":1832,"interventions":1835},"NCT05688345","Comparison of Recovery Profiles Among Propofol, Remimazolam, and Dexmedetomidine After Intraoperative Sedation",[92],"2023-08-12","2023-08-13","2023-02-23",[1765,1795,1833,1796,1797,1834],"Dexmedetomidine","Brachial Plexus Block",[1765,1795,1833],{"trials":1837,"activeCount":101},[],{"intervention":1839,"totalTrials":97,"cells":1840},"Entecavir",{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1845,"PHASE3":1847,"PHASE4":1859,"NA":1898},{"trials":1842,"activeCount":101},[],{"trials":1844,"activeCount":101},[],{"trials":1846,"activeCount":101},[],{"trials":1848,"activeCount":101},[1849],{"nctId":1850,"briefTitle":1851,"status":232,"phases":1852,"primaryCompletion":978,"completion":978,"start":1853,"enrollment":1854,"conditions":1855,"interventions":1857},"NCT01595685","Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B",[91],"2012-05",98,[1856],"Chronic Viral Hepatitis B Without Delta-agent",[1858,1839],"Telbivudine",{"trials":1860,"activeCount":101},[1861,1871,1879,1889],{"nctId":1862,"briefTitle":1863,"status":232,"phases":1864,"primaryCompletion":902,"completion":979,"start":1865,"enrollment":1866,"conditions":1867,"interventions":1868},"NCT01023217","Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir",[92],"2009-11",90,[198],[1869,1839,1870],"Adefovir","Lamivudine",{"nctId":1872,"briefTitle":1873,"status":127,"phases":1874,"primaryCompletion":932,"completion":1875,"start":1876,"enrollment":1866,"conditions":1877,"interventions":1878},"NCT02482272","Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B",[92],"2017-05","2015-05",[198],[1870,1869,1839],{"nctId":1880,"briefTitle":1881,"status":232,"phases":1882,"primaryCompletion":1883,"completion":1883,"start":1884,"enrollment":1885,"conditions":1886,"interventions":1887},"NCT01639092","Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B",[92],"2018-03-29","2012-09-28",88,[1856],[1888,1888,1839],"Tenofovir",{"nctId":1890,"briefTitle":1891,"status":232,"phases":1892,"primaryCompletion":1893,"completion":1893,"start":1894,"enrollment":1895,"conditions":1896,"interventions":1897},"NCT01639066","Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B",[92],"2017-09-22","2012-09-25",102,[1856],[1888,1839,1888],{"trials":1899,"activeCount":101},[],{"intervention":1901,"totalTrials":834,"cells":1902},"Normal saline",{"EARLY_PHASE1":1903,"PHASE1":1905,"PHASE2":1907,"PHASE3":1930,"PHASE4":1932,"NA":1956},{"trials":1904,"activeCount":101},[],{"trials":1906,"activeCount":101},[],{"trials":1908,"activeCount":101},[1909,1919],{"nctId":1910,"briefTitle":1911,"status":232,"phases":1912,"primaryCompletion":1913,"completion":1913,"start":1914,"enrollment":1280,"conditions":1915,"interventions":1917},"NCT03191240","AMCPR (Augmented-Medication CardioPulmonary Resuscitation) Trial for OHCA",[90],"2021-08-31","2017-12-31",[1916],"Out-of-Hospital Cardiac Arrest",[1918,1901],"Vasopressins",{"nctId":1920,"briefTitle":1921,"status":232,"phases":1922,"primaryCompletion":1923,"completion":1923,"start":1924,"enrollment":9,"conditions":1925,"interventions":1928},"NCT02303548","Bicarbonate in Patients With Out-of-hospital Cardiac Arrest",[90],"2016-02","2014-10",[1926,1927],"Cardiac Arrest","Metabolic Acidosis",[1929,1901],"Sodium bicarbonate",{"trials":1931,"activeCount":101},[],{"trials":1933,"activeCount":101},[1934,1944],{"nctId":1935,"briefTitle":1936,"status":232,"phases":1937,"primaryCompletion":1938,"completion":1938,"start":1939,"enrollment":532,"conditions":1940,"interventions":1942},"NCT04162834","Effect of Papaverine on Renal Artery Blood Flow Volume",[92],"2021-04-15","2019-11-21",[1941],"Kidney Cancer",[1943,1901],"Papaverine",{"nctId":1945,"briefTitle":1946,"status":127,"phases":1947,"primaryCompletion":1948,"completion":1949,"start":1950,"enrollment":1951,"conditions":1952,"interventions":1955},"NCT03522688","Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation",[92],"2023-07-14","2024-07-07","2017-07-11",214,[1953,1954],"Acute Kidney Injury","Liver Diseases",[1833,1901],{"trials":1957,"activeCount":101},[],{"intervention":1795,"totalTrials":834,"cells":1959},{"EARLY_PHASE1":1960,"PHASE1":1962,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1992},{"trials":1961,"activeCount":101},[],{"trials":1963,"activeCount":101},[1964],{"nctId":1965,"briefTitle":1966,"status":232,"phases":1967,"primaryCompletion":1968,"completion":1969,"start":1970,"enrollment":1329,"conditions":1971,"interventions":1972},"NCT00908726","Population Pharmacokinetics\u002FPharmacodynamics (PK\u002FPD) of Microemulsion Propofol in Healthy Volunteers",[89],"2010-05","2011-06","2009-05",[30],[1973],"propofol",{"trials":1975,"activeCount":101},[],{"trials":1977,"activeCount":101},[],{"trials":1979,"activeCount":101},[1980,1984,1988],{"nctId":1788,"briefTitle":1789,"status":232,"phases":1981,"primaryCompletion":1791,"completion":1791,"start":1792,"enrollment":1793,"conditions":1982,"interventions":1983},[92],[1765,1795,1796,1797,1798],[1765,1795],{"nctId":1809,"briefTitle":1810,"status":232,"phases":1985,"primaryCompletion":1812,"completion":1812,"start":1813,"enrollment":306,"conditions":1986,"interventions":1987},[92],[1815],[1765,1795],{"nctId":1826,"briefTitle":1827,"status":232,"phases":1989,"primaryCompletion":1829,"completion":1830,"start":1831,"enrollment":292,"conditions":1990,"interventions":1991},[92],[1765,1795,1833,1796,1797,1834],[1765,1795,1833],{"trials":1993,"activeCount":101},[],{"intervention":1995,"totalTrials":176,"cells":1996},"Valsartan",{"EARLY_PHASE1":1997,"PHASE1":1999,"PHASE2":2001,"PHASE3":2003,"PHASE4":2005,"NA":2029},{"trials":1998,"activeCount":101},[],{"trials":2000,"activeCount":101},[],{"trials":2002,"activeCount":101},[],{"trials":2004,"activeCount":101},[],{"trials":2006,"activeCount":101},[2007,2019],{"nctId":2008,"briefTitle":2009,"status":232,"phases":2010,"primaryCompletion":2011,"completion":2011,"start":2012,"enrollment":2013,"conditions":2014,"interventions":2017},"NCT02687932","Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation",[92],"2018-01-02","2016-03",118,[2015,2016],"Mitral Valve Insufficiency","Left Ventricular Dysfunction",[2018,1995],"LCZ696",{"nctId":2020,"briefTitle":2021,"status":232,"phases":2022,"primaryCompletion":2023,"completion":2023,"start":130,"enrollment":2024,"conditions":2025,"interventions":2027},"NCT02973035","Amlodipine Versus Valsartan for Improvement of Diastolic Dysfunction Associated With Hypertension",[92],"2020-01-06",104,[2026],"Hypertension",[2028,1995],"Amlodipine",{"trials":2030,"activeCount":101},[],{"intervention":138,"totalTrials":176,"cells":2032},{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2037,"PHASE3":2039,"PHASE4":2041,"NA":2051},{"trials":2034,"activeCount":101},[],{"trials":2036,"activeCount":101},[],{"trials":2038,"activeCount":101},[],{"trials":2040,"activeCount":101},[],{"trials":2042,"activeCount":101},[2043,2047],{"nctId":125,"briefTitle":126,"status":127,"phases":2044,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":2045,"interventions":2046},[92],[134,135],[137,138,96],{"nctId":165,"briefTitle":166,"status":127,"phases":2048,"primaryCompletion":129,"completion":130,"start":131,"enrollment":168,"conditions":2049,"interventions":2050},[92],[134,135],[123,138,96],{"trials":2052,"activeCount":101},[],{"intervention":2054,"totalTrials":176,"cells":2055},"Rosuvastatin",{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2060,"PHASE3":2062,"PHASE4":2064,"NA":2083},{"trials":2057,"activeCount":101},[],{"trials":2059,"activeCount":101},[],{"trials":2061,"activeCount":101},[],{"trials":2063,"activeCount":101},[],{"trials":2065,"activeCount":101},[2066,2075],{"nctId":2067,"briefTitle":2068,"status":232,"phases":2069,"primaryCompletion":2070,"completion":2070,"start":2071,"enrollment":11,"conditions":2072,"interventions":2074},"NCT01490398","Rosuvastatin Effect on Serial Echocardiographic Measurement of Coronary Flow Velocity Reserve",[92],"2013-10","2011-12",[2026,2073],"Cardiovascular Risk Factors",[2054],{"nctId":2076,"briefTitle":2077,"status":232,"phases":2078,"primaryCompletion":2079,"completion":2079,"start":2080,"enrollment":532,"conditions":2081,"interventions":2082},"NCT02482207","Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients With Cardiovascular Risk",[92],"2019-11-26","2015-11",[2026],[2054],{"trials":2084,"activeCount":101},[],{"intervention":1869,"totalTrials":176,"cells":2086},{"EARLY_PHASE1":2087,"PHASE1":2089,"PHASE2":2091,"PHASE3":2093,"PHASE4":2095,"NA":2105},{"trials":2088,"activeCount":101},[],{"trials":2090,"activeCount":101},[],{"trials":2092,"activeCount":101},[],{"trials":2094,"activeCount":101},[],{"trials":2096,"activeCount":101},[2097,2101],{"nctId":1862,"briefTitle":1863,"status":232,"phases":2098,"primaryCompletion":902,"completion":979,"start":1865,"enrollment":1866,"conditions":2099,"interventions":2100},[92],[198],[1869,1839,1870],{"nctId":1872,"briefTitle":1873,"status":127,"phases":2102,"primaryCompletion":932,"completion":1875,"start":1876,"enrollment":1866,"conditions":2103,"interventions":2104},[92],[198],[1870,1869,1839],{"trials":2106,"activeCount":101},[],{"intervention":1870,"totalTrials":176,"cells":2108},{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2115,"PHASE4":2117,"NA":2127},{"trials":2110,"activeCount":101},[],{"trials":2112,"activeCount":101},[],{"trials":2114,"activeCount":101},[],{"trials":2116,"activeCount":101},[],{"trials":2118,"activeCount":101},[2119,2123],{"nctId":1862,"briefTitle":1863,"status":232,"phases":2120,"primaryCompletion":902,"completion":979,"start":1865,"enrollment":1866,"conditions":2121,"interventions":2122},[92],[198],[1869,1839,1870],{"nctId":1872,"briefTitle":1873,"status":127,"phases":2124,"primaryCompletion":932,"completion":1875,"start":1876,"enrollment":1866,"conditions":2125,"interventions":2126},[92],[198],[1870,1869,1839],{"trials":2128,"activeCount":101},[],{"intervention":924,"totalTrials":176,"cells":2130},{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2141,"PHASE4":2143,"NA":2155},{"trials":2132,"activeCount":101},[],{"trials":2134,"activeCount":101},[],{"trials":2136,"activeCount":101},[2137],{"nctId":912,"briefTitle":913,"status":127,"phases":2138,"primaryCompletion":915,"completion":916,"start":917,"enrollment":25,"conditions":2139,"interventions":2140},[89,90],[919,920,921],[908,909,910,923,924,925,926],{"trials":2142,"activeCount":101},[],{"trials":2144,"activeCount":101},[2145],{"nctId":2146,"briefTitle":2147,"status":127,"phases":2148,"primaryCompletion":2149,"completion":2149,"start":276,"enrollment":2150,"conditions":2151,"interventions":2153},"NCT02075242","TO Compare the Triple Drug Therapy and Dual Therapy .",[92],"2016-01",170,[2152],"HEPATITIS",[2154,924],"Mycophenolate Mofetil",{"trials":2156,"activeCount":101},[],{"intervention":925,"totalTrials":176,"cells":2158},{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2163,"PHASE3":2169,"PHASE4":2171,"NA":2177},{"trials":2160,"activeCount":101},[],{"trials":2162,"activeCount":101},[],{"trials":2164,"activeCount":101},[2165],{"nctId":912,"briefTitle":913,"status":127,"phases":2166,"primaryCompletion":915,"completion":916,"start":917,"enrollment":25,"conditions":2167,"interventions":2168},[89,90],[919,920,921],[908,909,910,923,924,925,926],{"trials":2170,"activeCount":101},[],{"trials":2172,"activeCount":101},[2173],{"nctId":2146,"briefTitle":2147,"status":127,"phases":2174,"primaryCompletion":2149,"completion":2149,"start":276,"enrollment":2150,"conditions":2175,"interventions":2176},[92],[2152],[2154,924],{"trials":2178,"activeCount":101},[],{"intervention":2180,"totalTrials":176,"cells":2181},"micafungin",{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2188,"PHASE4":2200,"NA":2214},{"trials":2183,"activeCount":101},[],{"trials":2185,"activeCount":101},[],{"trials":2187,"activeCount":101},[],{"trials":2189,"activeCount":101},[2190],{"nctId":2191,"briefTitle":2192,"status":127,"phases":2193,"primaryCompletion":2194,"completion":978,"start":2195,"enrollment":761,"conditions":2196,"interventions":2198},"NCT01974375","Micafungin Versus Fluconazole for Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients",[91],"2014-06","2012-08",[2197],"Liver Transplant Recipient",[2180,2199],"Fluconazole",{"trials":2201,"activeCount":101},[2202],{"nctId":2203,"briefTitle":2204,"status":127,"phases":2205,"primaryCompletion":1853,"completion":1853,"start":2206,"enrollment":2207,"conditions":2208,"interventions":2212},"NCT01135589","Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation",[92],"2010-04",145,[2209,2210,2211],"Neutropenia","Hematopoietic Stem Cell Transplantation","Invasive Fungal Disease",[2213],"Micafungin",{"trials":2215,"activeCount":101},[],{"intervention":1888,"totalTrials":176,"cells":2217},{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2224,"PHASE4":2226,"NA":2236},{"trials":2219,"activeCount":101},[],{"trials":2221,"activeCount":101},[],{"trials":2223,"activeCount":101},[],{"trials":2225,"activeCount":101},[],{"trials":2227,"activeCount":101},[2228,2232],{"nctId":1880,"briefTitle":1881,"status":232,"phases":2229,"primaryCompletion":1883,"completion":1883,"start":1884,"enrollment":1885,"conditions":2230,"interventions":2231},[92],[1856],[1888,1888,1839],{"nctId":1890,"briefTitle":1891,"status":232,"phases":2233,"primaryCompletion":1893,"completion":1893,"start":1894,"enrollment":1895,"conditions":2234,"interventions":2235},[92],[1856],[1888,1839,1888],{"trials":2237,"activeCount":101},[],{"intervention":2239,"totalTrials":259,"cells":2240},"Bepotastine",{"EARLY_PHASE1":2241,"PHASE1":2243,"PHASE2":2245,"PHASE3":2247,"PHASE4":2249,"NA":2262},{"trials":2242,"activeCount":101},[],{"trials":2244,"activeCount":101},[],{"trials":2246,"activeCount":101},[],{"trials":2248,"activeCount":101},[],{"trials":2250,"activeCount":101},[2251],{"nctId":2252,"briefTitle":2253,"status":232,"phases":2254,"primaryCompletion":2255,"completion":2256,"start":2257,"enrollment":9,"conditions":2258,"interventions":2261},"NCT04877678","Effects of Second-generation Antihistamine Bepotastine on Cough Outcomes in Cough Patients With Allergic Rhinitis",[92],"2022-09-01","2022-10-31","2021-10-01",[2259,2260],"Allergic Rhinitis","Cough",[2239],{"trials":2263,"activeCount":101},[],{"intervention":2265,"totalTrials":259,"cells":2266},"entecavir, lamivudine",{"EARLY_PHASE1":2267,"PHASE1":2269,"PHASE2":2271,"PHASE3":2273,"PHASE4":2275,"NA":2286},{"trials":2268,"activeCount":101},[],{"trials":2270,"activeCount":101},[],{"trials":2272,"activeCount":101},[],{"trials":2274,"activeCount":101},[],{"trials":2276,"activeCount":101},[2277],{"nctId":2278,"briefTitle":2279,"status":2280,"phases":2281,"primaryCompletion":2282,"completion":2282,"start":988,"enrollment":97,"conditions":2283,"interventions":2285},"NCT01354652","Lactic Acidosis During Entecavir(ETV)Treatment","TERMINATED",[92],"2013-09",[2284],"Lactic Acidosis",[2265],{"trials":2287,"activeCount":101},[],{"intervention":2289,"totalTrials":259,"cells":2290},"Epaxal Berna",{"EARLY_PHASE1":2291,"PHASE1":2293,"PHASE2":2295,"PHASE3":2297,"PHASE4":2299,"NA":2313},{"trials":2292,"activeCount":101},[],{"trials":2294,"activeCount":101},[],{"trials":2296,"activeCount":101},[],{"trials":2298,"activeCount":101},[],{"trials":2300,"activeCount":101},[2301],{"nctId":2302,"briefTitle":2303,"status":232,"phases":2304,"primaryCompletion":2305,"completion":2306,"start":2307,"enrollment":2308,"conditions":2309,"interventions":2312},"NCT01341808","Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients",[92],"2013-02","2013-03","2011-04",493,[2310,1762,1623,2311],"Inflammatory Bowel Disease","Hepatitis A",[2289],{"trials":2314,"activeCount":101},[],{"intervention":2018,"totalTrials":259,"cells":2316},{"EARLY_PHASE1":2317,"PHASE1":2319,"PHASE2":2321,"PHASE3":2323,"PHASE4":2325,"NA":2331},{"trials":2318,"activeCount":101},[],{"trials":2320,"activeCount":101},[],{"trials":2322,"activeCount":101},[],{"trials":2324,"activeCount":101},[],{"trials":2326,"activeCount":101},[2327],{"nctId":2008,"briefTitle":2009,"status":232,"phases":2328,"primaryCompletion":2011,"completion":2011,"start":2012,"enrollment":2013,"conditions":2329,"interventions":2330},[92],[2015,2016],[2018,1995],{"trials":2332,"activeCount":101},[],{"intervention":2334,"totalTrials":259,"cells":2335},"Pitavastatin",{"EARLY_PHASE1":2336,"PHASE1":2338,"PHASE2":2340,"PHASE3":2342,"PHASE4":2344,"NA":2356},{"trials":2337,"activeCount":101},[],{"trials":2339,"activeCount":101},[],{"trials":2341,"activeCount":101},[],{"trials":2343,"activeCount":101},[],{"trials":2345,"activeCount":101},[2346],{"nctId":2347,"briefTitle":2348,"status":232,"phases":2349,"primaryCompletion":2350,"completion":2350,"start":2351,"enrollment":2352,"conditions":2353,"interventions":2355},"NCT02144922","Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients",[92],"2016-10","2014-05",85,[2026,2354],"Cardiovascular Risk",[2334],{"trials":2357,"activeCount":101},[],{"intervention":2359,"totalTrials":259,"cells":2360},"flowable thrombin containing collagen hemostat matrix",{"EARLY_PHASE1":2361,"PHASE1":2363,"PHASE2":2365,"PHASE3":2367,"PHASE4":2369,"NA":2382},{"trials":2362,"activeCount":101},[],{"trials":2364,"activeCount":101},[],{"trials":2366,"activeCount":101},[],{"trials":2368,"activeCount":101},[],{"trials":2370,"activeCount":101},[2371],{"nctId":2372,"briefTitle":2373,"status":127,"phases":2374,"primaryCompletion":2375,"completion":2376,"start":2377,"enrollment":651,"conditions":2378,"interventions":2380},"NCT04357483","Effect of Thrombin-containing Collagen-based Hemostatic Matrix",[92],"2020-07-31","2020-09-30","2018-02-01",[2379],"Pancreatic Tumor",[2359,2381],"thrombin coated L-dopa contained collagen patch",{"trials":2383,"activeCount":101},[],{"intervention":2381,"totalTrials":259,"cells":2385},{"EARLY_PHASE1":2386,"PHASE1":2388,"PHASE2":2390,"PHASE3":2392,"PHASE4":2394,"NA":2400},{"trials":2387,"activeCount":101},[],{"trials":2389,"activeCount":101},[],{"trials":2391,"activeCount":101},[],{"trials":2393,"activeCount":101},[],{"trials":2395,"activeCount":101},[2396],{"nctId":2372,"briefTitle":2373,"status":127,"phases":2397,"primaryCompletion":2375,"completion":2376,"start":2377,"enrollment":651,"conditions":2398,"interventions":2399},[92],[2379],[2359,2381],{"trials":2401,"activeCount":101},[],{"intervention":2403,"totalTrials":259,"cells":2404},"Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days",{"EARLY_PHASE1":2405,"PHASE1":2407,"PHASE2":2409,"PHASE3":2411,"PHASE4":2413,"NA":2424},{"trials":2406,"activeCount":101},[],{"trials":2408,"activeCount":101},[],{"trials":2410,"activeCount":101},[],{"trials":2412,"activeCount":101},[],{"trials":2414,"activeCount":101},[2415],{"nctId":2416,"briefTitle":2417,"status":127,"phases":2418,"primaryCompletion":2419,"completion":2419,"start":2420,"enrollment":651,"conditions":2421,"interventions":2423},"NCT04449185","Change of Gut Microbiome and Symptom After H.Pylori Eradication Therapy in Patients With Functional Dyspepsia",[92],"2021-10-30","2020-06-30",[2422],"Dyspepsia",[2403],{"trials":2425,"activeCount":101},[],{"intervention":2028,"totalTrials":259,"cells":2427},{"EARLY_PHASE1":2428,"PHASE1":2430,"PHASE2":2432,"PHASE3":2434,"PHASE4":2436,"NA":2442},{"trials":2429,"activeCount":101},[],{"trials":2431,"activeCount":101},[],{"trials":2433,"activeCount":101},[],{"trials":2435,"activeCount":101},[],{"trials":2437,"activeCount":101},[2438],{"nctId":2020,"briefTitle":2021,"status":232,"phases":2439,"primaryCompletion":2023,"completion":2023,"start":130,"enrollment":2024,"conditions":2440,"interventions":2441},[92],[2026],[2028,1995],{"trials":2443,"activeCount":101},[],{"intervention":2445,"totalTrials":259,"cells":2446},"Tachosil",{"EARLY_PHASE1":2447,"PHASE1":2449,"PHASE2":2451,"PHASE3":2453,"PHASE4":2455,"NA":2467},{"trials":2448,"activeCount":101},[],{"trials":2450,"activeCount":101},[],{"trials":2452,"activeCount":101},[],{"trials":2454,"activeCount":101},[],{"trials":2456,"activeCount":101},[2457],{"nctId":2458,"briefTitle":2459,"status":127,"phases":2460,"primaryCompletion":2461,"completion":2461,"start":2462,"enrollment":2463,"conditions":2464,"interventions":2466},"NCT02629510","The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP)",[92],"2017-08","2015-01",268,[2465,32],"Cervical Intraepithelial Neoplasia",[2445],{"trials":2468,"activeCount":101},[],{"intervention":2470,"totalTrials":259,"cells":2471},"pantoprazole",{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2478,"PHASE4":2480,"NA":2494},{"trials":2473,"activeCount":101},[],{"trials":2475,"activeCount":101},[],{"trials":2477,"activeCount":101},[],{"trials":2479,"activeCount":101},[],{"trials":2481,"activeCount":101},[2482],{"nctId":2483,"briefTitle":2484,"status":232,"phases":2485,"primaryCompletion":1968,"completion":2486,"start":234,"enrollment":2487,"conditions":2488,"interventions":2490},"NCT00841854","Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication",[92],"2010-11",199,[2489],"Helicobacter Infection",[2470,2491,2492,2493],"bismuth","metronidazole","tetracycline",{"trials":2495,"activeCount":101},[],{"intervention":2491,"totalTrials":259,"cells":2497},{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2502,"PHASE3":2504,"PHASE4":2506,"NA":2512},{"trials":2499,"activeCount":101},[],{"trials":2501,"activeCount":101},[],{"trials":2503,"activeCount":101},[],{"trials":2505,"activeCount":101},[],{"trials":2507,"activeCount":101},[2508],{"nctId":2483,"briefTitle":2484,"status":232,"phases":2509,"primaryCompletion":1968,"completion":2486,"start":234,"enrollment":2487,"conditions":2510,"interventions":2511},[92],[2489],[2470,2491,2492,2493],{"trials":2513,"activeCount":101},[],{"intervention":2492,"totalTrials":259,"cells":2515},{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2520,"PHASE3":2522,"PHASE4":2524,"NA":2530},{"trials":2517,"activeCount":101},[],{"trials":2519,"activeCount":101},[],{"trials":2521,"activeCount":101},[],{"trials":2523,"activeCount":101},[],{"trials":2525,"activeCount":101},[2526],{"nctId":2483,"briefTitle":2484,"status":232,"phases":2527,"primaryCompletion":1968,"completion":2486,"start":234,"enrollment":2487,"conditions":2528,"interventions":2529},[92],[2489],[2470,2491,2492,2493],{"trials":2531,"activeCount":101},[],{"intervention":2493,"totalTrials":259,"cells":2533},{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2538,"PHASE3":2540,"PHASE4":2542,"NA":2548},{"trials":2535,"activeCount":101},[],{"trials":2537,"activeCount":101},[],{"trials":2539,"activeCount":101},[],{"trials":2541,"activeCount":101},[],{"trials":2543,"activeCount":101},[2544],{"nctId":2483,"briefTitle":2484,"status":232,"phases":2545,"primaryCompletion":1968,"completion":2486,"start":234,"enrollment":2487,"conditions":2546,"interventions":2547},[92],[2489],[2470,2491,2492,2493],{"trials":2549,"activeCount":101},[],{"intervention":2551,"totalTrials":259,"cells":2552},"Solifenacin",{"EARLY_PHASE1":2553,"PHASE1":2555,"PHASE2":2557,"PHASE3":2559,"PHASE4":2561,"NA":2574},{"trials":2554,"activeCount":101},[],{"trials":2556,"activeCount":101},[],{"trials":2558,"activeCount":101},[],{"trials":2560,"activeCount":101},[],{"trials":2562,"activeCount":101},[2563],{"nctId":2564,"briefTitle":2565,"status":232,"phases":2566,"primaryCompletion":2567,"completion":2567,"start":2568,"enrollment":2569,"conditions":2570,"interventions":2573},"NCT00979472","Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency",[92],"2010-06","2009-04",291,[2571,2572],"Urinary Bladder, Overactive","Overactive Bladder",[2551],{"trials":2575,"activeCount":101},[],{"intervention":1943,"totalTrials":259,"cells":2577},{"EARLY_PHASE1":2578,"PHASE1":2580,"PHASE2":2582,"PHASE3":2584,"PHASE4":2586,"NA":2592},{"trials":2579,"activeCount":101},[],{"trials":2581,"activeCount":101},[],{"trials":2583,"activeCount":101},[],{"trials":2585,"activeCount":101},[],{"trials":2587,"activeCount":101},[2588],{"nctId":1935,"briefTitle":1936,"status":232,"phases":2589,"primaryCompletion":1938,"completion":1938,"start":1939,"enrollment":532,"conditions":2590,"interventions":2591},[92],[1941],[1943,1901],{"trials":2593,"activeCount":101},[],{"intervention":2595,"totalTrials":259,"cells":2596},"Peginterferon alfa-2a plus ribavirin for HCV genotype 1",{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2601,"PHASE3":2603,"PHASE4":2605,"NA":2617},{"trials":2598,"activeCount":101},[],{"trials":2600,"activeCount":101},[],{"trials":2602,"activeCount":101},[],{"trials":2604,"activeCount":101},[],{"trials":2606,"activeCount":101},[2607],{"nctId":2608,"briefTitle":2609,"status":232,"phases":2610,"primaryCompletion":2071,"completion":1853,"start":2611,"enrollment":2612,"conditions":2613,"interventions":2615},"NCT01596517","Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C",[92],"2003-06",272,[2614],"Chronic Hepatitis C",[2595,2616],"Peginterferon alfa-2a plus ribavirin for HCV genotype 2\u002F3",{"trials":2618,"activeCount":101},[],{"intervention":2616,"totalTrials":259,"cells":2620},{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2625,"PHASE3":2627,"PHASE4":2629,"NA":2635},{"trials":2622,"activeCount":101},[],{"trials":2624,"activeCount":101},[],{"trials":2626,"activeCount":101},[],{"trials":2628,"activeCount":101},[],{"trials":2630,"activeCount":101},[2631],{"nctId":2608,"briefTitle":2609,"status":232,"phases":2632,"primaryCompletion":2071,"completion":1853,"start":2611,"enrollment":2612,"conditions":2633,"interventions":2634},[92],[2614],[2595,2616],{"trials":2636,"activeCount":101},[],{"intervention":2638,"totalTrials":259,"cells":2639},"routine dose tacrolimus and less myfortic",{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2646,"PHASE4":2648,"NA":2662},{"trials":2641,"activeCount":101},[],{"trials":2643,"activeCount":101},[],{"trials":2645,"activeCount":101},[],{"trials":2647,"activeCount":101},[],{"trials":2649,"activeCount":101},[2650],{"nctId":2651,"briefTitle":2652,"status":232,"phases":2653,"primaryCompletion":2654,"completion":2655,"start":2656,"enrollment":2657,"conditions":2658,"interventions":2660},"NCT01159080","Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients",[92],"2016-10-30","2016-11-30","2010-04-01",350,[2659],"Kidney Transplantation",[2638,2661],"reduced dose tacrolimus and conventional myfortic",{"trials":2663,"activeCount":101},[],{"intervention":2661,"totalTrials":259,"cells":2665},{"EARLY_PHASE1":2666,"PHASE1":2668,"PHASE2":2670,"PHASE3":2672,"PHASE4":2674,"NA":2680},{"trials":2667,"activeCount":101},[],{"trials":2669,"activeCount":101},[],{"trials":2671,"activeCount":101},[],{"trials":2673,"activeCount":101},[],{"trials":2675,"activeCount":101},[2676],{"nctId":2651,"briefTitle":2652,"status":232,"phases":2677,"primaryCompletion":2654,"completion":2655,"start":2656,"enrollment":2657,"conditions":2678,"interventions":2679},[92],[2659],[2638,2661],{"trials":2681,"activeCount":101},[],{"intervention":2683,"totalTrials":259,"cells":2684},"Fibrinogen\u002Fthrombin-coated collagen patch",{"EARLY_PHASE1":2685,"PHASE1":2687,"PHASE2":2689,"PHASE3":2691,"PHASE4":2693,"NA":2707},{"trials":2686,"activeCount":101},[],{"trials":2688,"activeCount":101},[],{"trials":2690,"activeCount":101},[],{"trials":2692,"activeCount":101},[],{"trials":2694,"activeCount":101},[2695],{"nctId":2696,"briefTitle":2697,"status":127,"phases":2698,"primaryCompletion":2699,"completion":2699,"start":2700,"enrollment":2701,"conditions":2702,"interventions":2706},"NCT03269955","The Effect of Application of TachoSil® in Pancreatoduodenectomy",[92],"2018-05","2017-02-27",126,[2703,2704,2705],"Pancreatic Neoplasm","Pancreatic Periampullary Cancer","Pancreatic Bordeline Tumor",[2683],{"trials":2708,"activeCount":101},[],{"intervention":2710,"totalTrials":259,"cells":2711},"Roflumilast escalation dosage",{"EARLY_PHASE1":2712,"PHASE1":2714,"PHASE2":2716,"PHASE3":2718,"PHASE4":2720,"NA":2730},{"trials":2713,"activeCount":101},[],{"trials":2715,"activeCount":101},[],{"trials":2717,"activeCount":101},[],{"trials":2719,"activeCount":101},[],{"trials":2721,"activeCount":101},[2722],{"nctId":2723,"briefTitle":2724,"status":127,"phases":2725,"primaryCompletion":275,"completion":275,"start":915,"enrollment":8,"conditions":2726,"interventions":2728},"NCT02018432","Strategy to Improve Adherence of Roflumilast",[92],[2727],"Chronic Obstructive Pulmonary Disease",[2710,2729],"Roflumilast conventional dosage",{"trials":2731,"activeCount":101},[],{"intervention":2729,"totalTrials":259,"cells":2733},{"EARLY_PHASE1":2734,"PHASE1":2736,"PHASE2":2738,"PHASE3":2740,"PHASE4":2742,"NA":2748},{"trials":2735,"activeCount":101},[],{"trials":2737,"activeCount":101},[],{"trials":2739,"activeCount":101},[],{"trials":2741,"activeCount":101},[],{"trials":2743,"activeCount":101},[2744],{"nctId":2723,"briefTitle":2724,"status":127,"phases":2745,"primaryCompletion":275,"completion":275,"start":915,"enrollment":8,"conditions":2746,"interventions":2747},[92],[2727],[2710,2729],{"trials":2749,"activeCount":101},[],{"intervention":2751,"totalTrials":259,"cells":2752},"bisoprolol",{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2759,"PHASE4":2761,"NA":2770},{"trials":2754,"activeCount":101},[],{"trials":2756,"activeCount":101},[],{"trials":2758,"activeCount":101},[],{"trials":2760,"activeCount":101},[],{"trials":2762,"activeCount":101},[2763],{"nctId":2764,"briefTitle":2765,"status":2280,"phases":2766,"primaryCompletion":2351,"completion":2351,"start":902,"enrollment":1079,"conditions":2767,"interventions":2769},"NCT01579058","Effect of Bisoprolol on Progression of Aortic Stenosis",[92],[2768],"Aortic Stenosis",[2751],{"trials":2771,"activeCount":101},[],{"intervention":2773,"totalTrials":259,"cells":2774},"Chromogranin A",{"EARLY_PHASE1":2775,"PHASE1":2777,"PHASE2":2779,"PHASE3":2781,"PHASE4":2783,"NA":2794},{"trials":2776,"activeCount":101},[],{"trials":2778,"activeCount":101},[],{"trials":2780,"activeCount":101},[],{"trials":2782,"activeCount":101},[],{"trials":2784,"activeCount":101},[2785],{"nctId":2786,"briefTitle":2787,"status":127,"phases":2788,"primaryCompletion":1875,"completion":1875,"start":2789,"enrollment":2790,"conditions":2791,"interventions":2793},"NCT02759718","Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors",[92],"2012-06",111,[2792],"Non Functioning Pancreatic Endocrine Tumor",[2773],{"trials":2795,"activeCount":101},[],{"intervention":297,"totalTrials":259,"cells":2797},{"EARLY_PHASE1":2798,"PHASE1":2800,"PHASE2":2802,"PHASE3":2804,"PHASE4":2806,"NA":2812},{"trials":2799,"activeCount":101},[],{"trials":2801,"activeCount":101},[],{"trials":2803,"activeCount":101},[],{"trials":2805,"activeCount":101},[],{"trials":2807,"activeCount":101},[2808],{"nctId":288,"briefTitle":289,"status":232,"phases":2809,"primaryCompletion":291,"completion":291,"start":130,"enrollment":292,"conditions":2810,"interventions":2811},[92],[294,295],[297,298,263],{"trials":2813,"activeCount":101},[],{"intervention":298,"totalTrials":259,"cells":2815},{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2820,"PHASE3":2822,"PHASE4":2824,"NA":2830},{"trials":2817,"activeCount":101},[],{"trials":2819,"activeCount":101},[],{"trials":2821,"activeCount":101},[],{"trials":2823,"activeCount":101},[],{"trials":2825,"activeCount":101},[2826],{"nctId":288,"briefTitle":289,"status":232,"phases":2827,"primaryCompletion":291,"completion":291,"start":130,"enrollment":292,"conditions":2828,"interventions":2829},[92],[294,295],[297,298,263],{"trials":2831,"activeCount":101},[],{"intervention":2833,"totalTrials":259,"cells":2834},"Rivaroxaban 2.5mg",{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2839,"PHASE3":2841,"PHASE4":2843,"NA":2857},{"trials":2836,"activeCount":101},[],{"trials":2838,"activeCount":101},[],{"trials":2840,"activeCount":101},[],{"trials":2842,"activeCount":101},[],{"trials":2844,"activeCount":101},[2845],{"nctId":2846,"briefTitle":2847,"status":232,"phases":2848,"primaryCompletion":2849,"completion":2850,"start":2851,"enrollment":1485,"conditions":2852,"interventions":2856},"NCT05797376","Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation",[92],"2024-11-12","2024-12-05","2021-08-24",[2853,148,2854,2855],"Atherosclerosis of Artery","Peripheral Arterial Disease","Carotid Stenosis",[2833],{"trials":2858,"activeCount":101},[],{"intervention":2860,"totalTrials":259,"cells":2861},"Irinotecan, 5FU, leucovorin",{"EARLY_PHASE1":2862,"PHASE1":2864,"PHASE2":2866,"PHASE3":2868,"PHASE4":2870,"NA":2881},{"trials":2863,"activeCount":101},[],{"trials":2865,"activeCount":101},[],{"trials":2867,"activeCount":101},[],{"trials":2869,"activeCount":101},[],{"trials":2871,"activeCount":101},[2872],{"nctId":2873,"briefTitle":2874,"status":127,"phases":2875,"primaryCompletion":2194,"completion":2876,"start":248,"enrollment":2877,"conditions":2878,"interventions":2880},"NCT01271582","Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients",[92],"2019-12",1500,[2879,21],"Stage IV Colorectal Cancer",[2860],{"trials":2882,"activeCount":101},[],{"intervention":2884,"totalTrials":259,"cells":2885},"polyethylene glycol, Bisacodyl",{"EARLY_PHASE1":2886,"PHASE1":2888,"PHASE2":2890,"PHASE3":2892,"PHASE4":2894,"NA":2907},{"trials":2887,"activeCount":101},[],{"trials":2889,"activeCount":101},[],{"trials":2891,"activeCount":101},[],{"trials":2893,"activeCount":101},[],{"trials":2895,"activeCount":101},[2896],{"nctId":2897,"briefTitle":2898,"status":2280,"phases":2899,"primaryCompletion":2305,"completion":2305,"start":2900,"enrollment":2901,"conditions":2902,"interventions":2905},"NCT01510977","Second Bowel Preparation for Colonoscopy Failure",[92],"2011-11",150,[2903,2904],"Colonoscopy Failure","Poor Bowel Preparation",[2884,2906],"polyethylene glycol",{"trials":2908,"activeCount":101},[],{"intervention":2906,"totalTrials":259,"cells":2910},{"EARLY_PHASE1":2911,"PHASE1":2913,"PHASE2":2915,"PHASE3":2917,"PHASE4":2919,"NA":2925},{"trials":2912,"activeCount":101},[],{"trials":2914,"activeCount":101},[],{"trials":2916,"activeCount":101},[],{"trials":2918,"activeCount":101},[],{"trials":2920,"activeCount":101},[2921],{"nctId":2897,"briefTitle":2898,"status":2280,"phases":2922,"primaryCompletion":2305,"completion":2305,"start":2900,"enrollment":2901,"conditions":2923,"interventions":2924},[92],[2903,2904],[2884,2906],{"trials":2926,"activeCount":101},[],{"intervention":2928,"totalTrials":259,"cells":2929},"flucinolone acetonide",{"EARLY_PHASE1":2930,"PHASE1":2932,"PHASE2":2934,"PHASE3":2936,"PHASE4":2938,"NA":2950},{"trials":2931,"activeCount":101},[],{"trials":2933,"activeCount":101},[],{"trials":2935,"activeCount":101},[],{"trials":2937,"activeCount":101},[],{"trials":2939,"activeCount":101},[2940],{"nctId":2941,"briefTitle":2942,"status":127,"phases":2943,"primaryCompletion":2944,"completion":1968,"start":235,"enrollment":16,"conditions":2945,"interventions":2949},"NCT00720928","Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease",[92],"2009-12",[2946,2947,2948],"Ocular Behcet's Disease,","Non-Infectious Uveitis","Refractory Uveitis",[2928],{"trials":2951,"activeCount":101},[],{"intervention":2953,"totalTrials":259,"cells":2954},"Ropivacaine solution",{"EARLY_PHASE1":2955,"PHASE1":2957,"PHASE2":2959,"PHASE3":2961,"PHASE4":2963,"NA":2977},{"trials":2956,"activeCount":101},[],{"trials":2958,"activeCount":101},[],{"trials":2960,"activeCount":101},[],{"trials":2962,"activeCount":101},[],{"trials":2964,"activeCount":101},[2965],{"nctId":2966,"briefTitle":2967,"status":232,"phases":2968,"primaryCompletion":2969,"completion":2970,"start":2971,"enrollment":2972,"conditions":2973,"interventions":2975},"NCT03679897","Comparison of 0.375% Ropivacaine and 0.25% Levobupivacaine for Infraclavicular Brachial Plexus Block",[92],"2018-12-07","2018-12-08","2018-09-18",46,[2974],"Regional Anesthesia",[2953,2976],"Levobupivacaine solution",{"trials":2978,"activeCount":101},[],{"intervention":2976,"totalTrials":259,"cells":2980},{"EARLY_PHASE1":2981,"PHASE1":2983,"PHASE2":2985,"PHASE3":2987,"PHASE4":2989,"NA":2995},{"trials":2982,"activeCount":101},[],{"trials":2984,"activeCount":101},[],{"trials":2986,"activeCount":101},[],{"trials":2988,"activeCount":101},[],{"trials":2990,"activeCount":101},[2991],{"nctId":2966,"briefTitle":2967,"status":232,"phases":2992,"primaryCompletion":2969,"completion":2970,"start":2971,"enrollment":2972,"conditions":2993,"interventions":2994},[92],[2974],[2953,2976],{"trials":2996,"activeCount":101},[],{"intervention":2998,"totalTrials":259,"cells":2999},"Sandostatin",{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3004,"PHASE3":3006,"PHASE4":3008,"NA":3017},{"trials":3001,"activeCount":101},[],{"trials":3003,"activeCount":101},[],{"trials":3005,"activeCount":101},[],{"trials":3007,"activeCount":101},[],{"trials":3009,"activeCount":101},[3010],{"nctId":3011,"briefTitle":3012,"status":127,"phases":3013,"primaryCompletion":931,"completion":2876,"start":916,"enrollment":259,"conditions":3014,"interventions":3016},"NCT02427295","Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues",[92],[3015],"Acromegaly",[2998],{"trials":3018,"activeCount":101},[],{"intervention":3020,"totalTrials":259,"cells":3021},"Standard 2 hours-infusion",{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3026,"PHASE3":3028,"PHASE4":3030,"NA":3042},{"trials":3023,"activeCount":101},[],{"trials":3025,"activeCount":101},[],{"trials":3027,"activeCount":101},[],{"trials":3029,"activeCount":101},[],{"trials":3031,"activeCount":101},[3032],{"nctId":3033,"briefTitle":3034,"status":232,"phases":3035,"primaryCompletion":3036,"completion":3037,"start":988,"enrollment":2207,"conditions":3038,"interventions":3039},"NCT01346826","Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)",[92],"2015-10","2016-04",[1762,1623],[3020,3040,3041],"Accelerated 1 hour-infusion","Accelerated 30 minutes-infusion",{"trials":3043,"activeCount":101},[],{"intervention":3040,"totalTrials":259,"cells":3045},{"EARLY_PHASE1":3046,"PHASE1":3048,"PHASE2":3050,"PHASE3":3052,"PHASE4":3054,"NA":3060},{"trials":3047,"activeCount":101},[],{"trials":3049,"activeCount":101},[],{"trials":3051,"activeCount":101},[],{"trials":3053,"activeCount":101},[],{"trials":3055,"activeCount":101},[3056],{"nctId":3033,"briefTitle":3034,"status":232,"phases":3057,"primaryCompletion":3036,"completion":3037,"start":988,"enrollment":2207,"conditions":3058,"interventions":3059},[92],[1762,1623],[3020,3040,3041],{"trials":3061,"activeCount":101},[],{"intervention":3041,"totalTrials":259,"cells":3063},{"EARLY_PHASE1":3064,"PHASE1":3066,"PHASE2":3068,"PHASE3":3070,"PHASE4":3072,"NA":3078},{"trials":3065,"activeCount":101},[],{"trials":3067,"activeCount":101},[],{"trials":3069,"activeCount":101},[],{"trials":3071,"activeCount":101},[],{"trials":3073,"activeCount":101},[3074],{"nctId":3033,"briefTitle":3034,"status":232,"phases":3075,"primaryCompletion":3036,"completion":3037,"start":988,"enrollment":2207,"conditions":3076,"interventions":3077},[92],[1762,1623],[3020,3040,3041],{"trials":3079,"activeCount":101},[],{"intervention":3081,"totalTrials":259,"cells":3082},"Thymoglobulin",{"EARLY_PHASE1":3083,"PHASE1":3085,"PHASE2":3087,"PHASE3":3089,"PHASE4":3091,"NA":3102},{"trials":3084,"activeCount":101},[],{"trials":3086,"activeCount":101},[],{"trials":3088,"activeCount":101},[],{"trials":3090,"activeCount":101},[],{"trials":3092,"activeCount":101},[3093],{"nctId":3094,"briefTitle":3095,"status":127,"phases":3096,"primaryCompletion":2699,"completion":2699,"start":3097,"enrollment":3098,"conditions":3099,"interventions":3101},"NCT02447822","Thymoglobulin Induction Therapy in Kidney Transplantation (6mg\u002Fkg vs 4mg\u002Fkg)",[92],"2015-06",154,[3100],"Kidney Failure",[3081],{"trials":3103,"activeCount":101},[],{"intervention":3105,"totalTrials":259,"cells":3106},"original sevoflurane",{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3113,"PHASE4":3115,"NA":3131},{"trials":3108,"activeCount":101},[],{"trials":3110,"activeCount":101},[],{"trials":3112,"activeCount":101},[],{"trials":3114,"activeCount":101},[],{"trials":3116,"activeCount":101},[3117],{"nctId":3118,"briefTitle":3119,"status":232,"phases":3120,"primaryCompletion":3121,"completion":3122,"start":3123,"enrollment":3124,"conditions":3125,"interventions":3129},"NCT01096212","Efficacy and Safety of Sevofran in Patients Scheduled for Elective Surgery Under General Anesthesia",[92],"2009-09","2010-03","2008-09",178,[3126,3127,3128],"General Anesthesia","Sevoflurane","Generic Drugs",[3105,3130],"generic sevoflurane",{"trials":3132,"activeCount":101},[],{"intervention":3130,"totalTrials":259,"cells":3134},{"EARLY_PHASE1":3135,"PHASE1":3137,"PHASE2":3139,"PHASE3":3141,"PHASE4":3143,"NA":3149},{"trials":3136,"activeCount":101},[],{"trials":3138,"activeCount":101},[],{"trials":3140,"activeCount":101},[],{"trials":3142,"activeCount":101},[],{"trials":3144,"activeCount":101},[3145],{"nctId":3118,"briefTitle":3119,"status":232,"phases":3146,"primaryCompletion":3121,"completion":3122,"start":3123,"enrollment":3124,"conditions":3147,"interventions":3148},[92],[3126,3127,3128],[3105,3130],{"trials":3150,"activeCount":101},[],{"intervention":3152,"totalTrials":259,"cells":3153},"Evogliptin",{"EARLY_PHASE1":3154,"PHASE1":3156,"PHASE2":3158,"PHASE3":3160,"PHASE4":3162,"NA":3174},{"trials":3155,"activeCount":101},[],{"trials":3157,"activeCount":101},[],{"trials":3159,"activeCount":101},[],{"trials":3161,"activeCount":101},[],{"trials":3163,"activeCount":101},[3164],{"nctId":3165,"briefTitle":3166,"status":127,"phases":3167,"primaryCompletion":3168,"completion":3168,"start":3169,"enrollment":3170,"conditions":3171,"interventions":3173},"NCT04521452","Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD",[92],"2024-09","2020-09",218,[3172],"CAVD",[3152],{"trials":3175,"activeCount":101},[],{"intervention":3177,"totalTrials":259,"cells":3178},"Oral administration of Ipragliflozin",{"EARLY_PHASE1":3179,"PHASE1":3181,"PHASE2":3183,"PHASE3":3185,"PHASE4":3187,"NA":3198},{"trials":3180,"activeCount":101},[],{"trials":3182,"activeCount":101},[],{"trials":3184,"activeCount":101},[],{"trials":3186,"activeCount":101},[],{"trials":3188,"activeCount":101},[3189],{"nctId":3190,"briefTitle":3191,"status":232,"phases":3192,"primaryCompletion":3193,"completion":3193,"start":3194,"enrollment":1598,"conditions":3195,"interventions":3197},"NCT02791035","Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin",[92],"2017-03","2016-06",[3196],"Type 2 Diabetes Mellitus",[3177],{"trials":3199,"activeCount":101},[],{"intervention":3201,"totalTrials":259,"cells":3202},"Escitalopram",{"EARLY_PHASE1":3203,"PHASE1":3205,"PHASE2":3207,"PHASE3":3209,"PHASE4":3211,"NA":3222},{"trials":3204,"activeCount":101},[],{"trials":3206,"activeCount":101},[],{"trials":3208,"activeCount":101},[],{"trials":3210,"activeCount":101},[],{"trials":3212,"activeCount":101},[3213],{"nctId":3214,"briefTitle":3215,"status":127,"phases":3216,"primaryCompletion":978,"completion":275,"start":943,"enrollment":3217,"conditions":3218,"interventions":3220},"NCT01278498","The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients",[92],444,[3219],"Depression",[3201,3221],"sugar pill",{"trials":3223,"activeCount":101},[],{"intervention":3221,"totalTrials":259,"cells":3225},{"EARLY_PHASE1":3226,"PHASE1":3228,"PHASE2":3230,"PHASE3":3232,"PHASE4":3234,"NA":3240},{"trials":3227,"activeCount":101},[],{"trials":3229,"activeCount":101},[],{"trials":3231,"activeCount":101},[],{"trials":3233,"activeCount":101},[],{"trials":3235,"activeCount":101},[3236],{"nctId":3214,"briefTitle":3215,"status":127,"phases":3237,"primaryCompletion":978,"completion":275,"start":943,"enrollment":3217,"conditions":3238,"interventions":3239},[92],[3219],[3201,3221],{"trials":3241,"activeCount":101},[],{"intervention":3243,"totalTrials":259,"cells":3244},"Fimasartan",{"EARLY_PHASE1":3245,"PHASE1":3247,"PHASE2":3249,"PHASE3":3251,"PHASE4":3253,"NA":3263},{"trials":3246,"activeCount":101},[],{"trials":3248,"activeCount":101},[],{"trials":3250,"activeCount":101},[],{"trials":3252,"activeCount":101},[],{"trials":3254,"activeCount":101},[3255],{"nctId":3256,"briefTitle":3257,"status":232,"phases":3258,"primaryCompletion":3259,"completion":3259,"start":979,"enrollment":651,"conditions":3260,"interventions":3261},"NCT01691118","A Trial of Fimasartan for Early Diastolic Heart Failure",[92],"2015-08",[2026],[3243,3262],"Antihypertensive treatment",{"trials":3264,"activeCount":101},[],{"intervention":3262,"totalTrials":259,"cells":3266},{"EARLY_PHASE1":3267,"PHASE1":3269,"PHASE2":3271,"PHASE3":3273,"PHASE4":3275,"NA":3281},{"trials":3268,"activeCount":101},[],{"trials":3270,"activeCount":101},[],{"trials":3272,"activeCount":101},[],{"trials":3274,"activeCount":101},[],{"trials":3276,"activeCount":101},[3277],{"nctId":3256,"briefTitle":3257,"status":232,"phases":3278,"primaryCompletion":3259,"completion":3259,"start":979,"enrollment":651,"conditions":3279,"interventions":3280},[92],[2026],[3243,3262],{"trials":3282,"activeCount":101},[],{"intervention":3284,"totalTrials":259,"cells":3285},"Alfuzosin",{"EARLY_PHASE1":3286,"PHASE1":3288,"PHASE2":3290,"PHASE3":3292,"PHASE4":3294,"NA":3306},{"trials":3287,"activeCount":101},[],{"trials":3289,"activeCount":101},[],{"trials":3291,"activeCount":101},[],{"trials":3293,"activeCount":101},[],{"trials":3295,"activeCount":101},[3296],{"nctId":3297,"briefTitle":3298,"status":232,"phases":3299,"primaryCompletion":235,"completion":3300,"start":3301,"enrollment":3302,"conditions":3303,"interventions":3305},"NCT00696761","The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)\u002FBPH Patients",[92],"2008-08","2006-05",232,[3304],"BPH",[3284,3284,3284,3284],{"trials":3307,"activeCount":101},[],{"intervention":3309,"totalTrials":259,"cells":3310},"aspirin and\u002For clopidogrel",{"EARLY_PHASE1":3311,"PHASE1":3313,"PHASE2":3315,"PHASE3":3317,"PHASE4":3319,"NA":3330},{"trials":3312,"activeCount":101},[],{"trials":3314,"activeCount":101},[],{"trials":3316,"activeCount":101},[],{"trials":3318,"activeCount":101},[],{"trials":3320,"activeCount":101},[3321],{"nctId":3322,"briefTitle":3323,"status":127,"phases":3324,"primaryCompletion":2351,"completion":2194,"start":2789,"enrollment":3325,"conditions":3326,"interventions":3329},"NCT01621451","Does Early Re-administration of Aspirin\u002FClopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD?",[92],400,[3327,3328],"Early Gastric Cancer","Gastric Dysplasia",[3309,3309],{"trials":3331,"activeCount":101},[],{"intervention":549,"totalTrials":834,"cells":3333},{"EARLY_PHASE1":3334,"PHASE1":3336,"PHASE2":3338,"PHASE3":3364,"PHASE4":3374,"NA":3376},{"trials":3335,"activeCount":101},[],{"trials":3337,"activeCount":101},[],{"trials":3339,"activeCount":101},[3340,3344,3353],{"nctId":1155,"briefTitle":1156,"status":127,"phases":3341,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":3342,"interventions":3343},[90],[1162],[1071,549],{"nctId":3345,"briefTitle":3346,"status":127,"phases":3347,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":3348,"conditions":3349,"interventions":3351},"NCT01461759","Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer",[90],59,[3350],"Advanced or Recurrent Endometrial Cancer",[3352,549],"Doctaxel",{"nctId":3354,"briefTitle":3355,"status":232,"phases":3356,"primaryCompletion":915,"completion":915,"start":235,"enrollment":3357,"conditions":3358,"interventions":3360},"NCT01490437","Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma",[90],42,[3359],"Urothelial Carcinoma",[3361,549,3362,3363],"Pemetrexed","Dexamethasone","Vitamins",{"trials":3365,"activeCount":101},[3366],{"nctId":3367,"briefTitle":3368,"status":2280,"phases":3369,"primaryCompletion":2351,"completion":2351,"start":2944,"enrollment":3370,"conditions":3371,"interventions":3372},"NCT01461772","Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer",[91],21,[32],[3373,549],"Carboplatin",{"trials":3375,"activeCount":101},[],{"trials":3377,"activeCount":101},[],{"intervention":3373,"totalTrials":171,"cells":3379},{"EARLY_PHASE1":3380,"PHASE1":3382,"PHASE2":3384,"PHASE3":3406,"PHASE4":3412,"NA":3414},{"trials":3381,"activeCount":101},[],{"trials":3383,"activeCount":101},[],{"trials":3385,"activeCount":101},[3386,3397],{"nctId":3387,"briefTitle":3388,"status":127,"phases":3389,"start":3390,"enrollment":3391,"conditions":3392,"interventions":3394},"NCT00886717","Paclitaxel-Loaded Polymeric Micelle and Carboplatin as First-Line Therapy in Treating Patients With Advanced Ovarian Cancer",[89,90],"2008-05",74,[3393],"Ovarian Cancer",[3395,3396],"carboplatin","paclitaxel-loaded polymeric micelle",{"nctId":3398,"briefTitle":3399,"status":232,"phases":3400,"primaryCompletion":3194,"completion":3194,"start":1159,"enrollment":3401,"conditions":3402,"interventions":3404},"NCT01462149","Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer",[90],43,[3403],"Advanced Ovarian Cancer",[3405,3373],"Neoadjuvant chemotherapy",{"trials":3407,"activeCount":101},[3408],{"nctId":3367,"briefTitle":3368,"status":2280,"phases":3409,"primaryCompletion":2351,"completion":2351,"start":2944,"enrollment":3370,"conditions":3410,"interventions":3411},[91],[32],[3373,549],{"trials":3413,"activeCount":101},[],{"trials":3415,"activeCount":101},[],{"intervention":950,"totalTrials":176,"cells":3417},{"EARLY_PHASE1":3418,"PHASE1":3420,"PHASE2":3422,"PHASE3":3428,"PHASE4":3438,"NA":3440},{"trials":3419,"activeCount":101},[],{"trials":3421,"activeCount":101},[],{"trials":3423,"activeCount":101},[3424],{"nctId":940,"briefTitle":941,"status":232,"phases":3425,"primaryCompletion":943,"completion":943,"start":944,"enrollment":945,"conditions":3426,"interventions":3427},[89,90],[947,948],[950,890,951,952,953,954],{"trials":3429,"activeCount":101},[3430],{"nctId":3431,"briefTitle":3432,"status":127,"phases":3433,"primaryCompletion":275,"completion":275,"start":3434,"enrollment":933,"conditions":3435,"interventions":3436},"NCT02351427","Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation",[91],"2015-02",[2659],[950,3437],"Steroid",{"trials":3439,"activeCount":101},[],{"trials":3441,"activeCount":101},[],{"intervention":3443,"totalTrials":176,"cells":3444},"Imatinib",{"EARLY_PHASE1":3445,"PHASE1":3447,"PHASE2":3449,"PHASE3":3461,"PHASE4":3470,"NA":3472},{"trials":3446,"activeCount":101},[],{"trials":3448,"activeCount":101},[],{"trials":3450,"activeCount":101},[3451],{"nctId":3452,"briefTitle":3453,"status":127,"phases":3454,"primaryCompletion":3455,"completion":3455,"start":3456,"enrollment":3457,"conditions":3458,"interventions":3459},"NCT01541709","Imatinib Dose Escalation to 800 mg\u002FDay in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI",[90],"2024-12-31","2012-03",23,[18],[3460],"imatinib",{"trials":3462,"activeCount":101},[3463],{"nctId":3464,"briefTitle":3465,"status":232,"phases":3466,"primaryCompletion":2306,"completion":2306,"start":2567,"enrollment":3467,"conditions":3468,"interventions":3469},"NCT01151852","Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT",[91],81,[18],[3443],{"trials":3471,"activeCount":101},[],{"trials":3473,"activeCount":101},[],{"intervention":3475,"totalTrials":176,"cells":3476},"Sorafenib",{"EARLY_PHASE1":3477,"PHASE1":3479,"PHASE2":3481,"PHASE3":3493,"PHASE4":3504,"NA":3506},{"trials":3478,"activeCount":101},[],{"trials":3480,"activeCount":101},[],{"trials":3482,"activeCount":101},[3483],{"nctId":3484,"briefTitle":3485,"status":127,"phases":3486,"primaryCompletion":1158,"completion":3487,"start":978,"enrollment":3488,"conditions":3489,"interventions":3491},"NCT02311205","Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)",[90],"2018-06",55,[15,3490],"Metastasis",[3492],"sorafenib",{"trials":3494,"activeCount":101},[3495],{"nctId":3496,"briefTitle":3497,"status":232,"phases":3498,"primaryCompletion":3499,"completion":3500,"start":3501,"enrollment":1866,"conditions":3502,"interventions":3503},"NCT01901692","Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion",[90,91],"2017-01-20","2017-08-31","2013-07-29",[15],[3475],{"trials":3505,"activeCount":101},[],{"trials":3507,"activeCount":101},[],{"intervention":3509,"totalTrials":176,"cells":3510},"[18F]fluoroestradiol",{"EARLY_PHASE1":3511,"PHASE1":3513,"PHASE2":3515,"PHASE3":3526,"PHASE4":3538,"NA":3540},{"trials":3512,"activeCount":101},[],{"trials":3514,"activeCount":101},[],{"trials":3516,"activeCount":101},[3517],{"nctId":3518,"briefTitle":3519,"status":232,"phases":3520,"primaryCompletion":3521,"completion":3521,"start":3522,"enrollment":3457,"conditions":3523,"interventions":3525},"NCT05960201","Diagnostic Performance of [18F]FES PET\u002FCT for Axillary LN Metastasis in Invasive Lobular Carcinoma",[90],"2024-08-20","2023-08-10",[3524],"Carcinoma, Lobular",[3509],{"trials":3527,"activeCount":101},[3528],{"nctId":3529,"briefTitle":3530,"status":232,"phases":3531,"primaryCompletion":970,"completion":970,"start":3532,"enrollment":3533,"conditions":3534,"interventions":3537},"NCT01986569","Diagnostic Accuracy and Safety Study of FES PET\u002FCT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer",[91],"2013-11",93,[3535,3536],"Recurrent Breast Cancer","Stage IV Breast Cancer",[3509],{"trials":3539,"activeCount":101},[],{"trials":3541,"activeCount":101},[],{"intervention":3543,"totalTrials":176,"cells":3544},"pemetrexed",{"EARLY_PHASE1":3545,"PHASE1":3547,"PHASE2":3549,"PHASE3":3555,"PHASE4":3569,"NA":3571},{"trials":3546,"activeCount":101},[],{"trials":3548,"activeCount":101},[],{"trials":3550,"activeCount":101},[3551],{"nctId":3354,"briefTitle":3355,"status":232,"phases":3552,"primaryCompletion":915,"completion":915,"start":235,"enrollment":3357,"conditions":3553,"interventions":3554},[90],[3359],[3361,549,3362,3363],{"trials":3556,"activeCount":101},[3557],{"nctId":3558,"briefTitle":3559,"status":127,"phases":3560,"primaryCompletion":2876,"completion":3561,"start":932,"enrollment":3391,"conditions":3562,"interventions":3566},"NCT03193788","Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy",[91],"2020-06",[3563,3564,3565],"Bladder Cancer","Ureter Cancer","Transitional Cell Carcinoma",[3543,3567,3568,3362],"Folic Acid","Vitamin B12",{"trials":3570,"activeCount":101},[],{"trials":3572,"activeCount":101},[],{"intervention":3362,"totalTrials":176,"cells":3574},{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3579,"PHASE3":3585,"PHASE4":3591,"NA":3593},{"trials":3576,"activeCount":101},[],{"trials":3578,"activeCount":101},[],{"trials":3580,"activeCount":101},[3581],{"nctId":3354,"briefTitle":3355,"status":232,"phases":3582,"primaryCompletion":915,"completion":915,"start":235,"enrollment":3357,"conditions":3583,"interventions":3584},[90],[3359],[3361,549,3362,3363],{"trials":3586,"activeCount":101},[3587],{"nctId":3558,"briefTitle":3559,"status":127,"phases":3588,"primaryCompletion":2876,"completion":3561,"start":932,"enrollment":3391,"conditions":3589,"interventions":3590},[91],[3563,3564,3565],[3543,3567,3568,3362],{"trials":3592,"activeCount":101},[],{"trials":3594,"activeCount":101},[],{"intervention":3596,"totalTrials":259,"cells":3597},"Treatment duration of cisplatin based chemotherapy",{"EARLY_PHASE1":3598,"PHASE1":3600,"PHASE2":3602,"PHASE3":3604,"PHASE4":3615,"NA":3617},{"trials":3599,"activeCount":101},[],{"trials":3601,"activeCount":101},[],{"trials":3603,"activeCount":101},[],{"trials":3605,"activeCount":101},[3606],{"nctId":3607,"briefTitle":3608,"status":127,"phases":3609,"primaryCompletion":3610,"completion":3611,"start":129,"enrollment":625,"conditions":3612,"interventions":3614},"NCT03296306","Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma",[91],"2021-08","2022-02",[3563,3564,3613,3565],"Urethral Cancer",[3596],{"trials":3616,"activeCount":101},[],{"trials":3618,"activeCount":101},[],{"intervention":3620,"totalTrials":259,"cells":3621},"cisplatin, mitomycin-C, doxifluridine",{"EARLY_PHASE1":3622,"PHASE1":3624,"PHASE2":3626,"PHASE3":3628,"PHASE4":3640,"NA":3642},{"trials":3623,"activeCount":101},[],{"trials":3625,"activeCount":101},[],{"trials":3627,"activeCount":101},[],{"trials":3629,"activeCount":101},[3630],{"nctId":3631,"briefTitle":3632,"status":232,"phases":3633,"primaryCompletion":3634,"completion":3122,"start":3635,"enrollment":3636,"conditions":3637,"interventions":3639},"NCT00296322","Trial of Adjuvant Chemotherapy for Gastric Cancer",[91],"2007-12","2001-10",528,[3638],"Stomach Cancer",[3620],{"trials":3641,"activeCount":101},[],{"trials":3643,"activeCount":101},[],{"intervention":3645,"totalTrials":259,"cells":3646},"S-1 Chemotherapy",{"EARLY_PHASE1":3647,"PHASE1":3649,"PHASE2":3651,"PHASE3":3653,"PHASE4":3664,"NA":3666},{"trials":3648,"activeCount":101},[],{"trials":3650,"activeCount":101},[],{"trials":3652,"activeCount":101},[],{"trials":3654,"activeCount":101},[3655],{"nctId":3656,"briefTitle":3657,"status":232,"phases":3658,"primaryCompletion":3659,"completion":3660,"start":3661,"enrollment":3401,"conditions":3662,"interventions":3663},"NCT00869635","S-1 and Photodynamic Therapy in Cholangiocarcinoma",[91],"2013-07","2013-08","2009-02",[545],[3645],{"trials":3665,"activeCount":101},[],{"trials":3667,"activeCount":101},[],{"intervention":1858,"totalTrials":259,"cells":3669},{"EARLY_PHASE1":3670,"PHASE1":3672,"PHASE2":3674,"PHASE3":3676,"PHASE4":3682,"NA":3684},{"trials":3671,"activeCount":101},[],{"trials":3673,"activeCount":101},[],{"trials":3675,"activeCount":101},[],{"trials":3677,"activeCount":101},[3678],{"nctId":1850,"briefTitle":1851,"status":232,"phases":3679,"primaryCompletion":978,"completion":978,"start":1853,"enrollment":1854,"conditions":3680,"interventions":3681},[91],[1856],[1858,1839],{"trials":3683,"activeCount":101},[],{"trials":3685,"activeCount":101},[],{"intervention":3687,"totalTrials":259,"cells":3688},"R-CHOP",{"EARLY_PHASE1":3689,"PHASE1":3691,"PHASE2":3693,"PHASE3":3695,"PHASE4":3706,"NA":3708},{"trials":3690,"activeCount":101},[],{"trials":3692,"activeCount":101},[],{"trials":3694,"activeCount":101},[],{"trials":3696,"activeCount":101},[3697],{"nctId":3698,"briefTitle":3699,"status":3700,"phases":3701,"primaryCompletion":3702,"completion":3702,"enrollment":101,"conditions":3703,"interventions":3705},"NCT02054559","R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL","WITHDRAWN",[91],"2020-01",[3704],"Diffuse Large B-cell Lymphoma",[3687],{"trials":3707,"activeCount":101},[],{"trials":3709,"activeCount":101},[],{"intervention":3711,"totalTrials":259,"cells":3712},"S-1 and cisplatin",{"EARLY_PHASE1":3713,"PHASE1":3715,"PHASE2":3717,"PHASE3":3719,"PHASE4":3730,"NA":3732},{"trials":3714,"activeCount":101},[],{"trials":3716,"activeCount":101},[],{"trials":3718,"activeCount":101},[],{"trials":3720,"activeCount":101},[3721],{"nctId":3722,"briefTitle":3723,"status":232,"phases":3724,"primaryCompletion":3725,"completion":3725,"start":248,"enrollment":3726,"conditions":3727,"interventions":3729},"NCT00915382","Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS",[91],"2013-05",625,[3728],"Advanced Gastric Cancer",[3711,3711],{"trials":3731,"activeCount":101},[],{"trials":3733,"activeCount":101},[],{"intervention":3437,"totalTrials":259,"cells":3735},{"EARLY_PHASE1":3736,"PHASE1":3738,"PHASE2":3740,"PHASE3":3742,"PHASE4":3748,"NA":3750},{"trials":3737,"activeCount":101},[],{"trials":3739,"activeCount":101},[],{"trials":3741,"activeCount":101},[],{"trials":3743,"activeCount":101},[3744],{"nctId":3431,"briefTitle":3432,"status":127,"phases":3745,"primaryCompletion":275,"completion":275,"start":3434,"enrollment":933,"conditions":3746,"interventions":3747},[91],[2659],[950,3437],{"trials":3749,"activeCount":101},[],{"trials":3751,"activeCount":101},[],{"intervention":3753,"totalTrials":259,"cells":3754},"L-carnitine",{"EARLY_PHASE1":3755,"PHASE1":3757,"PHASE2":3759,"PHASE3":3761,"PHASE4":3770,"NA":3772},{"trials":3756,"activeCount":101},[],{"trials":3758,"activeCount":101},[],{"trials":3760,"activeCount":101},[],{"trials":3762,"activeCount":101},[3763],{"nctId":3764,"briefTitle":3765,"status":232,"phases":3766,"primaryCompletion":3767,"completion":3767,"start":596,"enrollment":834,"conditions":3768,"interventions":3769},"NCT03426722","L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors",[91],"2019-12-24",[1031],[3753],{"trials":3771,"activeCount":101},[],{"trials":3773,"activeCount":101},[],{"intervention":3775,"totalTrials":259,"cells":3776},"Carvedilol+Empagliflozin",{"EARLY_PHASE1":3777,"PHASE1":3779,"PHASE2":3781,"PHASE3":3783,"PHASE4":3796,"NA":3798},{"trials":3778,"activeCount":101},[],{"trials":3780,"activeCount":101},[],{"trials":3782,"activeCount":101},[],{"trials":3784,"activeCount":101},[3785],{"nctId":3786,"briefTitle":3787,"status":232,"phases":3788,"primaryCompletion":3789,"completion":3789,"start":3790,"enrollment":11,"conditions":3791,"interventions":3793},"NCT04345796","Pharmacological Reduction of Right Ventricular Enlargement",[91],"2024-06-03","2021-02-15",[825,3792],"Right Ventricular Dilatation",[3775,3794,3795],"Carvedilol","Empagliflozin",{"trials":3797,"activeCount":101},[],{"trials":3799,"activeCount":101},[],{"intervention":3794,"totalTrials":259,"cells":3801},{"EARLY_PHASE1":3802,"PHASE1":3804,"PHASE2":3806,"PHASE3":3808,"PHASE4":3814,"NA":3816},{"trials":3803,"activeCount":101},[],{"trials":3805,"activeCount":101},[],{"trials":3807,"activeCount":101},[],{"trials":3809,"activeCount":101},[3810],{"nctId":3786,"briefTitle":3787,"status":232,"phases":3811,"primaryCompletion":3789,"completion":3789,"start":3790,"enrollment":11,"conditions":3812,"interventions":3813},[91],[825,3792],[3775,3794,3795],{"trials":3815,"activeCount":101},[],{"trials":3817,"activeCount":101},[],{"intervention":3795,"totalTrials":259,"cells":3819},{"EARLY_PHASE1":3820,"PHASE1":3822,"PHASE2":3824,"PHASE3":3826,"PHASE4":3832,"NA":3834},{"trials":3821,"activeCount":101},[],{"trials":3823,"activeCount":101},[],{"trials":3825,"activeCount":101},[],{"trials":3827,"activeCount":101},[3828],{"nctId":3786,"briefTitle":3787,"status":232,"phases":3829,"primaryCompletion":3789,"completion":3789,"start":3790,"enrollment":11,"conditions":3830,"interventions":3831},[91],[825,3792],[3775,3794,3795],{"trials":3833,"activeCount":101},[],{"trials":3835,"activeCount":101},[],{"intervention":2199,"totalTrials":259,"cells":3837},{"EARLY_PHASE1":3838,"PHASE1":3840,"PHASE2":3842,"PHASE3":3844,"PHASE4":3850,"NA":3852},{"trials":3839,"activeCount":101},[],{"trials":3841,"activeCount":101},[],{"trials":3843,"activeCount":101},[],{"trials":3845,"activeCount":101},[3846],{"nctId":2191,"briefTitle":2192,"status":127,"phases":3847,"primaryCompletion":2194,"completion":978,"start":2195,"enrollment":761,"conditions":3848,"interventions":3849},[91],[2197],[2180,2199],{"trials":3851,"activeCount":101},[],{"trials":3853,"activeCount":101},[],{"intervention":3855,"totalTrials":259,"cells":3856},"FEC3-D3",{"EARLY_PHASE1":3857,"PHASE1":3859,"PHASE2":3861,"PHASE3":3863,"PHASE4":3873,"NA":3875},{"trials":3858,"activeCount":101},[],{"trials":3860,"activeCount":101},[],{"trials":3862,"activeCount":101},[],{"trials":3864,"activeCount":101},[3865],{"nctId":3866,"briefTitle":3867,"status":232,"phases":3868,"primaryCompletion":275,"completion":275,"start":3869,"enrollment":3870,"conditions":3871,"interventions":3872},"NCT02001506","Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer",[91],"2012-11",250,[27],[3855],{"trials":3874,"activeCount":101},[],{"trials":3876,"activeCount":101},[],{"intervention":3567,"totalTrials":259,"cells":3878},{"EARLY_PHASE1":3879,"PHASE1":3881,"PHASE2":3883,"PHASE3":3885,"PHASE4":3891,"NA":3893},{"trials":3880,"activeCount":101},[],{"trials":3882,"activeCount":101},[],{"trials":3884,"activeCount":101},[],{"trials":3886,"activeCount":101},[3887],{"nctId":3558,"briefTitle":3559,"status":127,"phases":3888,"primaryCompletion":2876,"completion":3561,"start":932,"enrollment":3391,"conditions":3889,"interventions":3890},[91],[3563,3564,3565],[3543,3567,3568,3362],{"trials":3892,"activeCount":101},[],{"trials":3894,"activeCount":101},[],{"intervention":3568,"totalTrials":259,"cells":3896},{"EARLY_PHASE1":3897,"PHASE1":3899,"PHASE2":3901,"PHASE3":3903,"PHASE4":3909,"NA":3911},{"trials":3898,"activeCount":101},[],{"trials":3900,"activeCount":101},[],{"trials":3902,"activeCount":101},[],{"trials":3904,"activeCount":101},[3905],{"nctId":3558,"briefTitle":3559,"status":127,"phases":3906,"primaryCompletion":2876,"completion":3561,"start":932,"enrollment":3391,"conditions":3907,"interventions":3908},[91],[3563,3564,3565],[3543,3567,3568,3362],{"trials":3910,"activeCount":101},[],{"trials":3912,"activeCount":101},[],{"intervention":3914,"totalTrials":259,"cells":3915},"Ertugliflozin",{"EARLY_PHASE1":3916,"PHASE1":3918,"PHASE2":3920,"PHASE3":3922,"PHASE4":3934,"NA":3936},{"trials":3917,"activeCount":101},[],{"trials":3919,"activeCount":101},[],{"trials":3921,"activeCount":101},[],{"trials":3923,"activeCount":101},[3924],{"nctId":3925,"briefTitle":3926,"status":232,"phases":3927,"primaryCompletion":3928,"completion":3928,"start":3929,"enrollment":3930,"conditions":3931,"interventions":3933},"NCT04231331","Ertugliflozin for Functional Mitral Regurgitation",[91],"2023-11-15","2020-11-04",128,[2015,3932],"Left Ventricular Systolic Dysfunction",[3914],{"trials":3935,"activeCount":101},[],{"trials":3937,"activeCount":101},[],{"intervention":3939,"totalTrials":259,"cells":3940},"F-18 FPCIT",{"EARLY_PHASE1":3941,"PHASE1":3943,"PHASE2":3945,"PHASE3":3947,"PHASE4":3959,"NA":3961},{"trials":3942,"activeCount":101},[],{"trials":3944,"activeCount":101},[],{"trials":3946,"activeCount":101},[],{"trials":3948,"activeCount":101},[3949],{"nctId":3950,"briefTitle":3951,"status":232,"phases":3952,"primaryCompletion":3953,"completion":3954,"start":3955,"enrollment":1793,"conditions":3956,"interventions":3958},"NCT00468078","Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients",[91],"2007-09","2007-10","2006-11",[3957],"Parkinson's Disease",[3939],{"trials":3960,"activeCount":101},[],{"trials":3962,"activeCount":101},[],{"intervention":3964,"totalTrials":259,"cells":3965},"Mitomycin, doxifluridine and cisplatin",{"EARLY_PHASE1":3966,"PHASE1":3968,"PHASE2":3970,"PHASE3":3972,"PHASE4":3983,"NA":3985},{"trials":3967,"activeCount":101},[],{"trials":3969,"activeCount":101},[],{"trials":3971,"activeCount":101},[],{"trials":3973,"activeCount":101},[3974],{"nctId":3975,"briefTitle":3632,"status":232,"phases":3976,"primaryCompletion":3977,"completion":2944,"start":3978,"enrollment":3979,"conditions":3980,"interventions":3981},"NCT00296335",[91],"2007-11","2002-02",855,[3638],[3964,3982],"Mitomycin and doxifluridine",{"trials":3984,"activeCount":101},[],{"trials":3986,"activeCount":101},[],{"intervention":3982,"totalTrials":259,"cells":3988},{"EARLY_PHASE1":3989,"PHASE1":3991,"PHASE2":3993,"PHASE3":3995,"PHASE4":4001,"NA":4003},{"trials":3990,"activeCount":101},[],{"trials":3992,"activeCount":101},[],{"trials":3994,"activeCount":101},[],{"trials":3996,"activeCount":101},[3997],{"nctId":3975,"briefTitle":3632,"status":232,"phases":3998,"primaryCompletion":3977,"completion":2944,"start":3978,"enrollment":3979,"conditions":3999,"interventions":4000},[91],[3638],[3964,3982],{"trials":4002,"activeCount":101},[],{"trials":4004,"activeCount":101},[],{"intervention":4006,"totalTrials":259,"cells":4007},"6% hydroxyethyl starch 130\u002F0.4",{"EARLY_PHASE1":4008,"PHASE1":4010,"PHASE2":4012,"PHASE3":4014,"PHASE4":4026,"NA":4028},{"trials":4009,"activeCount":101},[],{"trials":4011,"activeCount":101},[],{"trials":4013,"activeCount":101},[],{"trials":4015,"activeCount":101},[4016],{"nctId":4017,"briefTitle":4018,"status":232,"phases":4019,"primaryCompletion":4020,"completion":917,"start":4021,"enrollment":1598,"conditions":4022,"interventions":4024},"NCT01758172","Comparison of Hemodynamic Effects of Two Colloid Therapies in Post-operative Patients Undergoing Pancreaticoduodenectomy",[91],"2010-10","2009-10",[4023],"Pancreaticoduodenectomy",[4006,4025],"Albumin",{"trials":4027,"activeCount":101},[],{"trials":4029,"activeCount":101},[],{"intervention":4025,"totalTrials":259,"cells":4031},{"EARLY_PHASE1":4032,"PHASE1":4034,"PHASE2":4036,"PHASE3":4038,"PHASE4":4044,"NA":4046},{"trials":4033,"activeCount":101},[],{"trials":4035,"activeCount":101},[],{"trials":4037,"activeCount":101},[],{"trials":4039,"activeCount":101},[4040],{"nctId":4017,"briefTitle":4018,"status":232,"phases":4041,"primaryCompletion":4020,"completion":917,"start":4021,"enrollment":1598,"conditions":4042,"interventions":4043},[91],[4023],[4006,4025],{"trials":4045,"activeCount":101},[],{"trials":4047,"activeCount":101},[],{"intervention":4049,"totalTrials":259,"cells":4050},"Sildenafil",{"EARLY_PHASE1":4051,"PHASE1":4053,"PHASE2":4055,"PHASE3":4057,"PHASE4":4068,"NA":4070},{"trials":4052,"activeCount":101},[],{"trials":4054,"activeCount":101},[],{"trials":4056,"activeCount":101},[],{"trials":4058,"activeCount":101},[4059],{"nctId":4060,"briefTitle":4061,"status":2280,"phases":4062,"primaryCompletion":3487,"completion":3487,"start":4063,"enrollment":176,"conditions":4064,"interventions":4067},"NCT02435303","Effect of Sildenafil for Sustained PAH After MV Surgery (SUPERIOR Trial)",[90,91],"2016-05",[4065,4066],"Hypertension, Pulmonary","Diseases of Mitral Valve",[4049],{"trials":4069,"activeCount":101},[],{"trials":4071,"activeCount":101},[],{"intervention":4073,"totalTrials":259,"cells":4074},"Adriamycin+Cyclophosphamide>Docetaxel",{"EARLY_PHASE1":4075,"PHASE1":4077,"PHASE2":4079,"PHASE3":4081,"PHASE4":4091,"NA":4093},{"trials":4076,"activeCount":101},[],{"trials":4078,"activeCount":101},[],{"trials":4080,"activeCount":101},[],{"trials":4082,"activeCount":101},[4083],{"nctId":4084,"briefTitle":4085,"status":127,"phases":4086,"primaryCompletion":1923,"completion":1923,"start":2789,"enrollment":4087,"conditions":4088,"interventions":4089},"NCT01622361","Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer",[91],290,[27],[4073,4090],"GnRHa with Tamoxifen",{"trials":4092,"activeCount":101},[],{"trials":4094,"activeCount":101},[],{"intervention":4090,"totalTrials":259,"cells":4096},{"EARLY_PHASE1":4097,"PHASE1":4099,"PHASE2":4101,"PHASE3":4103,"PHASE4":4109,"NA":4111},{"trials":4098,"activeCount":101},[],{"trials":4100,"activeCount":101},[],{"trials":4102,"activeCount":101},[],{"trials":4104,"activeCount":101},[4105],{"nctId":4084,"briefTitle":4085,"status":127,"phases":4106,"primaryCompletion":1923,"completion":1923,"start":2789,"enrollment":4087,"conditions":4107,"interventions":4108},[91],[27],[4073,4090],{"trials":4110,"activeCount":101},[],{"trials":4112,"activeCount":101},[],{"intervention":4114,"totalTrials":259,"cells":4115},"intravenous acetaminophen",{"EARLY_PHASE1":4116,"PHASE1":4118,"PHASE2":4120,"PHASE3":4122,"PHASE4":4135,"NA":4137},{"trials":4117,"activeCount":101},[],{"trials":4119,"activeCount":101},[],{"trials":4121,"activeCount":101},[],{"trials":4123,"activeCount":101},[4124],{"nctId":4125,"briefTitle":4126,"status":232,"phases":4127,"primaryCompletion":4128,"completion":4129,"start":4130,"enrollment":4131,"conditions":4132,"interventions":4134},"NCT04959591","Use of Intravenous Acetaminophen in Pediatrics Undergoing Spinal Fusion Surgery",[91],"2022-04-15","2022-04-22","2021-06-01",99,[4133],"Scoliosis; Adolescence",[4114,4114],{"trials":4136,"activeCount":101},[],{"trials":4138,"activeCount":101},[],{"intervention":4140,"totalTrials":259,"cells":4141},"Ginkgo biloba & Methylprednisolone",{"EARLY_PHASE1":4142,"PHASE1":4144,"PHASE2":4146,"PHASE3":4148,"PHASE4":4158,"NA":4160},{"trials":4143,"activeCount":101},[],{"trials":4145,"activeCount":101},[],{"trials":4147,"activeCount":101},[],{"trials":4149,"activeCount":101},[4150],{"nctId":4151,"briefTitle":4152,"status":232,"phases":4153,"primaryCompletion":978,"completion":3097,"start":916,"enrollment":426,"conditions":4154,"interventions":4156},"NCT02098330","The Efficacy of Steroid Therapy in Vestibular Neuritis",[91],[4155],"Vestibular Neuritis",[4140,4157],"Ginkgo biloba",{"trials":4159,"activeCount":101},[],{"trials":4161,"activeCount":101},[],{"intervention":4157,"totalTrials":259,"cells":4163},{"EARLY_PHASE1":4164,"PHASE1":4166,"PHASE2":4168,"PHASE3":4170,"PHASE4":4176,"NA":4178},{"trials":4165,"activeCount":101},[],{"trials":4167,"activeCount":101},[],{"trials":4169,"activeCount":101},[],{"trials":4171,"activeCount":101},[4172],{"nctId":4151,"briefTitle":4152,"status":232,"phases":4173,"primaryCompletion":978,"completion":3097,"start":916,"enrollment":426,"conditions":4174,"interventions":4175},[91],[4155],[4140,4157],{"trials":4177,"activeCount":101},[],{"trials":4179,"activeCount":101},[],{"intervention":4181,"totalTrials":259,"cells":4182},"PemCarbo",{"EARLY_PHASE1":4183,"PHASE1":4185,"PHASE2":4187,"PHASE3":4189,"PHASE4":4201,"NA":4203},{"trials":4184,"activeCount":101},[],{"trials":4186,"activeCount":101},[],{"trials":4188,"activeCount":101},[],{"trials":4190,"activeCount":101},[4191],{"nctId":4192,"briefTitle":4193,"status":127,"phases":4194,"primaryCompletion":4195,"completion":2080,"start":3456,"enrollment":4196,"conditions":4197,"interventions":4199},"NCT01593293","Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer",[91],"2014-11",266,[4198],"Non-small Cell Lung Cancer",[4181,4200],"Pem only",{"trials":4202,"activeCount":101},[],{"trials":4204,"activeCount":101},[],{"intervention":4200,"totalTrials":259,"cells":4206},{"EARLY_PHASE1":4207,"PHASE1":4209,"PHASE2":4211,"PHASE3":4213,"PHASE4":4219,"NA":4221},{"trials":4208,"activeCount":101},[],{"trials":4210,"activeCount":101},[],{"trials":4212,"activeCount":101},[],{"trials":4214,"activeCount":101},[4215],{"nctId":4192,"briefTitle":4193,"status":127,"phases":4216,"primaryCompletion":4195,"completion":2080,"start":3456,"enrollment":4196,"conditions":4217,"interventions":4218},[91],[4198],[4181,4200],{"trials":4220,"activeCount":101},[],{"trials":4222,"activeCount":101},[],{"intervention":4224,"totalTrials":259,"cells":4225},"donepezil",{"EARLY_PHASE1":4226,"PHASE1":4228,"PHASE2":4230,"PHASE3":4232,"PHASE4":4243,"NA":4245},{"trials":4227,"activeCount":101},[],{"trials":4229,"activeCount":101},[],{"trials":4231,"activeCount":101},[],{"trials":4233,"activeCount":101},[4234],{"nctId":4235,"briefTitle":4236,"status":232,"phases":4237,"primaryCompletion":4238,"completion":2350,"start":978,"enrollment":4239,"conditions":4240,"interventions":4242},"NCT02550665","Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg",[91],"2016-08",176,[4241],"Alzheimer's Disease",[4224],{"trials":4244,"activeCount":101},[],{"trials":4246,"activeCount":101},[],{"intervention":4248,"totalTrials":259,"cells":4249},"Pyridoxine",{"EARLY_PHASE1":4250,"PHASE1":4252,"PHASE2":4254,"PHASE3":4256,"PHASE4":4267,"NA":4269},{"trials":4251,"activeCount":101},[],{"trials":4253,"activeCount":101},[],{"trials":4255,"activeCount":101},[],{"trials":4257,"activeCount":101},[4258],{"nctId":4259,"briefTitle":4260,"status":232,"phases":4261,"primaryCompletion":1094,"completion":1094,"start":4262,"enrollment":4263,"conditions":4264,"interventions":4266},"NCT00446147","Study of Pyridoxine for Hand-Foot Syndrome",[91],"2004-06",389,[4265],"Hand-foot Syndrome",[4248],{"trials":4268,"activeCount":101},[],{"trials":4270,"activeCount":101},[],{"intervention":4272,"totalTrials":259,"cells":4273},"Regorafenib\u002FFOLFOX",{"EARLY_PHASE1":4274,"PHASE1":4276,"PHASE2":4278,"PHASE3":4280,"PHASE4":4289,"NA":4291},{"trials":4275,"activeCount":101},[],{"trials":4277,"activeCount":101},[],{"trials":4279,"activeCount":101},[],{"trials":4281,"activeCount":101},[4282],{"nctId":4283,"briefTitle":4284,"status":3700,"phases":4285,"primaryCompletion":4063,"completion":1875,"start":4286,"enrollment":101,"conditions":4287,"interventions":4288},"NCT01786538","Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines",[91],"2013-06",[1208],[4272],{"trials":4290,"activeCount":101},[],{"trials":4292,"activeCount":101},[],{"intervention":4294,"totalTrials":259,"cells":4295},"Bacillus Licheniformis",{"EARLY_PHASE1":4296,"PHASE1":4298,"PHASE2":4300,"PHASE3":4302,"PHASE4":4317,"NA":4319},{"trials":4297,"activeCount":101},[],{"trials":4299,"activeCount":101},[],{"trials":4301,"activeCount":101},[],{"trials":4303,"activeCount":101},[4304],{"nctId":4305,"briefTitle":4306,"status":127,"phases":4307,"primaryCompletion":1913,"completion":4308,"start":4309,"enrollment":4310,"conditions":4311,"interventions":4316},"NCT03978949","Prevention of Radiotherapy Induced Enteropathy by Probiotics (PREP)",[91],"2024-08-31","2019-06-01",248,[4312,4313,4314,4315],"Radiotherapy","Toxicity","Diarrhea","Probiotics",[4294],{"trials":4318,"activeCount":101},[],{"trials":4320,"activeCount":101},[],{"intervention":909,"totalTrials":97,"cells":4322},{"EARLY_PHASE1":4323,"PHASE1":4325,"PHASE2":4327,"PHASE3":4354,"PHASE4":4356,"NA":4358},{"trials":4324,"activeCount":101},[],{"trials":4326,"activeCount":101},[],{"trials":4328,"activeCount":101},[4329,4333,4337,4341,4350],{"nctId":899,"briefTitle":900,"status":232,"phases":4330,"primaryCompletion":902,"completion":902,"start":903,"enrollment":904,"conditions":4331,"interventions":4332},[89,90],[906],[908,909,910,890],{"nctId":912,"briefTitle":913,"status":127,"phases":4334,"primaryCompletion":915,"completion":916,"start":917,"enrollment":25,"conditions":4335,"interventions":4336},[89,90],[919,920,921],[908,909,910,923,924,925,926],{"nctId":928,"briefTitle":929,"status":127,"phases":4338,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":4339,"interventions":4340},[89,90],[935,936,937],[910,890,908,909],{"nctId":4342,"briefTitle":4343,"status":2280,"phases":4344,"primaryCompletion":1158,"completion":1158,"start":1923,"enrollment":1121,"conditions":4345,"interventions":4347},"NCT02685111","Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)",[90],[27,2209,4346],"Febrile Neutropenia",[4348,4349],"Filgrastim","Peg-filgrastim",{"nctId":975,"briefTitle":976,"status":127,"phases":4351,"primaryCompletion":978,"completion":275,"start":979,"enrollment":25,"conditions":4352,"interventions":4353},[90],[981],[910,890,908,909],{"trials":4355,"activeCount":101},[],{"trials":4357,"activeCount":101},[],{"trials":4359,"activeCount":101},[],{"intervention":1087,"totalTrials":834,"cells":4361},{"EARLY_PHASE1":4362,"PHASE1":4364,"PHASE2":4366,"PHASE3":4400,"PHASE4":4402,"NA":4404},{"trials":4363,"activeCount":101},[],{"trials":4365,"activeCount":101},[],{"trials":4367,"activeCount":101},[4368,4381,4389,4393],{"nctId":4369,"briefTitle":4370,"status":127,"phases":4371,"primaryCompletion":4372,"completion":465,"start":4373,"enrollment":4374,"conditions":4375,"interventions":4378},"NCT05904457","A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer",[90],"2025-01-31","2023-01-02",32,[921,4376,4377],"Advanced Solid Tumors","Metastatic Cancer",[4379,4380],"bevacizumab","erlotinib",{"nctId":4382,"briefTitle":4383,"status":232,"phases":4384,"primaryCompletion":4385,"completion":4386,"start":4385,"enrollment":945,"conditions":4387,"interventions":4388},"NCT00378066","Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer",[90],"2006-08","2008-10",[1208],[1087],{"nctId":1073,"briefTitle":1074,"status":232,"phases":4390,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":1079,"conditions":4391,"interventions":4392},[90],[1081,1082,1083,1084],[1086,1087,1052,1088,1089],{"nctId":4394,"briefTitle":4395,"status":232,"phases":4396,"primaryCompletion":4397,"completion":2789,"start":248,"enrollment":1793,"conditions":4398,"interventions":4399},"NCT00862342","Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)",[90],"2010-12",[1208],[1087],{"trials":4401,"activeCount":101},[],{"trials":4403,"activeCount":101},[],{"trials":4405,"activeCount":101},[],{"intervention":910,"totalTrials":834,"cells":4407},{"EARLY_PHASE1":4408,"PHASE1":4410,"PHASE2":4412,"PHASE3":4430,"PHASE4":4432,"NA":4434},{"trials":4409,"activeCount":101},[],{"trials":4411,"activeCount":101},[],{"trials":4413,"activeCount":101},[4414,4418,4422,4426],{"nctId":899,"briefTitle":900,"status":232,"phases":4415,"primaryCompletion":902,"completion":902,"start":903,"enrollment":904,"conditions":4416,"interventions":4417},[89,90],[906],[908,909,910,890],{"nctId":912,"briefTitle":913,"status":127,"phases":4419,"primaryCompletion":915,"completion":916,"start":917,"enrollment":25,"conditions":4420,"interventions":4421},[89,90],[919,920,921],[908,909,910,923,924,925,926],{"nctId":928,"briefTitle":929,"status":127,"phases":4423,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":4424,"interventions":4425},[89,90],[935,936,937],[910,890,908,909],{"nctId":975,"briefTitle":976,"status":127,"phases":4427,"primaryCompletion":978,"completion":275,"start":979,"enrollment":25,"conditions":4428,"interventions":4429},[90],[981],[910,890,908,909],{"trials":4431,"activeCount":101},[],{"trials":4433,"activeCount":101},[],{"trials":4435,"activeCount":101},[],{"intervention":4437,"totalTrials":171,"cells":4438},"RAD001",{"EARLY_PHASE1":4439,"PHASE1":4441,"PHASE2":4443,"PHASE3":4469,"PHASE4":4471,"NA":4473},{"trials":4440,"activeCount":101},[],{"trials":4442,"activeCount":101},[],{"trials":4444,"activeCount":101},[4445,4455,4461],{"nctId":4446,"briefTitle":4447,"status":232,"phases":4448,"primaryCompletion":4449,"start":2206,"enrollment":4450,"conditions":4451,"interventions":4454},"NCT01830153","RAD001 in Advanced Sarcoma",[90],"2013-01",41,[4452,4453],"Soft Tissue Sarcomas","Bone Sarcomas",[4437],{"nctId":4456,"briefTitle":4457,"status":232,"phases":4458,"primaryCompletion":276,"completion":276,"start":2900,"enrollment":1236,"conditions":4459,"interventions":4460},"NCT01482299","RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240\u002F4 Expression",[90],[1067],[4437],{"nctId":4462,"briefTitle":4463,"status":232,"phases":4464,"primaryCompletion":4465,"completion":2306,"start":235,"enrollment":4466,"conditions":4467,"interventions":4468},"NCT00729482","RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment",[90],"2011-09",54,[1067],[4437],{"trials":4470,"activeCount":101},[],{"trials":4472,"activeCount":101},[],{"trials":4474,"activeCount":101},[],{"intervention":4476,"totalTrials":171,"cells":4477},"Paclitaxel",{"EARLY_PHASE1":4478,"PHASE1":4480,"PHASE2":4482,"PHASE3":4510,"PHASE4":4512,"NA":4514},{"trials":4479,"activeCount":101},[],{"trials":4481,"activeCount":101},[],{"trials":4483,"activeCount":101},[4484,4490,4501],{"nctId":4485,"briefTitle":4486,"status":232,"phases":4487,"primaryCompletion":1555,"completion":1555,"start":2080,"enrollment":1556,"conditions":4488,"interventions":4489},"NCT02607332","Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib",[90],[18],[4476],{"nctId":4491,"briefTitle":4492,"status":232,"phases":4493,"primaryCompletion":4494,"completion":4495,"start":4496,"enrollment":2013,"conditions":4497,"interventions":4499},"NCT02263495","Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer",[90],"2017-05-11","2019-06-17","2014-12-19",[4498],"Metastatic Breast Cancer",[4476,4500,548],"Eribulin",{"nctId":4502,"briefTitle":4503,"status":232,"phases":4504,"primaryCompletion":4505,"completion":4506,"start":4507,"enrollment":426,"conditions":4508,"interventions":4509},"NCT03944304","Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.",[90],"2025-01-06","2025-10-14","2019-05-27",[18],[4476],{"trials":4511,"activeCount":101},[],{"trials":4513,"activeCount":101},[],{"trials":4515,"activeCount":101},[],{"intervention":4517,"totalTrials":176,"cells":4518},"donor natural killer cell",{"EARLY_PHASE1":4519,"PHASE1":4521,"PHASE2":4523,"PHASE3":4546,"PHASE4":4548,"NA":4550},{"trials":4520,"activeCount":101},[],{"trials":4522,"activeCount":101},[],{"trials":4524,"activeCount":101},[4525,4538],{"nctId":4526,"briefTitle":4527,"status":232,"phases":4528,"primaryCompletion":2305,"completion":2305,"start":248,"enrollment":1040,"conditions":4529,"interventions":4537},"NCT00823524","Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer",[89,90],[4530,4531,34,4532,4533,4534,972,4535,4536],"Brain and Central Nervous System Tumors","Chronic Myeloproliferative Disorders","Lymphoma","Lymphoproliferative Disorder","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic\u002FMyeloproliferative Neoplasms","Unspecified Adult Solid Tumor, Protocol Specific",[4517],{"nctId":4539,"briefTitle":4540,"status":232,"phases":4541,"primaryCompletion":1876,"completion":1876,"start":2305,"enrollment":11,"conditions":4542,"interventions":4545},"NCT01795378","Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation",[89,90],[4543,4544],"Acute Myelogenous Leukemia","Acute Lymphoblastic Leukemia",[4517],{"trials":4547,"activeCount":101},[],{"trials":4549,"activeCount":101},[],{"trials":4551,"activeCount":101},[],{"intervention":282,"totalTrials":176,"cells":4553},{"EARLY_PHASE1":4554,"PHASE1":4556,"PHASE2":4558,"PHASE3":4581,"PHASE4":4583,"NA":4585},{"trials":4555,"activeCount":101},[],{"trials":4557,"activeCount":101},[],{"trials":4559,"activeCount":101},[4560,4564],{"nctId":272,"briefTitle":273,"status":232,"phases":4561,"primaryCompletion":275,"completion":275,"start":276,"enrollment":277,"conditions":4562,"interventions":4563},[90],[279,280],[282,263],{"nctId":4565,"briefTitle":4566,"status":127,"phases":4567,"primaryCompletion":4568,"completion":4568,"start":4569,"enrollment":4239,"conditions":4570,"interventions":4578},"NCT03139487","A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism",[90],"2021-09-30","2017-08-07",[4571,763,3638,15,4572,4573,4574,4575,4576,4577],"Cancer-associated Thrombosis","Pancreatic Cancer","Duodenal Cancer","Esophagogastric Junction Cancer","Malignant Gastrointestinal Stromal Tumor","Ampulla of Vater Cancer","Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)",[282,4579,4580],"Dalteparin","apixaban",{"trials":4582,"activeCount":101},[],{"trials":4584,"activeCount":101},[],{"trials":4586,"activeCount":101},[],{"intervention":4588,"totalTrials":176,"cells":4589},"GemOx",{"EARLY_PHASE1":4590,"PHASE1":4592,"PHASE2":4594,"PHASE3":4611,"PHASE4":4613,"NA":4615},{"trials":4591,"activeCount":101},[],{"trials":4593,"activeCount":101},[],{"trials":4595,"activeCount":101},[4596,4604],{"nctId":4597,"briefTitle":4598,"status":127,"phases":4599,"primaryCompletion":3097,"start":4020,"enrollment":8,"conditions":4600,"interventions":4602},"NCT01487915","Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma",[90],[4601],"Advanced Urothelial Carcinoma",[4603,4588],"GCb",{"nctId":4605,"briefTitle":4606,"status":232,"phases":4607,"primaryCompletion":2070,"completion":2070,"start":4386,"enrollment":1206,"conditions":4608,"interventions":4609},"NCT01487720","GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer",[90],[24],[4610],"GEMOX",{"trials":4612,"activeCount":101},[],{"trials":4614,"activeCount":101},[],{"trials":4616,"activeCount":101},[],{"intervention":4618,"totalTrials":176,"cells":4619},"dovitinib",{"EARLY_PHASE1":4620,"PHASE1":4622,"PHASE2":4624,"PHASE3":4640,"PHASE4":4642,"NA":4644},{"trials":4621,"activeCount":101},[],{"trials":4623,"activeCount":101},[],{"trials":4625,"activeCount":101},[4626,4632],{"nctId":4627,"briefTitle":4628,"status":232,"phases":4629,"primaryCompletion":2306,"completion":2306,"start":4465,"enrollment":933,"conditions":4630,"interventions":4631},"NCT01440959","Dovitinib for Imatinib\u002FSumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258",[90],[18],[4618],{"nctId":4633,"briefTitle":4634,"status":232,"phases":4635,"primaryCompletion":1923,"completion":970,"start":979,"enrollment":4636,"conditions":4637,"interventions":4638},"NCT01719549","Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1",[90],19,[21],[4639],"Dovitinib",{"trials":4641,"activeCount":101},[],{"trials":4643,"activeCount":101},[],{"trials":4645,"activeCount":101},[],{"intervention":4647,"totalTrials":176,"cells":4648},"Intravitreal Aflibercept",{"EARLY_PHASE1":4649,"PHASE1":4651,"PHASE2":4653,"PHASE3":4674,"PHASE4":4676,"NA":4678},{"trials":4650,"activeCount":101},[],{"trials":4652,"activeCount":101},[],{"trials":4654,"activeCount":101},[4655,4664],{"nctId":4656,"briefTitle":4657,"status":232,"phases":4658,"primaryCompletion":4659,"completion":1876,"start":2070,"enrollment":3401,"conditions":4660,"interventions":4662},"NCT01971190","Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy",[90],"2015-04",[4661],"Central Serous Chorioretinopathy",[4647,4663],"Sham",{"nctId":4665,"briefTitle":4666,"status":232,"phases":4667,"primaryCompletion":4668,"completion":4668,"start":4669,"enrollment":4670,"conditions":4671,"interventions":4673},"NCT03006081","The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy",[90],"2018-08-30","2016-04-14",38,[4672],"Diabetic Retinopathy",[4647],{"trials":4675,"activeCount":101},[],{"trials":4677,"activeCount":101},[],{"trials":4679,"activeCount":101},[],{"intervention":4681,"totalTrials":176,"cells":4682},"gemcitabine",{"EARLY_PHASE1":4683,"PHASE1":4685,"PHASE2":4687,"PHASE3":4701,"PHASE4":4703,"NA":4705},{"trials":4684,"activeCount":101},[],{"trials":4686,"activeCount":101},[],{"trials":4688,"activeCount":101},[4689,4697],{"nctId":4690,"briefTitle":4691,"status":2280,"phases":4692,"primaryCompletion":4693,"completion":4693,"start":1096,"enrollment":3401,"conditions":4694,"interventions":4696},"NCT00337259","Gemcitabine for Marginal Zone Lymphoma",[90],"2009-03",[1099,4695],"Marginal Zone Lymphoma",[4681],{"nctId":4491,"briefTitle":4492,"status":232,"phases":4698,"primaryCompletion":4494,"completion":4495,"start":4496,"enrollment":2013,"conditions":4699,"interventions":4700},[90],[4498],[4476,4500,548],{"trials":4702,"activeCount":101},[],{"trials":4704,"activeCount":101},[],{"trials":4706,"activeCount":101},[],{"intervention":584,"totalTrials":176,"cells":4708},{"EARLY_PHASE1":4709,"PHASE1":4711,"PHASE2":4713,"PHASE3":4727,"PHASE4":4729,"NA":4731},{"trials":4710,"activeCount":101},[],{"trials":4712,"activeCount":101},[],{"trials":4714,"activeCount":101},[4715,4719],{"nctId":574,"briefTitle":575,"status":232,"phases":4716,"primaryCompletion":577,"completion":248,"start":578,"enrollment":9,"conditions":4717,"interventions":4718},[90],[34],[565,581,582,583,584,585,586,587,588],{"nctId":4720,"briefTitle":4721,"status":232,"phases":4722,"primaryCompletion":2567,"completion":2567,"start":4723,"enrollment":4724,"conditions":4725,"interventions":4726},"NCT00627666","Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer",[90],"2003-01",52,[34,972,4535],[908,992,994,584,585],{"trials":4728,"activeCount":101},[],{"trials":4730,"activeCount":101},[],{"trials":4732,"activeCount":101},[],{"intervention":586,"totalTrials":176,"cells":4734},{"EARLY_PHASE1":4735,"PHASE1":4737,"PHASE2":4739,"PHASE3":4749,"PHASE4":4751,"NA":4753},{"trials":4736,"activeCount":101},[],{"trials":4738,"activeCount":101},[],{"trials":4740,"activeCount":101},[4741,4745],{"nctId":574,"briefTitle":575,"status":232,"phases":4742,"primaryCompletion":577,"completion":248,"start":578,"enrollment":9,"conditions":4743,"interventions":4744},[90],[34],[565,581,582,583,584,585,586,587,588],{"nctId":940,"briefTitle":941,"status":232,"phases":4746,"primaryCompletion":943,"completion":943,"start":944,"enrollment":945,"conditions":4747,"interventions":4748},[89,90],[947,948],[950,890,951,952,953,954],{"trials":4750,"activeCount":101},[],{"trials":4752,"activeCount":101},[],{"trials":4754,"activeCount":101},[],{"intervention":551,"totalTrials":176,"cells":4756},{"EARLY_PHASE1":4757,"PHASE1":4759,"PHASE2":4761,"PHASE3":4779,"PHASE4":4781,"NA":4783},{"trials":4758,"activeCount":101},[],{"trials":4760,"activeCount":101},[],{"trials":4762,"activeCount":101},[4763,4767],{"nctId":537,"briefTitle":538,"status":232,"phases":4764,"primaryCompletion":540,"completion":541,"start":542,"enrollment":543,"conditions":4765,"interventions":4766},[90],[545,546,547,518,548,549],[551,518],{"nctId":4768,"briefTitle":4769,"status":232,"phases":4770,"primaryCompletion":4771,"completion":4772,"start":4773,"enrollment":1485,"conditions":4774,"interventions":4776},"NCT01375972","Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma",[90],"2011-07","2011-08","2008-03",[4775],"Metastatic Biliary Cancer",[4777,4778],"S-1 plus cisplatin","Gemcitabine plus Cisplatin",{"trials":4780,"activeCount":101},[],{"trials":4782,"activeCount":101},[],{"trials":4784,"activeCount":101},[],{"intervention":4786,"totalTrials":259,"cells":4787},"PDR001",{"EARLY_PHASE1":4788,"PHASE1":4790,"PHASE2":4792,"PHASE3":4806,"PHASE4":4808,"NA":4810},{"trials":4789,"activeCount":101},[],{"trials":4791,"activeCount":101},[],{"trials":4793,"activeCount":101},[4794],{"nctId":4795,"briefTitle":4796,"status":127,"phases":4797,"primaryCompletion":2420,"completion":4798,"start":4799,"enrollment":4800,"conditions":4801,"interventions":4805},"NCT03693326","PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS\u002FNRAS Mutation or no Actionable Genetic Abnormalities",[90],"2022-06-30","2018-11-01",70,[4802,4803,4804],"Cancer","Lung Cancer Metastatic","Immunotherapy",[4786],{"trials":4807,"activeCount":101},[],{"trials":4809,"activeCount":101},[],{"trials":4811,"activeCount":101},[],{"intervention":4813,"totalTrials":259,"cells":4814},"Mesenchymal Stem Cell",{"EARLY_PHASE1":4815,"PHASE1":4817,"PHASE2":4819,"PHASE3":4829,"PHASE4":4831,"NA":4833},{"trials":4816,"activeCount":101},[],{"trials":4818,"activeCount":101},[],{"trials":4820,"activeCount":101},[4821],{"nctId":4822,"briefTitle":4823,"status":127,"phases":4824,"primaryCompletion":130,"completion":130,"start":4825,"enrollment":25,"conditions":4826,"interventions":4828},"NCT02112500","Mesenchymal Stem Cell in Patients With Acute Severe Respiratory Failure",[90],"2014-02",[4827],"Respiratory Distress Syndrome, Adult",[4813],{"trials":4830,"activeCount":101},[],{"trials":4832,"activeCount":101},[],{"trials":4834,"activeCount":101},[],{"intervention":4836,"totalTrials":259,"cells":4837},"alpha-lipoic acids",{"EARLY_PHASE1":4838,"PHASE1":4840,"PHASE2":4842,"PHASE3":4852,"PHASE4":4854,"NA":4856},{"trials":4839,"activeCount":101},[],{"trials":4841,"activeCount":101},[],{"trials":4843,"activeCount":101},[4844],{"nctId":4845,"briefTitle":4846,"status":3700,"phases":4847,"primaryCompletion":4848,"completion":915,"start":2307,"enrollment":101,"conditions":4849,"interventions":4851},"NCT01396733","Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer",[90],"2012-12",[4850,4802],"Thyroid",[4836],{"trials":4853,"activeCount":101},[],{"trials":4855,"activeCount":101},[],{"trials":4857,"activeCount":101},[],{"intervention":4859,"totalTrials":259,"cells":4860},"Genexol PM",{"EARLY_PHASE1":4861,"PHASE1":4863,"PHASE2":4865,"PHASE3":4875,"PHASE4":4877,"NA":4879},{"trials":4862,"activeCount":101},[],{"trials":4864,"activeCount":101},[],{"trials":4866,"activeCount":101},[4867],{"nctId":4868,"briefTitle":4869,"status":232,"phases":4870,"primaryCompletion":4871,"completion":4772,"start":3634,"enrollment":4872,"conditions":4873,"interventions":4874},"NCT01426126","Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum",[90],"2010-07",37,[3563,3564],[4859],{"trials":4876,"activeCount":101},[],{"trials":4878,"activeCount":101},[],{"trials":4880,"activeCount":101},[],{"intervention":4380,"totalTrials":259,"cells":4882},{"EARLY_PHASE1":4883,"PHASE1":4885,"PHASE2":4887,"PHASE3":4893,"PHASE4":4895,"NA":4897},{"trials":4884,"activeCount":101},[],{"trials":4886,"activeCount":101},[],{"trials":4888,"activeCount":101},[4889],{"nctId":4369,"briefTitle":4370,"status":127,"phases":4890,"primaryCompletion":4372,"completion":465,"start":4373,"enrollment":4374,"conditions":4891,"interventions":4892},[90],[921,4376,4377],[4379,4380],{"trials":4894,"activeCount":101},[],{"trials":4896,"activeCount":101},[],{"trials":4898,"activeCount":101},[],{"intervention":4900,"totalTrials":259,"cells":4901},"Capecitabine\u002FCisplatin + Sorafenib",{"EARLY_PHASE1":4902,"PHASE1":4904,"PHASE2":4906,"PHASE3":4919,"PHASE4":4921,"NA":4923},{"trials":4903,"activeCount":101},[],{"trials":4905,"activeCount":101},[],{"trials":4907,"activeCount":101},[4908],{"nctId":4909,"briefTitle":4910,"status":232,"phases":4911,"primaryCompletion":3532,"completion":4912,"start":4913,"enrollment":277,"conditions":4914,"interventions":4917},"NCT01187212","Sorafenib Trial in Advanced and\u002For Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE",[90],"2014-08","2010-08",[4915,4916],"Malignant Neoplasm of Stomach","Effects of Chemotherapy",[4900,4918],"Capecitabine\u002FCisplatin",{"trials":4920,"activeCount":101},[],{"trials":4922,"activeCount":101},[],{"trials":4924,"activeCount":101},[],{"intervention":4918,"totalTrials":259,"cells":4926},{"EARLY_PHASE1":4927,"PHASE1":4929,"PHASE2":4931,"PHASE3":4937,"PHASE4":4939,"NA":4941},{"trials":4928,"activeCount":101},[],{"trials":4930,"activeCount":101},[],{"trials":4932,"activeCount":101},[4933],{"nctId":4909,"briefTitle":4910,"status":232,"phases":4934,"primaryCompletion":3532,"completion":4912,"start":4913,"enrollment":277,"conditions":4935,"interventions":4936},[90],[4915,4916],[4900,4918],{"trials":4938,"activeCount":101},[],{"trials":4940,"activeCount":101},[],{"trials":4942,"activeCount":101},[],{"intervention":4944,"totalTrials":259,"cells":4945},"Capecitabine, Oxaliplatin, Cetuximab",{"EARLY_PHASE1":4946,"PHASE1":4948,"PHASE2":4950,"PHASE3":4959,"PHASE4":4961,"NA":4963},{"trials":4947,"activeCount":101},[],{"trials":4949,"activeCount":101},[],{"trials":4951,"activeCount":101},[4952],{"nctId":4953,"briefTitle":4954,"status":232,"phases":4955,"primaryCompletion":3123,"completion":3123,"start":3955,"enrollment":4956,"conditions":4957,"interventions":4958},"NCT00398398","Study of XELOX With Cetuximab in Advanced Gastric Cancer",[90],44,[21],[4944],{"trials":4960,"activeCount":101},[],{"trials":4962,"activeCount":101},[],{"trials":4964,"activeCount":101},[],{"intervention":4966,"totalTrials":259,"cells":4967},"Nilotinib+mVPD",{"EARLY_PHASE1":4968,"PHASE1":4970,"PHASE2":4972,"PHASE3":4982,"PHASE4":4984,"NA":4986},{"trials":4969,"activeCount":101},[],{"trials":4971,"activeCount":101},[],{"trials":4973,"activeCount":101},[4974],{"nctId":4975,"briefTitle":4976,"status":232,"phases":4977,"primaryCompletion":2789,"completion":4978,"start":248,"enrollment":4979,"conditions":4980,"interventions":4981},"NCT00844298","Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",[90],"2014-07",91,[34],[4966],{"trials":4983,"activeCount":101},[],{"trials":4985,"activeCount":101},[],{"trials":4987,"activeCount":101},[],{"intervention":3396,"totalTrials":259,"cells":4989},{"EARLY_PHASE1":4990,"PHASE1":4992,"PHASE2":4994,"PHASE3":5000,"PHASE4":5002,"NA":5004},{"trials":4991,"activeCount":101},[],{"trials":4993,"activeCount":101},[],{"trials":4995,"activeCount":101},[4996],{"nctId":3387,"briefTitle":3388,"status":127,"phases":4997,"start":3390,"enrollment":3391,"conditions":4998,"interventions":4999},[89,90],[3393],[3395,3396],{"trials":5001,"activeCount":101},[],{"trials":5003,"activeCount":101},[],{"trials":5005,"activeCount":101},[],{"intervention":5007,"totalTrials":259,"cells":5008},"Prednisone",{"EARLY_PHASE1":5009,"PHASE1":5011,"PHASE2":5013,"PHASE3":5023,"PHASE4":5025,"NA":5027},{"trials":5010,"activeCount":101},[],{"trials":5012,"activeCount":101},[],{"trials":5014,"activeCount":101},[5015],{"nctId":5016,"briefTitle":5017,"status":232,"phases":5018,"primaryCompletion":5019,"completion":5019,"start":4912,"enrollment":1133,"conditions":5020,"interventions":5022},"NCT03440515","Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor",[90],"2017-06",[5021],"Gastrointestinal Stromal Tumor(GIST)",[5007],{"trials":5024,"activeCount":101},[],{"trials":5026,"activeCount":101},[],{"trials":5028,"activeCount":101},[],{"intervention":5030,"totalTrials":259,"cells":5031},"Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy",{"EARLY_PHASE1":5032,"PHASE1":5034,"PHASE2":5036,"PHASE3":5047,"PHASE4":5049,"NA":5051},{"trials":5033,"activeCount":101},[],{"trials":5035,"activeCount":101},[],{"trials":5037,"activeCount":101},[5038],{"nctId":5039,"briefTitle":5040,"status":127,"phases":5041,"primaryCompletion":5042,"completion":5042,"start":5043,"enrollment":933,"conditions":5044,"interventions":5046},"NCT03383406","A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma",[90],"2025-12-31","2016-12-01",[5045],"Diffuse Large B Cell Lymphoma",[5030],{"trials":5048,"activeCount":101},[],{"trials":5050,"activeCount":101},[],{"trials":5052,"activeCount":101},[],{"intervention":4603,"totalTrials":259,"cells":5054},{"EARLY_PHASE1":5055,"PHASE1":5057,"PHASE2":5059,"PHASE3":5065,"PHASE4":5067,"NA":5069},{"trials":5056,"activeCount":101},[],{"trials":5058,"activeCount":101},[],{"trials":5060,"activeCount":101},[5061],{"nctId":4597,"briefTitle":4598,"status":127,"phases":5062,"primaryCompletion":3097,"start":4020,"enrollment":8,"conditions":5063,"interventions":5064},[90],[4601],[4603,4588],{"trials":5066,"activeCount":101},[],{"trials":5068,"activeCount":101},[],{"trials":5070,"activeCount":101},[],{"intervention":5072,"totalTrials":259,"cells":5073},"Letrozole, Lapatinib",{"EARLY_PHASE1":5074,"PHASE1":5076,"PHASE2":5078,"PHASE3":5088,"PHASE4":5090,"NA":5092},{"trials":5075,"activeCount":101},[],{"trials":5077,"activeCount":101},[],{"trials":5079,"activeCount":101},[5080],{"nctId":5081,"briefTitle":5082,"status":232,"phases":5083,"primaryCompletion":5084,"completion":2351,"start":5085,"enrollment":1556,"conditions":5086,"interventions":5087},"NCT01275859","Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer",[90],"2014-04","2010-09",[27],[5072],{"trials":5089,"activeCount":101},[],{"trials":5091,"activeCount":101},[],{"trials":5093,"activeCount":101},[],{"intervention":5095,"totalTrials":259,"cells":5096},"Docetaxel, Capecitabine, Cisplatin, Bevacizumab",{"EARLY_PHASE1":5097,"PHASE1":5099,"PHASE2":5101,"PHASE3":5111,"PHASE4":5113,"NA":5115},{"trials":5098,"activeCount":101},[],{"trials":5100,"activeCount":101},[],{"trials":5102,"activeCount":101},[5103],{"nctId":5104,"briefTitle":5105,"status":232,"phases":5106,"primaryCompletion":1158,"completion":5107,"start":4871,"enrollment":5108,"conditions":5109,"interventions":5110},"NCT01471470","Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer",[90],"2018-07",31,[3728],[5095],{"trials":5112,"activeCount":101},[],{"trials":5114,"activeCount":101},[],{"trials":5116,"activeCount":101},[],{"intervention":5118,"totalTrials":259,"cells":5119},"Rituximab+mVPDL",{"EARLY_PHASE1":5120,"PHASE1":5122,"PHASE2":5124,"PHASE3":5135,"PHASE4":5137,"NA":5139},{"trials":5121,"activeCount":101},[],{"trials":5123,"activeCount":101},[],{"trials":5125,"activeCount":101},[5126],{"nctId":5127,"briefTitle":5128,"status":127,"phases":5129,"primaryCompletion":5130,"completion":5131,"start":2900,"enrollment":1793,"conditions":5132,"interventions":5134},"NCT01429610","Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia",[90],"2018-01-01","2019-01-01",[5133],"Precursor Cell Lymphoblastic Leukemia-Lymphoma",[5118],{"trials":5136,"activeCount":101},[],{"trials":5138,"activeCount":101},[],{"trials":5140,"activeCount":101},[],{"intervention":5142,"totalTrials":259,"cells":5143},"Gefitinib",{"EARLY_PHASE1":5144,"PHASE1":5146,"PHASE2":5148,"PHASE3":5157,"PHASE4":5159,"NA":5161},{"trials":5145,"activeCount":101},[],{"trials":5147,"activeCount":101},[],{"trials":5149,"activeCount":101},[5150],{"nctId":5151,"briefTitle":5152,"status":127,"phases":5153,"primaryCompletion":4286,"completion":2080,"start":5154,"enrollment":651,"conditions":5155,"interventions":5156},"NCT01510990","First Line Gefitinib by FDG-PET Metabolic Response",[90],"2012-04",[4198],[5142],{"trials":5158,"activeCount":101},[],{"trials":5160,"activeCount":101},[],{"trials":5162,"activeCount":101},[],{"intervention":5164,"totalTrials":259,"cells":5165},"Docetaxel, Oxaliplatin, S-1 and Durvalumab",{"EARLY_PHASE1":5166,"PHASE1":5168,"PHASE2":5170,"PHASE3":5182,"PHASE4":5184,"NA":5186},{"trials":5167,"activeCount":101},[],{"trials":5169,"activeCount":101},[],{"trials":5171,"activeCount":101},[5172],{"nctId":5173,"briefTitle":5174,"status":232,"phases":5175,"primaryCompletion":5176,"completion":5176,"start":5177,"enrollment":1576,"conditions":5178,"interventions":5180},"NCT04221555","Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma",[90],"2025-04-08","2020-05-13",[5179],"Resectable Gastric or Gastroesophageal Junction Adenocarcinoma",[5164,5181],"Durvalumab and Tremelimumab",{"trials":5183,"activeCount":101},[],{"trials":5185,"activeCount":101},[],{"trials":5187,"activeCount":101},[],{"intervention":5181,"totalTrials":259,"cells":5189},{"EARLY_PHASE1":5190,"PHASE1":5192,"PHASE2":5194,"PHASE3":5200,"PHASE4":5202,"NA":5204},{"trials":5191,"activeCount":101},[],{"trials":5193,"activeCount":101},[],{"trials":5195,"activeCount":101},[5196],{"nctId":5173,"briefTitle":5174,"status":232,"phases":5197,"primaryCompletion":5176,"completion":5176,"start":5177,"enrollment":1576,"conditions":5198,"interventions":5199},[90],[5179],[5164,5181],{"trials":5201,"activeCount":101},[],{"trials":5203,"activeCount":101},[],{"trials":5205,"activeCount":101},[],{"intervention":1918,"totalTrials":259,"cells":5207},{"EARLY_PHASE1":5208,"PHASE1":5210,"PHASE2":5212,"PHASE3":5218,"PHASE4":5220,"NA":5222},{"trials":5209,"activeCount":101},[],{"trials":5211,"activeCount":101},[],{"trials":5213,"activeCount":101},[5214],{"nctId":1910,"briefTitle":1911,"status":232,"phases":5215,"primaryCompletion":1913,"completion":1913,"start":1914,"enrollment":1280,"conditions":5216,"interventions":5217},[90],[1916],[1918,1901],{"trials":5219,"activeCount":101},[],{"trials":5221,"activeCount":101},[],{"trials":5223,"activeCount":101},[],{"intervention":5225,"totalTrials":259,"cells":5226},"Cetuximab, irinotecan",{"EARLY_PHASE1":5227,"PHASE1":5229,"PHASE2":5231,"PHASE3":5240,"PHASE4":5242,"NA":5244},{"trials":5228,"activeCount":101},[],{"trials":5230,"activeCount":101},[],{"trials":5232,"activeCount":101},[5233],{"nctId":5234,"briefTitle":5235,"status":232,"phases":5236,"primaryCompletion":3121,"completion":4465,"start":4773,"enrollment":426,"conditions":5237,"interventions":5239},"NCT00637091","Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions",[90],[5238],"Advanced Colorectal Cancer",[5225],{"trials":5241,"activeCount":101},[],{"trials":5243,"activeCount":101},[],{"trials":5245,"activeCount":101},[],{"intervention":5247,"totalTrials":259,"cells":5248},"Osimertinib",{"EARLY_PHASE1":5249,"PHASE1":5251,"PHASE2":5253,"PHASE3":5265,"PHASE4":5267,"NA":5269},{"trials":5250,"activeCount":101},[],{"trials":5252,"activeCount":101},[],{"trials":5254,"activeCount":101},[5255],{"nctId":5256,"briefTitle":5257,"status":232,"phases":5258,"primaryCompletion":5259,"completion":5260,"start":5261,"enrollment":1329,"conditions":5262,"interventions":5264},"NCT03394118","TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy",[90],"2021-03-11","2021-04-08","2017-08-11",[5263],"NSCLC",[5247],{"trials":5266,"activeCount":101},[],{"trials":5268,"activeCount":101},[],{"trials":5270,"activeCount":101},[],{"intervention":4663,"totalTrials":259,"cells":5272},{"EARLY_PHASE1":5273,"PHASE1":5275,"PHASE2":5277,"PHASE3":5283,"PHASE4":5285,"NA":5287},{"trials":5274,"activeCount":101},[],{"trials":5276,"activeCount":101},[],{"trials":5278,"activeCount":101},[5279],{"nctId":4656,"briefTitle":4657,"status":232,"phases":5280,"primaryCompletion":4659,"completion":1876,"start":2070,"enrollment":3401,"conditions":5281,"interventions":5282},[90],[4661],[4647,4663],{"trials":5284,"activeCount":101},[],{"trials":5286,"activeCount":101},[],{"trials":5288,"activeCount":101},[],{"intervention":5290,"totalTrials":259,"cells":5291},"daborafenib plus trametinib",{"EARLY_PHASE1":5292,"PHASE1":5294,"PHASE2":5296,"PHASE3":5306,"PHASE4":5308,"NA":5310},{"trials":5293,"activeCount":101},[],{"trials":5295,"activeCount":101},[],{"trials":5297,"activeCount":101},[5298],{"nctId":5299,"briefTitle":5300,"status":127,"phases":5301,"primaryCompletion":2420,"completion":4798,"start":5302,"enrollment":1097,"conditions":5303,"interventions":5305},"NCT03543306","Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation",[90],"2018-06-30",[4802,4803,5304],"BRAF V600E",[5290],{"trials":5307,"activeCount":101},[],{"trials":5309,"activeCount":101},[],{"trials":5311,"activeCount":101},[],{"intervention":5313,"totalTrials":259,"cells":5314},"intrapleural docetaxel administration",{"EARLY_PHASE1":5315,"PHASE1":5317,"PHASE2":5319,"PHASE3":5331,"PHASE4":5333,"NA":5335},{"trials":5316,"activeCount":101},[],{"trials":5318,"activeCount":101},[],{"trials":5320,"activeCount":101},[5321],{"nctId":5322,"briefTitle":5323,"status":232,"phases":5324,"primaryCompletion":5325,"completion":5325,"start":5326,"enrollment":834,"conditions":5327,"interventions":5330},"NCT03394105","Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer",[90],"2018-06-22","2016-07-26",[5328,5329],"Pleural Effusion, Malignant","Non-small Cell Carcinoma",[5313],{"trials":5332,"activeCount":101},[],{"trials":5334,"activeCount":101},[],{"trials":5336,"activeCount":101},[],{"intervention":5338,"totalTrials":259,"cells":5339},"ADT",{"EARLY_PHASE1":5340,"PHASE1":5342,"PHASE2":5344,"PHASE3":5354,"PHASE4":5356,"NA":5358},{"trials":5341,"activeCount":101},[],{"trials":5343,"activeCount":101},[],{"trials":5345,"activeCount":101},[5346],{"nctId":5347,"briefTitle":5348,"status":127,"phases":5349,"primaryCompletion":2070,"start":4871,"enrollment":1866,"conditions":5350,"interventions":5352},"NCT01487902","The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer",[90],[5351],"Castration-resistant Prostate Cancer",[5338,5353],"No ADT",{"trials":5355,"activeCount":101},[],{"trials":5357,"activeCount":101},[],{"trials":5359,"activeCount":101},[],{"intervention":5353,"totalTrials":259,"cells":5361},{"EARLY_PHASE1":5362,"PHASE1":5364,"PHASE2":5366,"PHASE3":5372,"PHASE4":5374,"NA":5376},{"trials":5363,"activeCount":101},[],{"trials":5365,"activeCount":101},[],{"trials":5367,"activeCount":101},[5368],{"nctId":5347,"briefTitle":5348,"status":127,"phases":5369,"primaryCompletion":2070,"start":4871,"enrollment":1866,"conditions":5370,"interventions":5371},[90],[5351],[5338,5353],{"trials":5373,"activeCount":101},[],{"trials":5375,"activeCount":101},[],{"trials":5377,"activeCount":101},[],{"intervention":5379,"totalTrials":259,"cells":5380},"Fluvoxamine",{"EARLY_PHASE1":5381,"PHASE1":5383,"PHASE2":5385,"PHASE3":5400,"PHASE4":5402,"NA":5404},{"trials":5382,"activeCount":101},[],{"trials":5384,"activeCount":101},[],{"trials":5386,"activeCount":101},[5387],{"nctId":5388,"briefTitle":5389,"status":5390,"phases":5391,"primaryCompletion":5392,"completion":5393,"start":5394,"enrollment":3325,"conditions":5395,"interventions":5399},"NCT04711863","Fluvoxamine for Adults With Mild to Moderate COVID-19","SUSPENDED",[90],"2021-05-31","2021-07-31","2021-01-16",[5396,5397,5398],"Severe Acute Respiratory Syndrome Coronavirus 2","Coronavirus Infection","Mild to Moderate COVID-19",[5379],{"trials":5401,"activeCount":101},[],{"trials":5403,"activeCount":101},[],{"trials":5405,"activeCount":101},[],{"intervention":926,"totalTrials":259,"cells":5407},{"EARLY_PHASE1":5408,"PHASE1":5410,"PHASE2":5412,"PHASE3":5418,"PHASE4":5420,"NA":5422},{"trials":5409,"activeCount":101},[],{"trials":5411,"activeCount":101},[],{"trials":5413,"activeCount":101},[5414],{"nctId":912,"briefTitle":913,"status":127,"phases":5415,"primaryCompletion":915,"completion":916,"start":917,"enrollment":25,"conditions":5416,"interventions":5417},[89,90],[919,920,921],[908,909,910,923,924,925,926],{"trials":5419,"activeCount":101},[],{"trials":5421,"activeCount":101},[],{"trials":5423,"activeCount":101},[],{"intervention":3405,"totalTrials":259,"cells":5425},{"EARLY_PHASE1":5426,"PHASE1":5428,"PHASE2":5430,"PHASE3":5436,"PHASE4":5438,"NA":5440},{"trials":5427,"activeCount":101},[],{"trials":5429,"activeCount":101},[],{"trials":5431,"activeCount":101},[5432],{"nctId":3398,"briefTitle":3399,"status":232,"phases":5433,"primaryCompletion":3194,"completion":3194,"start":1159,"enrollment":3401,"conditions":5434,"interventions":5435},[90],[3403],[3405,3373],{"trials":5437,"activeCount":101},[],{"trials":5439,"activeCount":101},[],{"trials":5441,"activeCount":101},[],{"intervention":5443,"totalTrials":259,"cells":5444},"NASOX",{"EARLY_PHASE1":5445,"PHASE1":5447,"PHASE2":5449,"PHASE3":5461,"PHASE4":5463,"NA":5465},{"trials":5446,"activeCount":101},[],{"trials":5448,"activeCount":101},[],{"trials":5450,"activeCount":101},[5451],{"nctId":5452,"briefTitle":5453,"status":232,"phases":5454,"primaryCompletion":5455,"completion":5456,"start":5457,"enrollment":426,"conditions":5458,"interventions":5460},"NCT04662112","Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma",[89,90],"2023-10-30","2024-12-30","2021-06-15",[4572,5459],"Pancreatic Ductal Adenocarcinoma",[5443],{"trials":5462,"activeCount":101},[],{"trials":5464,"activeCount":101},[],{"trials":5466,"activeCount":101},[],{"intervention":1086,"totalTrials":259,"cells":5468},{"EARLY_PHASE1":5469,"PHASE1":5471,"PHASE2":5473,"PHASE3":5479,"PHASE4":5481,"NA":5483},{"trials":5470,"activeCount":101},[],{"trials":5472,"activeCount":101},[],{"trials":5474,"activeCount":101},[5475],{"nctId":1073,"briefTitle":1074,"status":232,"phases":5476,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":1079,"conditions":5477,"interventions":5478},[90],[1081,1082,1083,1084],[1086,1087,1052,1088,1089],{"trials":5480,"activeCount":101},[],{"trials":5482,"activeCount":101},[],{"trials":5484,"activeCount":101},[],{"intervention":1088,"totalTrials":259,"cells":5486},{"EARLY_PHASE1":5487,"PHASE1":5489,"PHASE2":5491,"PHASE3":5497,"PHASE4":5499,"NA":5501},{"trials":5488,"activeCount":101},[],{"trials":5490,"activeCount":101},[],{"trials":5492,"activeCount":101},[5493],{"nctId":1073,"briefTitle":1074,"status":232,"phases":5494,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":1079,"conditions":5495,"interventions":5496},[90],[1081,1082,1083,1084],[1086,1087,1052,1088,1089],{"trials":5498,"activeCount":101},[],{"trials":5500,"activeCount":101},[],{"trials":5502,"activeCount":101},[],{"intervention":1089,"totalTrials":259,"cells":5504},{"EARLY_PHASE1":5505,"PHASE1":5507,"PHASE2":5509,"PHASE3":5515,"PHASE4":5517,"NA":5519},{"trials":5506,"activeCount":101},[],{"trials":5508,"activeCount":101},[],{"trials":5510,"activeCount":101},[5511],{"nctId":1073,"briefTitle":1074,"status":232,"phases":5512,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":1079,"conditions":5513,"interventions":5514},[90],[1081,1082,1083,1084],[1086,1087,1052,1088,1089],{"trials":5516,"activeCount":101},[],{"trials":5518,"activeCount":101},[],{"trials":5520,"activeCount":101},[],{"intervention":5522,"totalTrials":259,"cells":5523},"Rituximab plus CHOP Immunochemotherapy",{"EARLY_PHASE1":5524,"PHASE1":5526,"PHASE2":5528,"PHASE3":5536,"PHASE4":5538,"NA":5540},{"trials":5525,"activeCount":101},[],{"trials":5527,"activeCount":101},[],{"trials":5529,"activeCount":101},[5530],{"nctId":5531,"briefTitle":5532,"status":127,"phases":5533,"primaryCompletion":4238,"completion":932,"start":4913,"enrollment":4374,"conditions":5534,"interventions":5535},"NCT01279902","Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL",[90],[3704],[5522],{"trials":5537,"activeCount":101},[],{"trials":5539,"activeCount":101},[],{"trials":5541,"activeCount":101},[],{"intervention":5543,"totalTrials":259,"cells":5544},"Gemcitabine plus Capecitabine",{"EARLY_PHASE1":5545,"PHASE1":5547,"PHASE2":5549,"PHASE3":5558,"PHASE4":5560,"NA":5562},{"trials":5546,"activeCount":101},[],{"trials":5548,"activeCount":101},[],{"trials":5550,"activeCount":101},[5551],{"nctId":5552,"briefTitle":5553,"status":232,"phases":5554,"primaryCompletion":4871,"completion":4772,"start":5555,"enrollment":3401,"conditions":5556,"interventions":5557},"NCT01268384","Neoadjuvant FDR GX in Locally Advanced Pancreatic Cancer",[90],"2006-04",[4572],[5543],{"trials":5559,"activeCount":101},[],{"trials":5561,"activeCount":101},[],{"trials":5563,"activeCount":101},[],{"intervention":5565,"totalTrials":259,"cells":5566},"[18F]FSPG",{"EARLY_PHASE1":5567,"PHASE1":5569,"PHASE2":5571,"PHASE3":5585,"PHASE4":5587,"NA":5589},{"trials":5568,"activeCount":101},[],{"trials":5570,"activeCount":101},[],{"trials":5572,"activeCount":101},[5573],{"nctId":5574,"briefTitle":5575,"status":232,"phases":5576,"primaryCompletion":5577,"completion":5577,"start":5578,"enrollment":5579,"conditions":5580,"interventions":5584},"NCT04488094","Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation",[90],"2023-03-31","2020-11-18",7,[5581,5582,5583],"Graft Rejection","Heart Transplantation","Liver Transplantation",[5565],{"trials":5586,"activeCount":101},[],{"trials":5588,"activeCount":101},[],{"trials":5590,"activeCount":101},[],{"intervention":5592,"totalTrials":259,"cells":5593},"Atorvastatin 20mg",{"EARLY_PHASE1":5594,"PHASE1":5596,"PHASE2":5598,"PHASE3":5609,"PHASE4":5611,"NA":5613},{"trials":5595,"activeCount":101},[],{"trials":5597,"activeCount":101},[],{"trials":5599,"activeCount":101},[5600],{"nctId":5601,"briefTitle":5602,"status":232,"phases":5603,"primaryCompletion":4568,"completion":4568,"start":5604,"enrollment":5605,"conditions":5606,"interventions":5608},"NCT01759836","Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer",[90],"2012-10",364,[5607],"Prostatic Neoplasms",[5592],{"trials":5610,"activeCount":101},[],{"trials":5612,"activeCount":101},[],{"trials":5614,"activeCount":101},[],{"intervention":5616,"totalTrials":259,"cells":5617},"durvalumab, tremelimumab, paclitaxel",{"EARLY_PHASE1":5618,"PHASE1":5620,"PHASE2":5622,"PHASE3":5634,"PHASE4":5636,"NA":5638},{"trials":5619,"activeCount":101},[],{"trials":5621,"activeCount":101},[],{"trials":5623,"activeCount":101},[5624],{"nctId":5625,"briefTitle":5626,"status":232,"phases":5627,"primaryCompletion":5628,"completion":5628,"start":5629,"enrollment":5630,"conditions":5631,"interventions":5633},"NCT03751761","GC 2nd Line Durvalumab(MEDI4736)\u002FTremelimumab Plus Paclitaxel Study",[89,90],"2023-08-30","2018-06-11",58,[5632],"Metastatic Gastric Cancer",[5616],{"trials":5635,"activeCount":101},[],{"trials":5637,"activeCount":101},[],{"trials":5639,"activeCount":101},[],{"intervention":5641,"totalTrials":259,"cells":5642},"Abb-R-CHOP",{"EARLY_PHASE1":5643,"PHASE1":5645,"PHASE2":5647,"PHASE3":5657,"PHASE4":5659,"NA":5661},{"trials":5644,"activeCount":101},[],{"trials":5646,"activeCount":101},[],{"trials":5648,"activeCount":101},[5649],{"nctId":5650,"briefTitle":5651,"status":127,"phases":5652,"primaryCompletion":3455,"completion":3455,"start":5653,"enrollment":5654,"conditions":5655,"interventions":5656},"NCT03399747","Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma",[90],"2016-12-07",36,[3704],[5641],{"trials":5658,"activeCount":101},[],{"trials":5660,"activeCount":101},[],{"trials":5662,"activeCount":101},[],{"intervention":5664,"totalTrials":259,"cells":5665},"Preoperative modified FOLFIRINOX and postoperative gemcitabine",{"EARLY_PHASE1":5666,"PHASE1":5668,"PHASE2":5670,"PHASE3":5680,"PHASE4":5682,"NA":5684},{"trials":5667,"activeCount":101},[],{"trials":5669,"activeCount":101},[],{"trials":5671,"activeCount":101},[5672],{"nctId":5673,"briefTitle":5674,"status":232,"phases":5675,"primaryCompletion":5676,"completion":5677,"start":4063,"enrollment":4956,"conditions":5678,"interventions":5679},"NCT02749136","Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer",[90],"2019-09","2019-11",[1487],[5664],{"trials":5681,"activeCount":101},[],{"trials":5683,"activeCount":101},[],{"trials":5685,"activeCount":101},[],{"intervention":5687,"totalTrials":259,"cells":5688},"Capecitabine, Cisplatin, Sorafenib",{"EARLY_PHASE1":5689,"PHASE1":5691,"PHASE2":5693,"PHASE3":5701,"PHASE4":5703,"NA":5705},{"trials":5690,"activeCount":101},[],{"trials":5692,"activeCount":101},[],{"trials":5694,"activeCount":101},[5695],{"nctId":5696,"briefTitle":5697,"status":232,"phases":5698,"primaryCompletion":2944,"completion":2944,"start":3977,"enrollment":1121,"conditions":5699,"interventions":5700},"NCT00565370","Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP",[89,90],[3728],[5687],{"trials":5702,"activeCount":101},[],{"trials":5704,"activeCount":101},[],{"trials":5706,"activeCount":101},[],{"intervention":5708,"totalTrials":259,"cells":5709},"Regorafenib\u002FNivolumab",{"EARLY_PHASE1":5710,"PHASE1":5712,"PHASE2":5714,"PHASE3":5726,"PHASE4":5728,"NA":5730},{"trials":5711,"activeCount":101},[],{"trials":5713,"activeCount":101},[],{"trials":5715,"activeCount":101},[5716],{"nctId":5717,"briefTitle":5718,"status":232,"phases":5719,"primaryCompletion":5720,"completion":5721,"start":5722,"enrollment":3357,"conditions":5723,"interventions":5725},"NCT04310709","Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma",[90],"2022-05-30","2022-11-30","2020-06-16",[1465,5724],"Hepatoma",[5708],{"trials":5727,"activeCount":101},[],{"trials":5729,"activeCount":101},[],{"trials":5731,"activeCount":101},[],{"intervention":5733,"totalTrials":259,"cells":5734},"The combined supplement of Ascorbic acid, Thiamine, and Cortisol",{"EARLY_PHASE1":5735,"PHASE1":5737,"PHASE2":5739,"PHASE3":5752,"PHASE4":5754,"NA":5756},{"trials":5736,"activeCount":101},[],{"trials":5738,"activeCount":101},[],{"trials":5740,"activeCount":101},[5741],{"nctId":5742,"briefTitle":5743,"status":232,"phases":5744,"primaryCompletion":5745,"completion":5746,"start":5747,"enrollment":1304,"conditions":5748,"interventions":5751},"NCT04921189","Steroid, Thiamine and Ascorbic Acid for Comatose Out-of-hospital Cardiac Arrest Survivors",[90],"2024-12-10","2025-06-09","2021-12-31",[5749,5750],"Out-Of-Hospital Cardiac Arrest","Postcardiac Arrest Syndrome",[5733],{"trials":5753,"activeCount":101},[],{"trials":5755,"activeCount":101},[],{"trials":5757,"activeCount":101},[],{"intervention":5759,"totalTrials":259,"cells":5760},"FOLFIRI.3",{"EARLY_PHASE1":5761,"PHASE1":5763,"PHASE2":5765,"PHASE3":5775,"PHASE4":5777,"NA":5779},{"trials":5762,"activeCount":101},[],{"trials":5764,"activeCount":101},[],{"trials":5766,"activeCount":101},[5767],{"nctId":5768,"briefTitle":5769,"status":232,"phases":5770,"primaryCompletion":4693,"completion":3121,"start":236,"enrollment":848,"conditions":5771,"interventions":5773},"NCT00786006","Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer",[90],[5772],"Metastatic Pancreatic Cancer",[5759,5774],"FOLFOX",{"trials":5776,"activeCount":101},[],{"trials":5778,"activeCount":101},[],{"trials":5780,"activeCount":101},[],{"intervention":5774,"totalTrials":259,"cells":5782},{"EARLY_PHASE1":5783,"PHASE1":5785,"PHASE2":5787,"PHASE3":5793,"PHASE4":5795,"NA":5797},{"trials":5784,"activeCount":101},[],{"trials":5786,"activeCount":101},[],{"trials":5788,"activeCount":101},[5789],{"nctId":5768,"briefTitle":5769,"status":232,"phases":5790,"primaryCompletion":4693,"completion":3121,"start":236,"enrollment":848,"conditions":5791,"interventions":5792},[90],[5772],[5759,5774],{"trials":5794,"activeCount":101},[],{"trials":5796,"activeCount":101},[],{"trials":5798,"activeCount":101},[],{"intervention":581,"totalTrials":259,"cells":5800},{"EARLY_PHASE1":5801,"PHASE1":5803,"PHASE2":5805,"PHASE3":5811,"PHASE4":5813,"NA":5815},{"trials":5802,"activeCount":101},[],{"trials":5804,"activeCount":101},[],{"trials":5806,"activeCount":101},[5807],{"nctId":574,"briefTitle":575,"status":232,"phases":5808,"primaryCompletion":577,"completion":248,"start":578,"enrollment":9,"conditions":5809,"interventions":5810},[90],[34],[565,581,582,583,584,585,586,587,588],{"trials":5812,"activeCount":101},[],{"trials":5814,"activeCount":101},[],{"trials":5816,"activeCount":101},[],{"intervention":582,"totalTrials":259,"cells":5818},{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5823,"PHASE3":5829,"PHASE4":5831,"NA":5833},{"trials":5820,"activeCount":101},[],{"trials":5822,"activeCount":101},[],{"trials":5824,"activeCount":101},[5825],{"nctId":574,"briefTitle":575,"status":232,"phases":5826,"primaryCompletion":577,"completion":248,"start":578,"enrollment":9,"conditions":5827,"interventions":5828},[90],[34],[565,581,582,583,584,585,586,587,588],{"trials":5830,"activeCount":101},[],{"trials":5832,"activeCount":101},[],{"trials":5834,"activeCount":101},[],{"intervention":587,"totalTrials":259,"cells":5836},{"EARLY_PHASE1":5837,"PHASE1":5839,"PHASE2":5841,"PHASE3":5847,"PHASE4":5849,"NA":5851},{"trials":5838,"activeCount":101},[],{"trials":5840,"activeCount":101},[],{"trials":5842,"activeCount":101},[5843],{"nctId":574,"briefTitle":575,"status":232,"phases":5844,"primaryCompletion":577,"completion":248,"start":578,"enrollment":9,"conditions":5845,"interventions":5846},[90],[34],[565,581,582,583,584,585,586,587,588],{"trials":5848,"activeCount":101},[],{"trials":5850,"activeCount":101},[],{"trials":5852,"activeCount":101},[],{"intervention":588,"totalTrials":259,"cells":5854},{"EARLY_PHASE1":5855,"PHASE1":5857,"PHASE2":5859,"PHASE3":5865,"PHASE4":5867,"NA":5869},{"trials":5856,"activeCount":101},[],{"trials":5858,"activeCount":101},[],{"trials":5860,"activeCount":101},[5861],{"nctId":574,"briefTitle":575,"status":232,"phases":5862,"primaryCompletion":577,"completion":248,"start":578,"enrollment":9,"conditions":5863,"interventions":5864},[90],[34],[565,581,582,583,584,585,586,587,588],{"trials":5866,"activeCount":101},[],{"trials":5868,"activeCount":101},[],{"trials":5870,"activeCount":101},[],{"intervention":4349,"totalTrials":259,"cells":5872},{"EARLY_PHASE1":5873,"PHASE1":5875,"PHASE2":5877,"PHASE3":5883,"PHASE4":5885,"NA":5887},{"trials":5874,"activeCount":101},[],{"trials":5876,"activeCount":101},[],{"trials":5878,"activeCount":101},[5879],{"nctId":4342,"briefTitle":4343,"status":2280,"phases":5880,"primaryCompletion":1158,"completion":1158,"start":1923,"enrollment":1121,"conditions":5881,"interventions":5882},[90],[27,2209,4346],[4348,4349],{"trials":5884,"activeCount":101},[],{"trials":5886,"activeCount":101},[],{"trials":5888,"activeCount":101},[],{"intervention":5890,"totalTrials":259,"cells":5891},"Paclitaxel\u002FCarboplatin\u002FGefitinib",{"EARLY_PHASE1":5892,"PHASE1":5894,"PHASE2":5896,"PHASE3":5908,"PHASE4":5910,"NA":5912},{"trials":5893,"activeCount":101},[],{"trials":5895,"activeCount":101},[],{"trials":5897,"activeCount":101},[5898],{"nctId":5899,"briefTitle":5900,"status":232,"phases":5901,"primaryCompletion":5902,"completion":4848,"start":2944,"enrollment":5903,"conditions":5904,"interventions":5906},"NCT01196234","Paclitaxel\u002FCarboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer",[90],"2012-02",84,[5905],"Non Small Cell Lung Cancer",[5890,5907],"Paclitaxel\u002FCarboplatin",{"trials":5909,"activeCount":101},[],{"trials":5911,"activeCount":101},[],{"trials":5913,"activeCount":101},[],{"intervention":5907,"totalTrials":259,"cells":5915},{"EARLY_PHASE1":5916,"PHASE1":5918,"PHASE2":5920,"PHASE3":5926,"PHASE4":5928,"NA":5930},{"trials":5917,"activeCount":101},[],{"trials":5919,"activeCount":101},[],{"trials":5921,"activeCount":101},[5922],{"nctId":5899,"briefTitle":5900,"status":232,"phases":5923,"primaryCompletion":5902,"completion":4848,"start":2944,"enrollment":5903,"conditions":5924,"interventions":5925},[90],[5905],[5890,5907],{"trials":5927,"activeCount":101},[],{"trials":5929,"activeCount":101},[],{"trials":5931,"activeCount":101},[],{"intervention":5933,"totalTrials":259,"cells":5934},"oxaliplatin, 5-fluorouracil",{"EARLY_PHASE1":5935,"PHASE1":5937,"PHASE2":5939,"PHASE3":5948,"PHASE4":5950,"NA":5952},{"trials":5936,"activeCount":101},[],{"trials":5938,"activeCount":101},[],{"trials":5940,"activeCount":101},[5941],{"nctId":5942,"briefTitle":5943,"status":232,"phases":5944,"primaryCompletion":2944,"completion":2944,"start":5945,"enrollment":4956,"conditions":5946,"interventions":5947},"NCT00976768","Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin",[90],"2004-10",[3728],[5933],{"trials":5949,"activeCount":101},[],{"trials":5951,"activeCount":101},[],{"trials":5953,"activeCount":101},[],{"intervention":5955,"totalTrials":259,"cells":5956},"docetaxel, capecitabine, cisplatin",{"EARLY_PHASE1":5957,"PHASE1":5959,"PHASE2":5961,"PHASE3":5971,"PHASE4":5973,"NA":5975},{"trials":5958,"activeCount":101},[],{"trials":5960,"activeCount":101},[],{"trials":5962,"activeCount":101},[5963],{"nctId":5964,"briefTitle":5965,"status":232,"phases":5966,"primaryCompletion":4465,"completion":4465,"start":5967,"enrollment":2972,"conditions":5968,"interventions":5970},"NCT00976976","Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer: Adjuvant DXP",[90],"2007-05",[5969],"Resected Advanced Gastric Cancer",[5955],{"trials":5972,"activeCount":101},[],{"trials":5974,"activeCount":101},[],{"trials":5976,"activeCount":101},[],{"intervention":5978,"totalTrials":259,"cells":5979},"Avelumab",{"EARLY_PHASE1":5980,"PHASE1":5982,"PHASE2":5984,"PHASE3":5993,"PHASE4":5995,"NA":5997},{"trials":5981,"activeCount":101},[],{"trials":5983,"activeCount":101},[],{"trials":5985,"activeCount":101},[5986],{"nctId":5987,"briefTitle":5988,"status":127,"phases":5989,"primaryCompletion":5393,"completion":5747,"start":5990,"enrollment":1206,"conditions":5991,"interventions":5992},"NCT03150706","Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer",[90],"2017-05-22",[1208],[5978],{"trials":5994,"activeCount":101},[],{"trials":5996,"activeCount":101},[],{"trials":5998,"activeCount":101},[],{"intervention":6000,"totalTrials":259,"cells":6001},"Zevalin-BuCyE",{"EARLY_PHASE1":6002,"PHASE1":6004,"PHASE2":6006,"PHASE3":6015,"PHASE4":6017,"NA":6019},{"trials":6003,"activeCount":101},[],{"trials":6005,"activeCount":101},[],{"trials":6007,"activeCount":101},[6008],{"nctId":6009,"briefTitle":6010,"status":232,"phases":6011,"primaryCompletion":3661,"completion":1968,"start":6012,"enrollment":4636,"conditions":6013,"interventions":6014},"NCT00336843","Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma",[90],"2005-11",[1099],[6000],{"trials":6016,"activeCount":101},[],{"trials":6018,"activeCount":101},[],{"trials":6020,"activeCount":101},[],{"intervention":6022,"totalTrials":259,"cells":6023},"Vorinostat, capecitabine, and cisplatin",{"EARLY_PHASE1":6024,"PHASE1":6026,"PHASE2":6028,"PHASE3":6038,"PHASE4":6040,"NA":6042},{"trials":6025,"activeCount":101},[],{"trials":6027,"activeCount":101},[],{"trials":6029,"activeCount":101},[6030],{"nctId":6031,"briefTitle":6032,"status":232,"phases":6033,"primaryCompletion":1923,"completion":3037,"start":6034,"enrollment":1236,"conditions":6035,"interventions":6037},"NCT01045538","Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP",[89,90],"2010-02",[21,6036],"Histone Deacetylase Inhibitor",[6022],{"trials":6039,"activeCount":101},[],{"trials":6041,"activeCount":101},[],{"trials":6043,"activeCount":101},[],{"intervention":6045,"totalTrials":259,"cells":6046},"Farlutal tab. 500mg\u002F Pfizer",{"EARLY_PHASE1":6047,"PHASE1":6049,"PHASE2":6051,"PHASE3":6060,"PHASE4":6062,"NA":6064},{"trials":6048,"activeCount":101},[],{"trials":6050,"activeCount":101},[],{"trials":6052,"activeCount":101},[6053],{"nctId":6054,"briefTitle":6055,"status":127,"phases":6056,"primaryCompletion":2256,"completion":5721,"start":6057,"enrollment":4450,"conditions":6058,"interventions":6059},"NCT03567655","Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Endometrial Cancer",[90],"2018-07-15",[1162],[6045],{"trials":6061,"activeCount":101},[],{"trials":6063,"activeCount":101},[],{"trials":6065,"activeCount":101},[],{"intervention":6067,"totalTrials":259,"cells":6068},"Adjuvant FL",{"EARLY_PHASE1":6069,"PHASE1":6071,"PHASE2":6073,"PHASE3":6086,"PHASE4":6088,"NA":6090},{"trials":6070,"activeCount":101},[],{"trials":6072,"activeCount":101},[],{"trials":6074,"activeCount":101},[6075],{"nctId":6076,"briefTitle":6077,"status":232,"phases":6078,"primaryCompletion":6079,"completion":6080,"start":6081,"enrollment":6082,"conditions":6083,"interventions":6084},"NCT00807911","Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer",[90],"2013-06-30","2014-09-05","2008-11-01",322,[1123],[6067,6085],"Adjuvant FOLFOX",{"trials":6087,"activeCount":101},[],{"trials":6089,"activeCount":101},[],{"trials":6091,"activeCount":101},[],{"intervention":6085,"totalTrials":259,"cells":6093},{"EARLY_PHASE1":6094,"PHASE1":6096,"PHASE2":6098,"PHASE3":6104,"PHASE4":6106,"NA":6108},{"trials":6095,"activeCount":101},[],{"trials":6097,"activeCount":101},[],{"trials":6099,"activeCount":101},[6100],{"nctId":6076,"briefTitle":6077,"status":232,"phases":6101,"primaryCompletion":6079,"completion":6080,"start":6081,"enrollment":6082,"conditions":6102,"interventions":6103},[90],[1123],[6067,6085],{"trials":6105,"activeCount":101},[],{"trials":6107,"activeCount":101},[],{"trials":6109,"activeCount":101},[],{"intervention":6111,"totalTrials":259,"cells":6112},"Capecitabine plus temozolomide VS Capecitabine",{"EARLY_PHASE1":6113,"PHASE1":6115,"PHASE2":6117,"PHASE3":6129,"PHASE4":6131,"NA":6133},{"trials":6114,"activeCount":101},[],{"trials":6116,"activeCount":101},[],{"trials":6118,"activeCount":101},[6119],{"nctId":6120,"briefTitle":6121,"status":232,"phases":6122,"primaryCompletion":6123,"completion":6123,"start":6124,"enrollment":6125,"conditions":6126,"interventions":6128},"NCT03156036","Preoperative CRT With Capecitabine ± Temozolomide in Patients With LARC",[90],"2021-02-02","2017-11-30",64,[6127],"Advanced Rectal Cancer",[6111],{"trials":6130,"activeCount":101},[],{"trials":6132,"activeCount":101},[],{"trials":6134,"activeCount":101},[],{"intervention":4579,"totalTrials":259,"cells":6136},{"EARLY_PHASE1":6137,"PHASE1":6139,"PHASE2":6141,"PHASE3":6147,"PHASE4":6149,"NA":6151},{"trials":6138,"activeCount":101},[],{"trials":6140,"activeCount":101},[],{"trials":6142,"activeCount":101},[6143],{"nctId":4565,"briefTitle":4566,"status":127,"phases":6144,"primaryCompletion":4568,"completion":4568,"start":4569,"enrollment":4239,"conditions":6145,"interventions":6146},[90],[4571,763,3638,15,4572,4573,4574,4575,4576,4577],[282,4579,4580],{"trials":6148,"activeCount":101},[],{"trials":6150,"activeCount":101},[],{"trials":6152,"activeCount":101},[],{"intervention":4580,"totalTrials":259,"cells":6154},{"EARLY_PHASE1":6155,"PHASE1":6157,"PHASE2":6159,"PHASE3":6165,"PHASE4":6167,"NA":6169},{"trials":6156,"activeCount":101},[],{"trials":6158,"activeCount":101},[],{"trials":6160,"activeCount":101},[6161],{"nctId":4565,"briefTitle":4566,"status":127,"phases":6162,"primaryCompletion":4568,"completion":4568,"start":4569,"enrollment":4239,"conditions":6163,"interventions":6164},[90],[4571,763,3638,15,4572,4573,4574,4575,4576,4577],[282,4579,4580],{"trials":6166,"activeCount":101},[],{"trials":6168,"activeCount":101},[],{"trials":6170,"activeCount":101},[],{"intervention":6172,"totalTrials":259,"cells":6173},"PDR001, Imatinib",{"EARLY_PHASE1":6174,"PHASE1":6176,"PHASE2":6178,"PHASE3":6189,"PHASE4":6191,"NA":6193},{"trials":6175,"activeCount":101},[],{"trials":6177,"activeCount":101},[],{"trials":6179,"activeCount":101},[6180],{"nctId":6181,"briefTitle":6182,"status":232,"phases":6183,"primaryCompletion":6184,"completion":6184,"start":6185,"enrollment":6186,"conditions":6187,"interventions":6188},"NCT03609424","PDR001 Plus Imatinib for Metastatic or Unresectable GIST",[89,90],"2021-11-11","2019-02-14",39,[18],[6172],{"trials":6190,"activeCount":101},[],{"trials":6192,"activeCount":101},[],{"trials":6194,"activeCount":101},[],{"intervention":6196,"totalTrials":259,"cells":6197},"Dovitinib and docetaxel",{"EARLY_PHASE1":6198,"PHASE1":6200,"PHASE2":6202,"PHASE3":6211,"PHASE4":6213,"NA":6215},{"trials":6199,"activeCount":101},[],{"trials":6201,"activeCount":101},[],{"trials":6203,"activeCount":101},[6204],{"nctId":6205,"briefTitle":6206,"status":232,"phases":6207,"primaryCompletion":3194,"completion":2350,"start":3660,"enrollment":6208,"conditions":6209,"interventions":6210},"NCT01921673","Dovitinib Plus Docetaxel in Gastric Cancer",[89,90],14,[21],[6196],{"trials":6212,"activeCount":101},[],{"trials":6214,"activeCount":101},[],{"trials":6216,"activeCount":101},[],{"intervention":6218,"totalTrials":259,"cells":6219},"Herceptin+XELOX",{"EARLY_PHASE1":6220,"PHASE1":6222,"PHASE2":6224,"PHASE3":6236,"PHASE4":6238,"NA":6240},{"trials":6221,"activeCount":101},[],{"trials":6223,"activeCount":101},[],{"trials":6225,"activeCount":101},[6226],{"nctId":6227,"briefTitle":6228,"status":232,"phases":6229,"primaryCompletion":6230,"completion":6231,"start":1969,"enrollment":3488,"conditions":6232,"interventions":6235},"NCT01396707","Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX",[90],"2018-11","2019-03",[6233,6234],"Metastatic or Recurrent Gastric Adenocarcinoma","Her-2 Positive Gastric Cancer",[6218],{"trials":6237,"activeCount":101},[],{"trials":6239,"activeCount":101},[],{"trials":6241,"activeCount":101},[],{"intervention":951,"totalTrials":259,"cells":6243},{"EARLY_PHASE1":6244,"PHASE1":6246,"PHASE2":6248,"PHASE3":6254,"PHASE4":6256,"NA":6258},{"trials":6245,"activeCount":101},[],{"trials":6247,"activeCount":101},[],{"trials":6249,"activeCount":101},[6250],{"nctId":940,"briefTitle":941,"status":232,"phases":6251,"primaryCompletion":943,"completion":943,"start":944,"enrollment":945,"conditions":6252,"interventions":6253},[89,90],[947,948],[950,890,951,952,953,954],{"trials":6255,"activeCount":101},[],{"trials":6257,"activeCount":101},[],{"trials":6259,"activeCount":101},[],{"intervention":952,"totalTrials":259,"cells":6261},{"EARLY_PHASE1":6262,"PHASE1":6264,"PHASE2":6266,"PHASE3":6272,"PHASE4":6274,"NA":6276},{"trials":6263,"activeCount":101},[],{"trials":6265,"activeCount":101},[],{"trials":6267,"activeCount":101},[6268],{"nctId":940,"briefTitle":941,"status":232,"phases":6269,"primaryCompletion":943,"completion":943,"start":944,"enrollment":945,"conditions":6270,"interventions":6271},[89,90],[947,948],[950,890,951,952,953,954],{"trials":6273,"activeCount":101},[],{"trials":6275,"activeCount":101},[],{"trials":6277,"activeCount":101},[],{"intervention":954,"totalTrials":259,"cells":6279},{"EARLY_PHASE1":6280,"PHASE1":6282,"PHASE2":6284,"PHASE3":6290,"PHASE4":6292,"NA":6294},{"trials":6281,"activeCount":101},[],{"trials":6283,"activeCount":101},[],{"trials":6285,"activeCount":101},[6286],{"nctId":940,"briefTitle":941,"status":232,"phases":6287,"primaryCompletion":943,"completion":943,"start":944,"enrollment":945,"conditions":6288,"interventions":6289},[89,90],[947,948],[950,890,951,952,953,954],{"trials":6291,"activeCount":101},[],{"trials":6293,"activeCount":101},[],{"trials":6295,"activeCount":101},[],{"intervention":6297,"totalTrials":259,"cells":6298},"Capmatinib",{"EARLY_PHASE1":6299,"PHASE1":6301,"PHASE2":6303,"PHASE3":6313,"PHASE4":6315,"NA":6317},{"trials":6300,"activeCount":101},[],{"trials":6302,"activeCount":101},[],{"trials":6304,"activeCount":101},[6305],{"nctId":6306,"briefTitle":6307,"status":127,"phases":6308,"primaryCompletion":2420,"completion":4798,"start":6309,"enrollment":1097,"conditions":6310,"interventions":6312},"NCT03693339","Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation",[90],"2018-10-30",[4802,4803,6311],"MET Gene Mutation",[6297],{"trials":6314,"activeCount":101},[],{"trials":6316,"activeCount":101},[],{"trials":6318,"activeCount":101},[],{"intervention":6320,"totalTrials":259,"cells":6321},"AC4-CDDP4",{"EARLY_PHASE1":6322,"PHASE1":6324,"PHASE2":6326,"PHASE3":6334,"PHASE4":6336,"NA":6338},{"trials":6323,"activeCount":101},[],{"trials":6325,"activeCount":101},[],{"trials":6327,"activeCount":101},[6328],{"nctId":6329,"briefTitle":6330,"status":232,"phases":6331,"primaryCompletion":4825,"completion":4978,"start":3456,"enrollment":1885,"conditions":6332,"interventions":6333},"NCT02001519","Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy",[90],[27],[6320],{"trials":6335,"activeCount":101},[],{"trials":6337,"activeCount":101},[],{"trials":6339,"activeCount":101},[],{"intervention":4777,"totalTrials":259,"cells":6341},{"EARLY_PHASE1":6342,"PHASE1":6344,"PHASE2":6346,"PHASE3":6352,"PHASE4":6354,"NA":6356},{"trials":6343,"activeCount":101},[],{"trials":6345,"activeCount":101},[],{"trials":6347,"activeCount":101},[6348],{"nctId":4768,"briefTitle":4769,"status":232,"phases":6349,"primaryCompletion":4771,"completion":4772,"start":4773,"enrollment":1485,"conditions":6350,"interventions":6351},[90],[4775],[4777,4778],{"trials":6353,"activeCount":101},[],{"trials":6355,"activeCount":101},[],{"trials":6357,"activeCount":101},[],{"intervention":6359,"totalTrials":259,"cells":6360},"Sunitinib",{"EARLY_PHASE1":6361,"PHASE1":6363,"PHASE2":6365,"PHASE3":6374,"PHASE4":6376,"NA":6378},{"trials":6362,"activeCount":101},[],{"trials":6364,"activeCount":101},[],{"trials":6366,"activeCount":101},[6367],{"nctId":6368,"briefTitle":6369,"status":127,"phases":6370,"primaryCompletion":4465,"completion":4465,"start":234,"enrollment":1016,"conditions":6371,"interventions":6373},"NCT01219751","Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma",[90],[6372],"Metastatic Renal Cell Carcinoma",[6359],{"trials":6375,"activeCount":101},[],{"trials":6377,"activeCount":101},[],{"trials":6379,"activeCount":101},[],{"intervention":3352,"totalTrials":259,"cells":6381},{"EARLY_PHASE1":6382,"PHASE1":6384,"PHASE2":6386,"PHASE3":6392,"PHASE4":6394,"NA":6396},{"trials":6383,"activeCount":101},[],{"trials":6385,"activeCount":101},[],{"trials":6387,"activeCount":101},[6388],{"nctId":3345,"briefTitle":3346,"status":127,"phases":6389,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":3348,"conditions":6390,"interventions":6391},[90],[3350],[3352,549],{"trials":6393,"activeCount":101},[],{"trials":6395,"activeCount":101},[],{"trials":6397,"activeCount":101},[],{"intervention":6399,"totalTrials":259,"cells":6400},"Cabometyx",{"EARLY_PHASE1":6401,"PHASE1":6403,"PHASE2":6405,"PHASE3":6418,"PHASE4":6420,"NA":6422},{"trials":6402,"activeCount":101},[],{"trials":6404,"activeCount":101},[],{"trials":6406,"activeCount":101},[6407],{"nctId":6408,"briefTitle":6409,"status":127,"phases":6410,"primaryCompletion":6411,"completion":6412,"start":6413,"enrollment":6414,"conditions":6415,"interventions":6417},"NCT04714697","Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma",[90],"2023-02-28","2025-02-28","2021-03-01",201,[6416],"Renal Cell Cancer",[6399],{"trials":6419,"activeCount":101},[],{"trials":6421,"activeCount":101},[],{"trials":6423,"activeCount":101},[],{"intervention":3363,"totalTrials":259,"cells":6425},{"EARLY_PHASE1":6426,"PHASE1":6428,"PHASE2":6430,"PHASE3":6436,"PHASE4":6438,"NA":6440},{"trials":6427,"activeCount":101},[],{"trials":6429,"activeCount":101},[],{"trials":6431,"activeCount":101},[6432],{"nctId":3354,"briefTitle":3355,"status":232,"phases":6433,"primaryCompletion":915,"completion":915,"start":235,"enrollment":3357,"conditions":6434,"interventions":6435},[90],[3359],[3361,549,3362,3363],{"trials":6437,"activeCount":101},[],{"trials":6439,"activeCount":101},[],{"trials":6441,"activeCount":101},[],{"intervention":6443,"totalTrials":259,"cells":6444},"Eglandin",{"EARLY_PHASE1":6445,"PHASE1":6447,"PHASE2":6449,"PHASE3":6460,"PHASE4":6462,"NA":6464},{"trials":6446,"activeCount":101},[],{"trials":6448,"activeCount":101},[],{"trials":6450,"activeCount":101},[6451],{"nctId":6452,"briefTitle":6453,"status":127,"phases":6454,"primaryCompletion":931,"completion":931,"start":6455,"enrollment":6456,"conditions":6457,"interventions":6459},"NCT02350218","Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION)",[90],"2015-03",76,[6458],"Evidence of Liver Transplantation",[6443],{"trials":6461,"activeCount":101},[],{"trials":6463,"activeCount":101},[],{"trials":6465,"activeCount":101},[],{"intervention":4500,"totalTrials":259,"cells":6467},{"EARLY_PHASE1":6468,"PHASE1":6470,"PHASE2":6472,"PHASE3":6478,"PHASE4":6480,"NA":6482},{"trials":6469,"activeCount":101},[],{"trials":6471,"activeCount":101},[],{"trials":6473,"activeCount":101},[6474],{"nctId":4491,"briefTitle":4492,"status":232,"phases":6475,"primaryCompletion":4494,"completion":4495,"start":4496,"enrollment":2013,"conditions":6476,"interventions":6477},[90],[4498],[4476,4500,548],{"trials":6479,"activeCount":101},[],{"trials":6481,"activeCount":101},[],{"trials":6483,"activeCount":101},[],{"intervention":6485,"totalTrials":259,"cells":6486},"Everolimus",{"EARLY_PHASE1":6487,"PHASE1":6489,"PHASE2":6491,"PHASE3":6503,"PHASE4":6505,"NA":6507},{"trials":6488,"activeCount":101},[],{"trials":6490,"activeCount":101},[],{"trials":6492,"activeCount":101},[6493],{"nctId":6494,"briefTitle":6495,"status":232,"phases":6496,"primaryCompletion":6497,"completion":6497,"start":276,"enrollment":6498,"conditions":6499,"interventions":6500},"NCT02344550","Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +\u002F- Everolimus for Premenopausal Women With Metastatic Breast Cancer",[90],"2018-10",137,[4498],[6485,6501,6502],"Letrozole","Leuprolide",{"trials":6504,"activeCount":101},[],{"trials":6506,"activeCount":101},[],{"trials":6508,"activeCount":101},[],{"intervention":6501,"totalTrials":259,"cells":6510},{"EARLY_PHASE1":6511,"PHASE1":6513,"PHASE2":6515,"PHASE3":6521,"PHASE4":6523,"NA":6525},{"trials":6512,"activeCount":101},[],{"trials":6514,"activeCount":101},[],{"trials":6516,"activeCount":101},[6517],{"nctId":6494,"briefTitle":6495,"status":232,"phases":6518,"primaryCompletion":6497,"completion":6497,"start":276,"enrollment":6498,"conditions":6519,"interventions":6520},[90],[4498],[6485,6501,6502],{"trials":6522,"activeCount":101},[],{"trials":6524,"activeCount":101},[],{"trials":6526,"activeCount":101},[],{"intervention":6502,"totalTrials":259,"cells":6528},{"EARLY_PHASE1":6529,"PHASE1":6531,"PHASE2":6533,"PHASE3":6539,"PHASE4":6541,"NA":6543},{"trials":6530,"activeCount":101},[],{"trials":6532,"activeCount":101},[],{"trials":6534,"activeCount":101},[6535],{"nctId":6494,"briefTitle":6495,"status":232,"phases":6536,"primaryCompletion":6497,"completion":6497,"start":276,"enrollment":6498,"conditions":6537,"interventions":6538},[90],[4498],[6485,6501,6502],{"trials":6540,"activeCount":101},[],{"trials":6542,"activeCount":101},[],{"trials":6544,"activeCount":101},[],{"intervention":6546,"totalTrials":259,"cells":6547},"Lopinavir\u002Fritonavir",{"EARLY_PHASE1":6548,"PHASE1":6550,"PHASE2":6552,"PHASE3":6565,"PHASE4":6567,"NA":6569},{"trials":6549,"activeCount":101},[],{"trials":6551,"activeCount":101},[],{"trials":6553,"activeCount":101},[6554],{"nctId":6555,"briefTitle":6556,"status":2280,"phases":6557,"primaryCompletion":6558,"completion":6558,"start":6559,"enrollment":6560,"conditions":6561,"interventions":6563},"NCT04307693","Comparison of Lopinavir\u002FRitonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)",[90],"2020-04-30","2020-03-11",65,[6562],"COVID-19",[6546,6564],"Hydroxychloroquine sulfate",{"trials":6566,"activeCount":101},[],{"trials":6568,"activeCount":101},[],{"trials":6570,"activeCount":101},[],{"intervention":6564,"totalTrials":259,"cells":6572},{"EARLY_PHASE1":6573,"PHASE1":6575,"PHASE2":6577,"PHASE3":6583,"PHASE4":6585,"NA":6587},{"trials":6574,"activeCount":101},[],{"trials":6576,"activeCount":101},[],{"trials":6578,"activeCount":101},[6579],{"nctId":6555,"briefTitle":6556,"status":2280,"phases":6580,"primaryCompletion":6558,"completion":6558,"start":6559,"enrollment":6560,"conditions":6581,"interventions":6582},[90],[6562],[6546,6564],{"trials":6584,"activeCount":101},[],{"trials":6586,"activeCount":101},[],{"trials":6588,"activeCount":101},[],{"intervention":6590,"totalTrials":259,"cells":6591},"bendamustine, rituximab",{"EARLY_PHASE1":6592,"PHASE1":6594,"PHASE2":6596,"PHASE3":6606,"PHASE4":6608,"NA":6610},{"trials":6593,"activeCount":101},[],{"trials":6595,"activeCount":101},[],{"trials":6597,"activeCount":101},[6598],{"nctId":6599,"briefTitle":6600,"status":127,"phases":6601,"primaryCompletion":6602,"completion":6603,"start":3259,"enrollment":1121,"conditions":6604,"interventions":6605},"NCT02753062","Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma",[90],"2018-08","2023-08",[5045],[6590],{"trials":6607,"activeCount":101},[],{"trials":6609,"activeCount":101},[],{"trials":6611,"activeCount":101},[],{"intervention":6613,"totalTrials":259,"cells":6614},"allogeneic, donor-derived NK cells",{"EARLY_PHASE1":6615,"PHASE1":6617,"PHASE2":6619,"PHASE3":6629,"PHASE4":6631,"NA":6633},{"trials":6616,"activeCount":101},[],{"trials":6618,"activeCount":101},[],{"trials":6620,"activeCount":101},[6621],{"nctId":6622,"briefTitle":6623,"status":2280,"phases":6624,"primaryCompletion":6625,"completion":6625,"start":3097,"enrollment":6626,"conditions":6627,"interventions":6628},"NCT02477787","Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS",[90],"2019-06",77,[4543],[6613],{"trials":6630,"activeCount":101},[],{"trials":6632,"activeCount":101},[],{"trials":6634,"activeCount":101},[],{"intervention":1929,"totalTrials":259,"cells":6636},{"EARLY_PHASE1":6637,"PHASE1":6639,"PHASE2":6641,"PHASE3":6647,"PHASE4":6649,"NA":6651},{"trials":6638,"activeCount":101},[],{"trials":6640,"activeCount":101},[],{"trials":6642,"activeCount":101},[6643],{"nctId":1920,"briefTitle":1921,"status":232,"phases":6644,"primaryCompletion":1923,"completion":1923,"start":1924,"enrollment":9,"conditions":6645,"interventions":6646},[90],[1926,1927],[1929,1901],{"trials":6648,"activeCount":101},[],{"trials":6650,"activeCount":101},[],{"trials":6652,"activeCount":101},[],{"intervention":6654,"totalTrials":259,"cells":6655},"Capecitabine, Oxaliplatin",{"EARLY_PHASE1":6656,"PHASE1":6658,"PHASE2":6660,"PHASE3":6671,"PHASE4":6673,"NA":6675},{"trials":6657,"activeCount":101},[],{"trials":6659,"activeCount":101},[],{"trials":6661,"activeCount":101},[6662],{"nctId":6663,"briefTitle":6664,"status":232,"phases":6665,"primaryCompletion":6666,"completion":275,"start":6667,"enrollment":4670,"conditions":6668,"interventions":6670},"NCT01643070","Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases",[90],"2014-09","2010-01",[1123,6669],"Liver Metastases",[6654],{"trials":6672,"activeCount":101},[],{"trials":6674,"activeCount":101},[],{"trials":6676,"activeCount":101},[],{"intervention":6678,"totalTrials":259,"cells":6679},"Sunitinib 2\u002F1",{"EARLY_PHASE1":6680,"PHASE1":6682,"PHASE2":6684,"PHASE3":6693,"PHASE4":6695,"NA":6697},{"trials":6681,"activeCount":101},[],{"trials":6683,"activeCount":101},[],{"trials":6685,"activeCount":101},[6686],{"nctId":6687,"briefTitle":6688,"status":232,"phases":6689,"primaryCompletion":2194,"completion":2194,"start":3954,"enrollment":6456,"conditions":6690,"interventions":6691},"NCT00570882","Study of Sunitinib Administered as 4\u002F2 vs. 2\u002F1 Schedule in Advanced Renal Cell Carcinoma (RCC)",[90],[6372],[6678,6692],"Sunitinib 4\u002F2",{"trials":6694,"activeCount":101},[],{"trials":6696,"activeCount":101},[],{"trials":6698,"activeCount":101},[],{"intervention":6692,"totalTrials":259,"cells":6700},{"EARLY_PHASE1":6701,"PHASE1":6703,"PHASE2":6705,"PHASE3":6711,"PHASE4":6713,"NA":6715},{"trials":6702,"activeCount":101},[],{"trials":6704,"activeCount":101},[],{"trials":6706,"activeCount":101},[6707],{"nctId":6687,"briefTitle":6688,"status":232,"phases":6708,"primaryCompletion":2194,"completion":2194,"start":3954,"enrollment":6456,"conditions":6709,"interventions":6710},[90],[6372],[6678,6692],{"trials":6712,"activeCount":101},[],{"trials":6714,"activeCount":101},[],{"trials":6716,"activeCount":101},[],{"intervention":6718,"totalTrials":259,"cells":6719},"FOLFIRINOX",{"EARLY_PHASE1":6720,"PHASE1":6722,"PHASE2":6724,"PHASE3":6736,"PHASE4":6738,"NA":6740},{"trials":6721,"activeCount":101},[],{"trials":6723,"activeCount":101},[],{"trials":6725,"activeCount":101},[6726],{"nctId":6727,"briefTitle":6728,"status":127,"phases":6729,"primaryCompletion":6730,"completion":6731,"start":6732,"enrollment":1016,"conditions":6733,"interventions":6735},"NCT04611724","A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer",[90],"2023-12-31","2024-09-30","2020-12-01",[6734],"Urachal Cancer",[6718],{"trials":6737,"activeCount":101},[],{"trials":6739,"activeCount":101},[],{"trials":6741,"activeCount":101},[],{"intervention":6743,"totalTrials":259,"cells":6744},"18F-Fluciclatide",{"EARLY_PHASE1":6745,"PHASE1":6747,"PHASE2":6749,"PHASE3":6758,"PHASE4":6760,"NA":6762},{"trials":6746,"activeCount":101},[],{"trials":6748,"activeCount":101},[],{"trials":6750,"activeCount":101},[6751],{"nctId":6752,"briefTitle":6753,"status":2280,"phases":6754,"primaryCompletion":3037,"completion":3037,"start":2282,"enrollment":904,"conditions":6755,"interventions":6757},"NCT01961583","[18F]Fluciclatide PET Imaging of Pazopanib Response",[90],[6756],"Kidney Neoplasm",[6743],{"trials":6759,"activeCount":101},[],{"trials":6761,"activeCount":101},[],{"trials":6763,"activeCount":101},[],{"intervention":6765,"totalTrials":259,"cells":6766},"TEMCAP",{"EARLY_PHASE1":6767,"PHASE1":6769,"PHASE2":6771,"PHASE3":6782,"PHASE4":6784,"NA":6786},{"trials":6768,"activeCount":101},[],{"trials":6770,"activeCount":101},[],{"trials":6772,"activeCount":101},[6773],{"nctId":6774,"briefTitle":6775,"status":232,"phases":6776,"primaryCompletion":6777,"completion":541,"start":542,"enrollment":5108,"conditions":6778,"interventions":6781},"NCT03079440","TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors",[90],"2020-11-15",[6779,6780,1108,518],"Neuroendocrine Tumors","Neuroendocrine Carcinoma",[6765],{"trials":6783,"activeCount":101},[],{"trials":6785,"activeCount":101},[],{"trials":6787,"activeCount":101},[],{"intervention":6789,"totalTrials":259,"cells":6790},"Trastuzumab, Capecitabine and Cisplatin",{"EARLY_PHASE1":6791,"PHASE1":6793,"PHASE2":6795,"PHASE3":6807,"PHASE4":6809,"NA":6811},{"trials":6792,"activeCount":101},[],{"trials":6794,"activeCount":101},[],{"trials":6796,"activeCount":101},[6797],{"nctId":6798,"briefTitle":6799,"status":232,"phases":6800,"primaryCompletion":6801,"completion":6802,"start":6803,"enrollment":1416,"conditions":6804,"interventions":6806},"NCT04309578","A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC",[90],"2024-07-09","2024-12-13","2020-03-12",[6805],"Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma",[6789],{"trials":6808,"activeCount":101},[],{"trials":6810,"activeCount":101},[],{"trials":6812,"activeCount":101},[],{"intervention":6814,"totalTrials":259,"cells":6815},"Gemcitabine and Docetaxel",{"EARLY_PHASE1":6816,"PHASE1":6818,"PHASE2":6820,"PHASE3":6828,"PHASE4":6830,"NA":6832},{"trials":6817,"activeCount":101},[],{"trials":6819,"activeCount":101},[],{"trials":6821,"activeCount":101},[6822],{"nctId":6823,"briefTitle":6824,"status":127,"phases":6825,"primaryCompletion":5085,"completion":5085,"start":3123,"enrollment":933,"conditions":6826,"interventions":6827},"NCT00807261","Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy",[90],[1042],[6814],{"trials":6829,"activeCount":101},[],{"trials":6831,"activeCount":101},[],{"trials":6833,"activeCount":101},[],{"intervention":6835,"totalTrials":176,"cells":6836},"Udenafil",{"EARLY_PHASE1":6837,"PHASE1":6839,"PHASE2":6860,"PHASE3":6862,"PHASE4":6864,"NA":6866},{"trials":6838,"activeCount":101},[],{"trials":6840,"activeCount":101},[6841,6850],{"nctId":6842,"briefTitle":6843,"status":232,"phases":6844,"primaryCompletion":2486,"start":1865,"enrollment":1097,"conditions":6845,"interventions":6849},"NCT01231997","Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients",[89],[6846,6847,6848],"Renal Insufficiency","Kidney Diseases","Urologic Diseases",[6835],{"nctId":6851,"briefTitle":6852,"status":232,"phases":6853,"primaryCompletion":6854,"start":1096,"enrollment":6855,"conditions":6856,"interventions":6859},"NCT01241032","Phase I Study to Investigate the Alcohol Interaction of DA8159",[89],"2007-02",24,[6857,6858],"Healthy Volunteers","Erectile Dysfunction",[6835],{"trials":6861,"activeCount":101},[],{"trials":6863,"activeCount":101},[],{"trials":6865,"activeCount":101},[],{"trials":6867,"activeCount":101},[],{"intervention":6869,"totalTrials":176,"cells":6870},"megace",{"EARLY_PHASE1":6871,"PHASE1":6873,"PHASE2":6889,"PHASE3":6891,"PHASE4":6893,"NA":6895},{"trials":6872,"activeCount":101},[],{"trials":6874,"activeCount":101},[6875,6882],{"nctId":6876,"briefTitle":6877,"status":127,"phases":6878,"primaryCompletion":4465,"start":4771,"enrollment":16,"conditions":6879,"interventions":6880},"NCT01383330","A Clinical Trial to Evaluate Pharmacokinetics of Daewon DW-ES(A) 625mg\u002F5ml, Daewon DW-ES(B) 625mg\u002F5ml and Megace 800mg\u002F20ml in Healthy Male Volunteers Under Fed Condition",[89],[6857],[6869,6881,6881],"DW-ES",{"nctId":6883,"briefTitle":6884,"status":232,"phases":6885,"primaryCompletion":2789,"start":4465,"enrollment":11,"conditions":6886,"interventions":6887},"NCT01456624","Phase 1 Study of Daewon-ES(B) & Megace in Healthy Male Volunteers Under Fasting and Fed Condition",[89],[30],[6888,6881],"Megace",{"trials":6890,"activeCount":101},[],{"trials":6892,"activeCount":101},[],{"trials":6894,"activeCount":101},[],{"trials":6896,"activeCount":101},[],{"intervention":6881,"totalTrials":176,"cells":6898},{"EARLY_PHASE1":6899,"PHASE1":6901,"PHASE2":6911,"PHASE3":6913,"PHASE4":6915,"NA":6917},{"trials":6900,"activeCount":101},[],{"trials":6902,"activeCount":101},[6903,6907],{"nctId":6876,"briefTitle":6877,"status":127,"phases":6904,"primaryCompletion":4465,"start":4771,"enrollment":16,"conditions":6905,"interventions":6906},[89],[6857],[6869,6881,6881],{"nctId":6883,"briefTitle":6884,"status":232,"phases":6908,"primaryCompletion":2789,"start":4465,"enrollment":11,"conditions":6909,"interventions":6910},[89],[30],[6888,6881],{"trials":6912,"activeCount":101},[],{"trials":6914,"activeCount":101},[],{"trials":6916,"activeCount":101},[],{"trials":6918,"activeCount":101},[],{"intervention":6920,"totalTrials":259,"cells":6921},"MR-MC-01",{"EARLY_PHASE1":6922,"PHASE1":6924,"PHASE2":6937,"PHASE3":6939,"PHASE4":6941,"NA":6943},{"trials":6923,"activeCount":101},[],{"trials":6925,"activeCount":101},[6926],{"nctId":6927,"briefTitle":6928,"status":127,"phases":6929,"primaryCompletion":6930,"completion":6931,"start":6932,"enrollment":171,"conditions":6933,"interventions":6936},"NCT04610359","Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis",[89],"2022-10","2022-12","2020-10-20",[6934,6935,4813],"Interstitial Cystitis","Stem Cell Transplant",[6920],{"trials":6938,"activeCount":101},[],{"trials":6940,"activeCount":101},[],{"trials":6942,"activeCount":101},[],{"trials":6944,"activeCount":101},[],{"intervention":6946,"totalTrials":259,"cells":6947},"Indobufen",{"EARLY_PHASE1":6948,"PHASE1":6950,"PHASE2":6958,"PHASE3":6960,"PHASE4":6962,"NA":6964},{"trials":6949,"activeCount":101},[],{"trials":6951,"activeCount":101},[6952],{"nctId":6953,"briefTitle":6954,"status":127,"phases":6955,"primaryCompletion":4397,"start":6667,"enrollment":904,"conditions":6956,"interventions":6957},"NCT01232023","Evaluation of Pharmacokinetic and Pharmacodynamic Characteristics of Indobufen, an Anticoagulant Agent",[89],[30],[6946],{"trials":6959,"activeCount":101},[],{"trials":6961,"activeCount":101},[],{"trials":6963,"activeCount":101},[],{"trials":6965,"activeCount":101},[],{"intervention":6967,"totalTrials":259,"cells":6968},"Pemetrexed and donor-derived NK cell",{"EARLY_PHASE1":6969,"PHASE1":6971,"PHASE2":6981,"PHASE3":6983,"PHASE4":6985,"NA":6987},{"trials":6970,"activeCount":101},[],{"trials":6972,"activeCount":101},[6973],{"nctId":6974,"briefTitle":6975,"status":232,"phases":6976,"primaryCompletion":6977,"completion":1027,"start":6978,"enrollment":97,"conditions":6979,"interventions":6980},"NCT03366064","Haploidentical NK Cells After Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)",[89],"2018-09-03","2017-11-09",[4198],[6967],{"trials":6982,"activeCount":101},[],{"trials":6984,"activeCount":101},[],{"trials":6986,"activeCount":101},[],{"trials":6988,"activeCount":101},[],{"intervention":6990,"totalTrials":259,"cells":6991},"prasugrel",{"EARLY_PHASE1":6992,"PHASE1":6994,"PHASE2":7002,"PHASE3":7004,"PHASE4":7006,"NA":7008},{"trials":6993,"activeCount":101},[],{"trials":6995,"activeCount":101},[6996],{"nctId":6997,"briefTitle":6998,"status":127,"phases":6999,"primaryCompletion":4825,"completion":4825,"start":276,"enrollment":35,"conditions":7000,"interventions":7001},"NCT02075268","Clinical Trial to Characterize Pharmacokinetic-pharmacodynamic (PKPD) of Prasugrel 10 mg or 30 mg in Healthy Volunteers",[89],[30],[6990],{"trials":7003,"activeCount":101},[],{"trials":7005,"activeCount":101},[],{"trials":7007,"activeCount":101},[],{"trials":7009,"activeCount":101},[],{"intervention":7011,"totalTrials":259,"cells":7012},"chloroquine phosphate 1000 mg",{"EARLY_PHASE1":7013,"PHASE1":7015,"PHASE2":7023,"PHASE3":7025,"PHASE4":7027,"NA":7029},{"trials":7014,"activeCount":101},[],{"trials":7016,"activeCount":101},[7017],{"nctId":7018,"briefTitle":7019,"status":232,"phases":7020,"primaryCompletion":1159,"completion":2071,"start":988,"enrollment":25,"conditions":7021,"interventions":7022},"NCT01366235","Clinical Trial for Evaluation of Ethnic Differences in Pharmacokinetics of Chloroquine, an Anti-malarial Drug",[89],[6857],[7011],{"trials":7024,"activeCount":101},[],{"trials":7026,"activeCount":101},[],{"trials":7028,"activeCount":101},[],{"trials":7030,"activeCount":101},[],{"intervention":7032,"totalTrials":259,"cells":7033},"Glucophage 500mg",{"EARLY_PHASE1":7034,"PHASE1":7036,"PHASE2":7045,"PHASE3":7047,"PHASE4":7049,"NA":7051},{"trials":7035,"activeCount":101},[],{"trials":7037,"activeCount":101},[7038],{"nctId":7039,"briefTitle":7040,"status":232,"phases":7041,"primaryCompletion":4913,"completion":4020,"start":1968,"enrollment":1416,"conditions":7042,"interventions":7043},"NCT01232036","Clinical Trial to Compare the Pharmacokinetics and Pharmacodynamics After Oral Administration of Glucophage and HL-018",[89],[30],[7032,7044],"HL-018 500mg",{"trials":7046,"activeCount":101},[],{"trials":7048,"activeCount":101},[],{"trials":7050,"activeCount":101},[],{"trials":7052,"activeCount":101},[],{"intervention":7044,"totalTrials":259,"cells":7054},{"EARLY_PHASE1":7055,"PHASE1":7057,"PHASE2":7063,"PHASE3":7065,"PHASE4":7067,"NA":7069},{"trials":7056,"activeCount":101},[],{"trials":7058,"activeCount":101},[7059],{"nctId":7039,"briefTitle":7040,"status":232,"phases":7060,"primaryCompletion":4913,"completion":4020,"start":1968,"enrollment":1416,"conditions":7061,"interventions":7062},[89],[30],[7032,7044],{"trials":7064,"activeCount":101},[],{"trials":7066,"activeCount":101},[],{"trials":7068,"activeCount":101},[],{"trials":7070,"activeCount":101},[],{"intervention":7072,"totalTrials":259,"cells":7073},"Multiple Oral Dose of",{"EARLY_PHASE1":7074,"PHASE1":7076,"PHASE2":7084,"PHASE3":7086,"PHASE4":7088,"NA":7090},{"trials":7075,"activeCount":101},[],{"trials":7077,"activeCount":101},[7078],{"nctId":7079,"briefTitle":7080,"status":232,"phases":7081,"primaryCompletion":1038,"start":4020,"enrollment":6855,"conditions":7082,"interventions":7083},"NCT01232049","Drug Interaction and Safety Between Pitavastatin and Valsartan (CWP-PTV-101)",[89],[30],[7072,7072],{"trials":7085,"activeCount":101},[],{"trials":7087,"activeCount":101},[],{"trials":7089,"activeCount":101},[],{"trials":7091,"activeCount":101},[],{"intervention":7093,"totalTrials":259,"cells":7094},"Amitriptyline",{"EARLY_PHASE1":7095,"PHASE1":7097,"PHASE2":7105,"PHASE3":7107,"PHASE4":7109,"NA":7111},{"trials":7096,"activeCount":101},[],{"trials":7098,"activeCount":101},[7099],{"nctId":7100,"briefTitle":7101,"status":127,"phases":7102,"primaryCompletion":3036,"start":3259,"enrollment":6855,"conditions":7103,"interventions":7104},"NCT02519400","A Genotype Stratification Study for Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Male Subjects",[89],[3219],[7093],{"trials":7106,"activeCount":101},[],{"trials":7108,"activeCount":101},[],{"trials":7110,"activeCount":101},[],{"trials":7112,"activeCount":101},[],{"intervention":7114,"totalTrials":259,"cells":7115},"ticagrelor\u002Fprasugrel",{"EARLY_PHASE1":7116,"PHASE1":7118,"PHASE2":7126,"PHASE3":7128,"PHASE4":7130,"NA":7132},{"trials":7117,"activeCount":101},[],{"trials":7119,"activeCount":101},[7120],{"nctId":7121,"briefTitle":7122,"status":232,"phases":7123,"primaryCompletion":3660,"completion":3660,"start":3659,"enrollment":904,"conditions":7124,"interventions":7125},"NCT01876797","PKPD Study of Ticagrelor and Prasugrel in Healthy Korean Males",[89],[30],[7114],{"trials":7127,"activeCount":101},[],{"trials":7129,"activeCount":101},[],{"trials":7131,"activeCount":101},[],{"trials":7133,"activeCount":101},[],{"intervention":7135,"totalTrials":259,"cells":7136},"RAD001, Capecitabine, Oxaliplatin",{"EARLY_PHASE1":7137,"PHASE1":7139,"PHASE2":7147,"PHASE3":7149,"PHASE4":7151,"NA":7153},{"trials":7138,"activeCount":101},[],{"trials":7140,"activeCount":101},[7141],{"nctId":7142,"briefTitle":7143,"status":232,"phases":7144,"primaryCompletion":4771,"completion":2282,"start":6034,"enrollment":426,"conditions":7145,"interventions":7146},"NCT01049620","RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX",[89],[3728],[7135],{"trials":7148,"activeCount":101},[],{"trials":7150,"activeCount":101},[],{"trials":7152,"activeCount":101},[],{"trials":7154,"activeCount":101},[],{"intervention":7156,"totalTrials":259,"cells":7157},"Ivabradine and placebo",{"EARLY_PHASE1":7158,"PHASE1":7160,"PHASE2":7169,"PHASE3":7171,"PHASE4":7173,"NA":7175},{"trials":7159,"activeCount":101},[],{"trials":7161,"activeCount":101},[7162],{"nctId":7163,"briefTitle":7164,"status":232,"phases":7165,"primaryCompletion":3953,"completion":3977,"start":5967,"enrollment":879,"conditions":7166,"interventions":7168},"NCT01804010","Pharmacokinetic, Pharmacodynamic Profiles and Safety After Oral Administration of Ivabradine in Male Healthy Korean Volunteers",[89],[7167],"Healthy Individual",[7156],{"trials":7170,"activeCount":101},[],{"trials":7172,"activeCount":101},[],{"trials":7174,"activeCount":101},[],{"trials":7176,"activeCount":101},[],{"intervention":7178,"totalTrials":259,"cells":7179},"Mirodenafil",{"EARLY_PHASE1":7180,"PHASE1":7182,"PHASE2":7190,"PHASE3":7192,"PHASE4":7194,"NA":7196},{"trials":7181,"activeCount":101},[],{"trials":7183,"activeCount":101},[7184],{"nctId":7185,"briefTitle":7186,"status":232,"phases":7187,"primaryCompletion":2071,"start":1865,"enrollment":904,"conditions":7188,"interventions":7189},"NCT01232010","Clinical Study to Investigate the Safety and Pharmacokinetics of SK3530 Tablet in Renal Impaired Male Patients",[89],[6846,6847,6848],[7178],{"trials":7191,"activeCount":101},[],{"trials":7193,"activeCount":101},[],{"trials":7195,"activeCount":101},[],{"trials":7197,"activeCount":101},[],{"intervention":7199,"totalTrials":259,"cells":7200},"Docetaxel, Capecitabine and Oxaliplatin",{"EARLY_PHASE1":7201,"PHASE1":7203,"PHASE2":7212,"PHASE3":7214,"PHASE4":7216,"NA":7218},{"trials":7202,"activeCount":101},[],{"trials":7204,"activeCount":101},[7205],{"nctId":7206,"briefTitle":7207,"status":232,"phases":7208,"primaryCompletion":3954,"completion":3954,"start":7209,"enrollment":1121,"conditions":7210,"interventions":7211},"NCT00446290","Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer",[89],"2006-03",[3638],[7199],{"trials":7213,"activeCount":101},[],{"trials":7215,"activeCount":101},[],{"trials":7217,"activeCount":101},[],{"trials":7219,"activeCount":101},[],{"intervention":7221,"totalTrials":259,"cells":7222},"dovitinib plus imatinib",{"EARLY_PHASE1":7223,"PHASE1":7225,"PHASE2":7233,"PHASE3":7235,"PHASE4":7237,"NA":7239},{"trials":7224,"activeCount":101},[],{"trials":7226,"activeCount":101},[7227],{"nctId":7228,"briefTitle":7229,"status":3700,"phases":7230,"primaryCompletion":4238,"completion":970,"start":6455,"enrollment":101,"conditions":7231,"interventions":7232},"NCT02268435","Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors",[89],[18],[7221],{"trials":7234,"activeCount":101},[],{"trials":7236,"activeCount":101},[],{"trials":7238,"activeCount":101},[],{"trials":7240,"activeCount":101},[],{"intervention":7242,"totalTrials":259,"cells":7243},"atazanavir",{"EARLY_PHASE1":7244,"PHASE1":7246,"PHASE2":7257,"PHASE3":7259,"PHASE4":7261,"NA":7263},{"trials":7245,"activeCount":101},[],{"trials":7247,"activeCount":101},[7248],{"nctId":7249,"briefTitle":7250,"status":127,"phases":7251,"start":1969,"enrollment":4374,"conditions":7252,"interventions":7254},"NCT01368783","Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers",[89],[7253],"Atazanavir",[7242,7253,7255,7256],"Atazanavir(ATZ) + Ritonavir","atazanavir(ATZ) + tenofovir(TDF) + ritonavir",{"trials":7258,"activeCount":101},[],{"trials":7260,"activeCount":101},[],{"trials":7262,"activeCount":101},[],{"trials":7264,"activeCount":101},[],{"intervention":7255,"totalTrials":259,"cells":7266},{"EARLY_PHASE1":7267,"PHASE1":7269,"PHASE2":7275,"PHASE3":7277,"PHASE4":7279,"NA":7281},{"trials":7268,"activeCount":101},[],{"trials":7270,"activeCount":101},[7271],{"nctId":7249,"briefTitle":7250,"status":127,"phases":7272,"start":1969,"enrollment":4374,"conditions":7273,"interventions":7274},[89],[7253],[7242,7253,7255,7256],{"trials":7276,"activeCount":101},[],{"trials":7278,"activeCount":101},[],{"trials":7280,"activeCount":101},[],{"trials":7282,"activeCount":101},[],{"intervention":7256,"totalTrials":259,"cells":7284},{"EARLY_PHASE1":7285,"PHASE1":7287,"PHASE2":7293,"PHASE3":7295,"PHASE4":7297,"NA":7299},{"trials":7286,"activeCount":101},[],{"trials":7288,"activeCount":101},[7289],{"nctId":7249,"briefTitle":7250,"status":127,"phases":7290,"start":1969,"enrollment":4374,"conditions":7291,"interventions":7292},[89],[7253],[7242,7253,7255,7256],{"trials":7294,"activeCount":101},[],{"trials":7296,"activeCount":101},[],{"trials":7298,"activeCount":101},[],{"trials":7300,"activeCount":101},[],{"intervention":7302,"totalTrials":259,"cells":7303},"Sonifilan",{"EARLY_PHASE1":7304,"PHASE1":7306,"PHASE2":7316,"PHASE3":7318,"PHASE4":7320,"NA":7322},{"trials":7305,"activeCount":101},[],{"trials":7307,"activeCount":101},[7308],{"nctId":7309,"briefTitle":7310,"status":127,"phases":7311,"primaryCompletion":7312,"completion":7312,"start":3725,"enrollment":7313,"conditions":7314,"interventions":7315},"NCT01926821","Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer During Radiation or Chemoradiation Therapy",[89],"2025-12",200,[32],[7302],{"trials":7317,"activeCount":101},[],{"trials":7319,"activeCount":101},[],{"trials":7321,"activeCount":101},[],{"trials":7323,"activeCount":101},[],{"intervention":7325,"totalTrials":259,"cells":7326},"therapeutic allogeneic lymphocytes",{"EARLY_PHASE1":7327,"PHASE1":7329,"PHASE2":7338,"PHASE3":7340,"PHASE4":7342,"NA":7344},{"trials":7328,"activeCount":101},[],{"trials":7330,"activeCount":101},[7331],{"nctId":7332,"briefTitle":7333,"status":232,"phases":7334,"primaryCompletion":577,"completion":577,"start":5967,"enrollment":7335,"conditions":7336,"interventions":7337},"NCT00569283","Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant",[89],18,[4802],[7325],{"trials":7339,"activeCount":101},[],{"trials":7341,"activeCount":101},[],{"trials":7343,"activeCount":101},[],{"trials":7345,"activeCount":101},[],{"intervention":7347,"totalTrials":259,"cells":7348},"haloperidol, PET",{"EARLY_PHASE1":7349,"PHASE1":7351,"PHASE2":7359,"PHASE3":7361,"PHASE4":7363,"NA":7365},{"trials":7350,"activeCount":101},[],{"trials":7352,"activeCount":101},[7353],{"nctId":7354,"briefTitle":7355,"status":232,"phases":7356,"primaryCompletion":4871,"completion":917,"start":1095,"enrollment":904,"conditions":7357,"interventions":7358},"NCT01193621","Early Clinical Evaluation of the Pharmacokinetics and Mechanism Based Pharmacodynamics of Haloperidol Using Positron Emission Tomography in Healthy Volunteers",[89],[30],[7347],{"trials":7360,"activeCount":101},[],{"trials":7362,"activeCount":101},[],{"trials":7364,"activeCount":101},[],{"trials":7366,"activeCount":101},[],{"intervention":7368,"totalTrials":259,"cells":7369},"[18F]PI-2620",{"EARLY_PHASE1":7370,"PHASE1":7384,"PHASE2":7386,"PHASE3":7388,"PHASE4":7390,"NA":7392},{"trials":7371,"activeCount":101},[7372],{"nctId":7373,"briefTitle":7374,"status":232,"phases":7375,"primaryCompletion":7376,"completion":7376,"start":7377,"enrollment":1079,"conditions":7378,"interventions":7383},"NCT03510572","Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain",[88],"2019-07-31","2018-06-04",[7379,7380,7381,7382],"Healthy Volunteer","Alzheimer Disease","Frontotemporal Dementia","Parkinson Disease",[7368],{"trials":7385,"activeCount":101},[],{"trials":7387,"activeCount":101},[],{"trials":7389,"activeCount":101},[],{"trials":7391,"activeCount":101},[],{"trials":7393,"activeCount":101},[],{"intervention":908,"totalTrials":5579,"cells":7395},{"EARLY_PHASE1":7396,"PHASE1":7398,"PHASE2":7400,"PHASE3":7426,"PHASE4":7428,"NA":7430},{"trials":7397,"activeCount":101},[],{"trials":7399,"activeCount":101},[],{"trials":7401,"activeCount":101},[7402,7406,7410,7414,7418,7422],{"nctId":899,"briefTitle":900,"status":232,"phases":7403,"primaryCompletion":902,"completion":902,"start":903,"enrollment":904,"conditions":7404,"interventions":7405},[89,90],[906],[908,909,910,890],{"nctId":912,"briefTitle":913,"status":127,"phases":7407,"primaryCompletion":915,"completion":916,"start":917,"enrollment":25,"conditions":7408,"interventions":7409},[89,90],[919,920,921],[908,909,910,923,924,925,926],{"nctId":928,"briefTitle":929,"status":127,"phases":7411,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":7412,"interventions":7413},[89,90],[935,936,937],[910,890,908,909],{"nctId":4720,"briefTitle":4721,"status":232,"phases":7415,"primaryCompletion":2567,"completion":2567,"start":4723,"enrollment":4724,"conditions":7416,"interventions":7417},[90],[34,972,4535],[908,992,994,584,585],{"nctId":975,"briefTitle":976,"status":127,"phases":7419,"primaryCompletion":978,"completion":275,"start":979,"enrollment":25,"conditions":7420,"interventions":7421},[90],[981],[910,890,908,909],{"nctId":984,"briefTitle":985,"status":232,"phases":7423,"primaryCompletion":987,"completion":987,"start":988,"enrollment":989,"conditions":7424,"interventions":7425},[90],[34],[908,992,923,993,994,585],{"trials":7427,"activeCount":101},[],{"trials":7429,"activeCount":101},[],{"trials":7431,"activeCount":101},[7432],{"nctId":7433,"briefTitle":7434,"status":232,"phases":7435,"primaryCompletion":3390,"completion":3123,"start":7436,"enrollment":933,"conditions":7437,"interventions":7439},"NCT00521430","Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease",[93],"2004-04",[34,4532,4534,972,7438,4536],"Nonmalignant Neoplasm",[908,992,993,994,585,7440],"methylprednisolone",{"intervention":585,"totalTrials":834,"cells":7442},{"EARLY_PHASE1":7443,"PHASE1":7445,"PHASE2":7447,"PHASE3":7461,"PHASE4":7463,"NA":7465},{"trials":7444,"activeCount":101},[],{"trials":7446,"activeCount":101},[],{"trials":7448,"activeCount":101},[7449,7453,7457],{"nctId":574,"briefTitle":575,"status":232,"phases":7450,"primaryCompletion":577,"completion":248,"start":578,"enrollment":9,"conditions":7451,"interventions":7452},[90],[34],[565,581,582,583,584,585,586,587,588],{"nctId":4720,"briefTitle":4721,"status":232,"phases":7454,"primaryCompletion":2567,"completion":2567,"start":4723,"enrollment":4724,"conditions":7455,"interventions":7456},[90],[34,972,4535],[908,992,994,584,585],{"nctId":984,"briefTitle":985,"status":232,"phases":7458,"primaryCompletion":987,"completion":987,"start":988,"enrollment":989,"conditions":7459,"interventions":7460},[90],[34],[908,992,923,993,994,585],{"trials":7462,"activeCount":101},[],{"trials":7464,"activeCount":101},[],{"trials":7466,"activeCount":101},[7467],{"nctId":7433,"briefTitle":7434,"status":232,"phases":7468,"primaryCompletion":3390,"completion":3123,"start":7436,"enrollment":933,"conditions":7469,"interventions":7470},[93],[34,4532,4534,972,7438,4536],[908,992,993,994,585,7440],{"intervention":992,"totalTrials":171,"cells":7472},{"EARLY_PHASE1":7473,"PHASE1":7475,"PHASE2":7477,"PHASE3":7487,"PHASE4":7489,"NA":7491},{"trials":7474,"activeCount":101},[],{"trials":7476,"activeCount":101},[],{"trials":7478,"activeCount":101},[7479,7483],{"nctId":4720,"briefTitle":4721,"status":232,"phases":7480,"primaryCompletion":2567,"completion":2567,"start":4723,"enrollment":4724,"conditions":7481,"interventions":7482},[90],[34,972,4535],[908,992,994,584,585],{"nctId":984,"briefTitle":985,"status":232,"phases":7484,"primaryCompletion":987,"completion":987,"start":988,"enrollment":989,"conditions":7485,"interventions":7486},[90],[34],[908,992,923,993,994,585],{"trials":7488,"activeCount":101},[],{"trials":7490,"activeCount":101},[],{"trials":7492,"activeCount":101},[7493],{"nctId":7433,"briefTitle":7434,"status":232,"phases":7494,"primaryCompletion":3390,"completion":3123,"start":7436,"enrollment":933,"conditions":7495,"interventions":7496},[93],[34,4532,4534,972,7438,4536],[908,992,993,994,585,7440],{"intervention":994,"totalTrials":171,"cells":7498},{"EARLY_PHASE1":7499,"PHASE1":7501,"PHASE2":7503,"PHASE3":7513,"PHASE4":7515,"NA":7517},{"trials":7500,"activeCount":101},[],{"trials":7502,"activeCount":101},[],{"trials":7504,"activeCount":101},[7505,7509],{"nctId":4720,"briefTitle":4721,"status":232,"phases":7506,"primaryCompletion":2567,"completion":2567,"start":4723,"enrollment":4724,"conditions":7507,"interventions":7508},[90],[34,972,4535],[908,992,994,584,585],{"nctId":984,"briefTitle":985,"status":232,"phases":7510,"primaryCompletion":987,"completion":987,"start":988,"enrollment":989,"conditions":7511,"interventions":7512},[90],[34],[908,992,923,993,994,585],{"trials":7514,"activeCount":101},[],{"trials":7516,"activeCount":101},[],{"trials":7518,"activeCount":101},[7519],{"nctId":7433,"briefTitle":7434,"status":232,"phases":7520,"primaryCompletion":3390,"completion":3123,"start":7436,"enrollment":933,"conditions":7521,"interventions":7522},[93],[34,4532,4534,972,7438,4536],[908,992,993,994,585,7440],{"intervention":1833,"totalTrials":171,"cells":7524},{"EARLY_PHASE1":7525,"PHASE1":7527,"PHASE2":7529,"PHASE3":7531,"PHASE4":7533,"NA":7543},{"trials":7526,"activeCount":101},[],{"trials":7528,"activeCount":101},[],{"trials":7530,"activeCount":101},[],{"trials":7532,"activeCount":101},[],{"trials":7534,"activeCount":101},[7535,7539],{"nctId":1826,"briefTitle":1827,"status":232,"phases":7536,"primaryCompletion":1829,"completion":1830,"start":1831,"enrollment":292,"conditions":7537,"interventions":7538},[92],[1765,1795,1833,1796,1797,1834],[1765,1795,1833],{"nctId":1945,"briefTitle":1946,"status":127,"phases":7540,"primaryCompletion":1948,"completion":1949,"start":1950,"enrollment":1951,"conditions":7541,"interventions":7542},[92],[1953,1954],[1833,1901],{"trials":7544,"activeCount":101},[7545],{"nctId":7546,"briefTitle":7547,"status":232,"phases":7548,"primaryCompletion":7549,"completion":7550,"start":7551,"enrollment":3930,"conditions":7552,"interventions":7553},"NCT03529643","Effect of Anesthetic Method on Optic Nerve Sheath Diameter in Patients Undergoing RALP",[93],"2018-08-16","2018-08-22","2018-05-24",[24],[1833],{"intervention":7555,"totalTrials":176,"cells":7556},"Ultrasound guided Rectus sheath block",{"EARLY_PHASE1":7557,"PHASE1":7559,"PHASE2":7561,"PHASE3":7563,"PHASE4":7565,"NA":7567},{"trials":7558,"activeCount":101},[],{"trials":7560,"activeCount":101},[],{"trials":7562,"activeCount":101},[],{"trials":7564,"activeCount":101},[],{"trials":7566,"activeCount":101},[],{"trials":7568,"activeCount":101},[7569,7580],{"nctId":7570,"briefTitle":7571,"status":232,"phases":7572,"primaryCompletion":7573,"completion":7574,"start":7575,"enrollment":651,"conditions":7576,"interventions":7578},"NCT03767816","The Visceral Analgesic Effect of Erector Spinae Plane Block in Laparoscopic Cholecystectomy",[93],"2019-03-30","2019-06-30","2018-12-17",[7577],"Visceral Pain, Postoperative",[7555,7579],"Ultrasound erector spinae plane block",{"nctId":7581,"briefTitle":7582,"status":232,"phases":7583,"primaryCompletion":7584,"completion":7585,"start":7586,"enrollment":7313,"conditions":7587,"interventions":7591},"NCT03413280","Preemptive Analgesic Effects of Rectus Sheath Block in Laparoscopic Cholecystectomy Patients",[93],"2017-08-25","2018-01-15","2017-03-28",[7588,7589,7590],"Preemptive Peripheral Nerve Block","Pain, Postoperative","Acute Pain",[7555,7592],"Intercostal nerve block",{"intervention":993,"totalTrials":176,"cells":7594},{"EARLY_PHASE1":7595,"PHASE1":7597,"PHASE2":7599,"PHASE3":7605,"PHASE4":7607,"NA":7609},{"trials":7596,"activeCount":101},[],{"trials":7598,"activeCount":101},[],{"trials":7600,"activeCount":101},[7601],{"nctId":984,"briefTitle":985,"status":232,"phases":7602,"primaryCompletion":987,"completion":987,"start":988,"enrollment":989,"conditions":7603,"interventions":7604},[90],[34],[908,992,923,993,994,585],{"trials":7606,"activeCount":101},[],{"trials":7608,"activeCount":101},[],{"trials":7610,"activeCount":101},[7611],{"nctId":7433,"briefTitle":7434,"status":232,"phases":7612,"primaryCompletion":3390,"completion":3123,"start":7436,"enrollment":933,"conditions":7613,"interventions":7614},[93],[34,4532,4534,972,7438,4536],[908,992,993,994,585,7440],{"intervention":7616,"totalTrials":176,"cells":7617},"Fentanyl",{"EARLY_PHASE1":7618,"PHASE1":7620,"PHASE2":7622,"PHASE3":7624,"PHASE4":7626,"NA":7628},{"trials":7619,"activeCount":101},[],{"trials":7621,"activeCount":101},[],{"trials":7623,"activeCount":101},[],{"trials":7625,"activeCount":101},[],{"trials":7627,"activeCount":101},[],{"trials":7629,"activeCount":101},[7630,7637],{"nctId":7631,"briefTitle":7632,"status":232,"phases":7633,"primaryCompletion":5085,"completion":4020,"start":3121,"enrollment":1079,"conditions":7634,"interventions":7636},"NCT01144312","Population Pharmacokinetics of Fentanyl in Patients Undergoing Living Donor Liver Transplantation",[93],[7635],"Living Donor Liver Transplantation",[7616],{"nctId":7638,"briefTitle":7639,"status":232,"phases":7640,"primaryCompletion":7641,"completion":7641,"start":4659,"enrollment":2790,"conditions":7642,"interventions":7643},"NCT02402621","Comparison Between Conventional and Model-based Infusion Strategy of IV PCA in Patients Undergoing RALP",[93],"2015-09",[24],[7644],"fentanyl",{"intervention":7646,"totalTrials":259,"cells":7647},"IDEAL-E observation",{"EARLY_PHASE1":7648,"PHASE1":7650,"PHASE2":7652,"PHASE3":7654,"PHASE4":7656,"NA":7658},{"trials":7649,"activeCount":101},[],{"trials":7651,"activeCount":101},[],{"trials":7653,"activeCount":101},[],{"trials":7655,"activeCount":101},[],{"trials":7657,"activeCount":101},[],{"trials":7659,"activeCount":101},[7660],{"nctId":7661,"briefTitle":7662,"status":3700,"phases":7663,"primaryCompletion":7664,"completion":7664,"start":1924,"enrollment":101,"conditions":7665,"interventions":7667},"NCT02421926","Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)",[],"2023-05",[7666],"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",[7646],{"intervention":7669,"totalTrials":259,"cells":7670},"[18F]FET",{"EARLY_PHASE1":7671,"PHASE1":7673,"PHASE2":7675,"PHASE3":7677,"PHASE4":7679,"NA":7681},{"trials":7672,"activeCount":101},[],{"trials":7674,"activeCount":101},[],{"trials":7676,"activeCount":101},[],{"trials":7678,"activeCount":101},[],{"trials":7680,"activeCount":101},[],{"trials":7682,"activeCount":101},[7683],{"nctId":7684,"briefTitle":7685,"status":127,"phases":7686,"primaryCompletion":5577,"completion":5577,"start":7687,"enrollment":933,"conditions":7688,"interventions":7690},"NCT05083936","Prospective Comparison of 18F-FDG and 18F-FET PET for Response Evaluation in Patients With Primary Central Nervous System Lymphoma",[93],"2021-08-27",[7689],"Patients With Suspected or Diagnosed Central Nervous System Lymphoma",[7669],{"intervention":7692,"totalTrials":259,"cells":7693},"Lanreotide autogel",{"EARLY_PHASE1":7694,"PHASE1":7696,"PHASE2":7698,"PHASE3":7700,"PHASE4":7702,"NA":7704},{"trials":7695,"activeCount":101},[],{"trials":7697,"activeCount":101},[],{"trials":7699,"activeCount":101},[],{"trials":7701,"activeCount":101},[],{"trials":7703,"activeCount":101},[],{"trials":7705,"activeCount":101},[7706],{"nctId":7707,"briefTitle":7708,"status":232,"phases":7709,"primaryCompletion":7710,"completion":7711,"start":7712,"enrollment":7713,"conditions":7714,"interventions":7715},"NCT04696042","Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs",[],"2024-01-30","2025-01-27","2021-01-01",71,[6779],[7692],{"intervention":7717,"totalTrials":259,"cells":7718},"solifenacin 5mg, 10mg",{"EARLY_PHASE1":7719,"PHASE1":7721,"PHASE2":7723,"PHASE3":7725,"PHASE4":7727,"NA":7729},{"trials":7720,"activeCount":101},[],{"trials":7722,"activeCount":101},[],{"trials":7724,"activeCount":101},[],{"trials":7726,"activeCount":101},[],{"trials":7728,"activeCount":101},[],{"trials":7730,"activeCount":101},[7731],{"nctId":7732,"briefTitle":7733,"status":232,"phases":7734,"primaryCompletion":3660,"completion":915,"start":4465,"enrollment":7735,"conditions":7736,"interventions":7737},"NCT01437670","Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin",[],262,[2572],[7717],{"intervention":7739,"totalTrials":259,"cells":7740},"acetazolamide",{"EARLY_PHASE1":7741,"PHASE1":7743,"PHASE2":7745,"PHASE3":7747,"PHASE4":7749,"NA":7751},{"trials":7742,"activeCount":101},[],{"trials":7744,"activeCount":101},[],{"trials":7746,"activeCount":101},[],{"trials":7748,"activeCount":101},[],{"trials":7750,"activeCount":101},[],{"trials":7752,"activeCount":101},[7753],{"nctId":7754,"briefTitle":7755,"status":127,"phases":7756,"primaryCompletion":988,"completion":988,"start":1968,"enrollment":2901,"conditions":7757,"interventions":7760},"NCT01131377","Acetazolamide Facilitates Ventilator Weaning",[93],[7758,7759],"Ventilator Weaning","Alkalosis, Metabolic",[7739,7761],"Saline",{"intervention":7761,"totalTrials":259,"cells":7763},{"EARLY_PHASE1":7764,"PHASE1":7766,"PHASE2":7768,"PHASE3":7770,"PHASE4":7772,"NA":7774},{"trials":7765,"activeCount":101},[],{"trials":7767,"activeCount":101},[],{"trials":7769,"activeCount":101},[],{"trials":7771,"activeCount":101},[],{"trials":7773,"activeCount":101},[],{"trials":7775,"activeCount":101},[7776],{"nctId":7754,"briefTitle":7755,"status":127,"phases":7777,"primaryCompletion":988,"completion":988,"start":1968,"enrollment":2901,"conditions":7778,"interventions":7779},[93],[7758,7759],[7739,7761],{"intervention":7781,"totalTrials":259,"cells":7782},"Methylphenidate",{"EARLY_PHASE1":7783,"PHASE1":7785,"PHASE2":7787,"PHASE3":7789,"PHASE4":7791,"NA":7793},{"trials":7784,"activeCount":101},[],{"trials":7786,"activeCount":101},[],{"trials":7788,"activeCount":101},[],{"trials":7790,"activeCount":101},[],{"trials":7792,"activeCount":101},[],{"trials":7794,"activeCount":101},[7795],{"nctId":7796,"briefTitle":7797,"status":127,"phases":7798,"primaryCompletion":2420,"completion":7799,"start":3434,"enrollment":196,"conditions":7800,"interventions":7802},"NCT02430896","Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD",[],"2020-12-31",[7801],"Attention Deficit Disorder With Hyperactivity",[7781,7803],"Atomoxetine",{"intervention":7803,"totalTrials":259,"cells":7805},{"EARLY_PHASE1":7806,"PHASE1":7808,"PHASE2":7810,"PHASE3":7812,"PHASE4":7814,"NA":7816},{"trials":7807,"activeCount":101},[],{"trials":7809,"activeCount":101},[],{"trials":7811,"activeCount":101},[],{"trials":7813,"activeCount":101},[],{"trials":7815,"activeCount":101},[],{"trials":7817,"activeCount":101},[7818],{"nctId":7796,"briefTitle":7797,"status":127,"phases":7819,"primaryCompletion":2420,"completion":7799,"start":3434,"enrollment":196,"conditions":7820,"interventions":7821},[],[7801],[7781,7803],{"intervention":7823,"totalTrials":259,"cells":7824},"lenograstim 10 microgram\u002Fkg\u002Fday",{"EARLY_PHASE1":7825,"PHASE1":7827,"PHASE2":7829,"PHASE3":7831,"PHASE4":7833,"NA":7835},{"trials":7826,"activeCount":101},[],{"trials":7828,"activeCount":101},[],{"trials":7830,"activeCount":101},[],{"trials":7832,"activeCount":101},[],{"trials":7834,"activeCount":101},[],{"trials":7836,"activeCount":101},[7837],{"nctId":7838,"briefTitle":7839,"status":127,"phases":7840,"primaryCompletion":4238,"completion":130,"start":4978,"enrollment":6855,"conditions":7841,"interventions":7843},"NCT02184897","Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization",[93],[7842],"Multiple Myeloma",[7823],{"intervention":7845,"totalTrials":259,"cells":7846},"Intravitreal Bevacizumab",{"EARLY_PHASE1":7847,"PHASE1":7849,"PHASE2":7851,"PHASE3":7853,"PHASE4":7855,"NA":7857},{"trials":7848,"activeCount":101},[],{"trials":7850,"activeCount":101},[],{"trials":7852,"activeCount":101},[],{"trials":7854,"activeCount":101},[],{"trials":7856,"activeCount":101},[],{"trials":7858,"activeCount":101},[7859],{"nctId":7860,"briefTitle":7861,"status":127,"phases":7862,"completion":3390,"start":3301,"enrollment":1079,"conditions":7863,"interventions":7865},"NCT00383812","Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy",[93],[7864],"Polypoidal Choroidal Vasculopathy",[7845],{"intervention":7579,"totalTrials":259,"cells":7867},{"EARLY_PHASE1":7868,"PHASE1":7870,"PHASE2":7872,"PHASE3":7874,"PHASE4":7876,"NA":7878},{"trials":7869,"activeCount":101},[],{"trials":7871,"activeCount":101},[],{"trials":7873,"activeCount":101},[],{"trials":7875,"activeCount":101},[],{"trials":7877,"activeCount":101},[],{"trials":7879,"activeCount":101},[7880],{"nctId":7570,"briefTitle":7571,"status":232,"phases":7881,"primaryCompletion":7573,"completion":7574,"start":7575,"enrollment":651,"conditions":7882,"interventions":7883},[93],[7577],[7555,7579],{"intervention":7885,"totalTrials":259,"cells":7886},"propofol, remifentanil, sevoflurane",{"EARLY_PHASE1":7887,"PHASE1":7889,"PHASE2":7891,"PHASE3":7893,"PHASE4":7895,"NA":7897},{"trials":7888,"activeCount":101},[],{"trials":7890,"activeCount":101},[],{"trials":7892,"activeCount":101},[],{"trials":7894,"activeCount":101},[],{"trials":7896,"activeCount":101},[],{"trials":7898,"activeCount":101},[7899],{"nctId":7900,"briefTitle":7901,"status":127,"phases":7902,"primaryCompletion":131,"completion":3121,"start":3954,"enrollment":3325,"conditions":7903,"interventions":7906},"NCT00935571","Incidence of Postthoracotomy Pain Following General Anesthesia: A Comparison Between TIVA and Inhalation Anesthesia",[],[7904,7905],"Lung Cancer","Neoplasms, Lung",[7885],{"intervention":7908,"totalTrials":259,"cells":7909},"Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use",{"EARLY_PHASE1":7910,"PHASE1":7912,"PHASE2":7914,"PHASE3":7916,"PHASE4":7918,"NA":7920},{"trials":7911,"activeCount":101},[],{"trials":7913,"activeCount":101},[],{"trials":7915,"activeCount":101},[],{"trials":7917,"activeCount":101},[],{"trials":7919,"activeCount":101},[],{"trials":7921,"activeCount":101},[7922],{"nctId":7923,"briefTitle":7924,"status":232,"phases":7925,"primaryCompletion":7926,"completion":7926,"start":7927,"enrollment":7928,"conditions":7929,"interventions":7931},"NCT06233708","Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant",[],"2022-05-31","2008-01-01",2092,[7930,15],"Hepatocellular Carcinoma Recurrent",[7908],{"intervention":7933,"totalTrials":259,"cells":7934},"Oral simethicone",{"EARLY_PHASE1":7935,"PHASE1":7937,"PHASE2":7939,"PHASE3":7941,"PHASE4":7943,"NA":7945},{"trials":7936,"activeCount":101},[],{"trials":7938,"activeCount":101},[],{"trials":7940,"activeCount":101},[],{"trials":7942,"activeCount":101},[],{"trials":7944,"activeCount":101},[],{"trials":7946,"activeCount":101},[7947],{"nctId":7948,"briefTitle":7949,"status":232,"phases":7950,"primaryCompletion":3532,"completion":276,"start":2305,"enrollment":5903,"conditions":7951,"interventions":7952},"NCT01790139","Oral Iohexol for Fecal\u002FFluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles",[93],[1081],[7933],{"intervention":7954,"totalTrials":259,"cells":7955},"Hyaluronic acid\u002Fchondroitin sulfate",{"EARLY_PHASE1":7956,"PHASE1":7958,"PHASE2":7960,"PHASE3":7962,"PHASE4":7964,"NA":7966},{"trials":7957,"activeCount":101},[],{"trials":7959,"activeCount":101},[],{"trials":7961,"activeCount":101},[],{"trials":7963,"activeCount":101},[],{"trials":7965,"activeCount":101},[],{"trials":7967,"activeCount":101},[7968],{"nctId":7969,"briefTitle":7970,"status":2280,"phases":7971,"primaryCompletion":5043,"completion":5043,"start":7972,"enrollment":16,"conditions":7973,"interventions":7974},"NCT01813565","The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid\u002FChondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis\u002FBladder Pain Syndrome.",[93],"2013-03-20",[6934],[7954],{"intervention":7976,"totalTrials":259,"cells":7977},"FloSeal application",{"EARLY_PHASE1":7978,"PHASE1":7980,"PHASE2":7982,"PHASE3":7984,"PHASE4":7986,"NA":7988},{"trials":7979,"activeCount":101},[],{"trials":7981,"activeCount":101},[],{"trials":7983,"activeCount":101},[],{"trials":7985,"activeCount":101},[],{"trials":7987,"activeCount":101},[],{"trials":7989,"activeCount":101},[7990],{"nctId":7991,"briefTitle":7992,"status":232,"phases":7993,"primaryCompletion":2080,"completion":2080,"start":979,"enrollment":426,"conditions":7994,"interventions":7997},"NCT01679483","Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer",[93],[7995,32,1162,3393,7996],"Gynecologic Cancer","Fallopian Tubal Cancer",[7976],{"intervention":7999,"totalTrials":259,"cells":8000},"nab paclitaxel plus gemcitabine",{"EARLY_PHASE1":8001,"PHASE1":8003,"PHASE2":8005,"PHASE3":8007,"PHASE4":8009,"NA":8011},{"trials":8002,"activeCount":101},[],{"trials":8004,"activeCount":101},[],{"trials":8006,"activeCount":101},[],{"trials":8008,"activeCount":101},[],{"trials":8010,"activeCount":101},[],{"trials":8012,"activeCount":101},[8013],{"nctId":8014,"briefTitle":8015,"status":232,"phases":8016,"primaryCompletion":8017,"completion":8018,"start":8019,"enrollment":8020,"conditions":8021,"interventions":8022},"NCT04133155","Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer",[],"2020-01-01","2020-02-01","2019-09-16",103,[4572,5772],[7999],{"intervention":8024,"totalTrials":259,"cells":8025},"IST and\u002For alloHCT",{"EARLY_PHASE1":8026,"PHASE1":8028,"PHASE2":8030,"PHASE3":8032,"PHASE4":8034,"NA":8036},{"trials":8027,"activeCount":101},[],{"trials":8029,"activeCount":101},[],{"trials":8031,"activeCount":101},[],{"trials":8033,"activeCount":101},[],{"trials":8035,"activeCount":101},[],{"trials":8037,"activeCount":101},[8038],{"nctId":8039,"briefTitle":8040,"status":2280,"phases":8041,"primaryCompletion":4063,"completion":4063,"start":3456,"enrollment":904,"conditions":8042,"interventions":8044},"NCT01547143","Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis",[93],[8043],"Hemophagocytic Lymphohistiocytosis",[8024],{"intervention":8046,"totalTrials":259,"cells":8047},"Isoniazid treatment",{"EARLY_PHASE1":8048,"PHASE1":8050,"PHASE2":8052,"PHASE3":8054,"PHASE4":8056,"NA":8058},{"trials":8049,"activeCount":101},[],{"trials":8051,"activeCount":101},[],{"trials":8053,"activeCount":101},[],{"trials":8055,"activeCount":101},[],{"trials":8057,"activeCount":101},[],{"trials":8059,"activeCount":101},[8060],{"nctId":8061,"briefTitle":8062,"status":232,"phases":8063,"primaryCompletion":3725,"completion":3532,"start":2567,"enrollment":8064,"conditions":8065,"interventions":8067},"NCT01087190","Isoniazid (INH) Treatment Based on ELISPOT Assay",[93],831,[8066],"Kidney Transplant Recipient",[8046],{"intervention":8069,"totalTrials":259,"cells":8070},"Basiliximab",{"EARLY_PHASE1":8071,"PHASE1":8073,"PHASE2":8075,"PHASE3":8077,"PHASE4":8079,"NA":8081},{"trials":8072,"activeCount":101},[],{"trials":8074,"activeCount":101},[],{"trials":8076,"activeCount":101},[],{"trials":8078,"activeCount":101},[],{"trials":8080,"activeCount":101},[],{"trials":8082,"activeCount":101},[8083],{"nctId":8084,"briefTitle":8085,"status":127,"phases":8086,"primaryCompletion":3097,"start":5154,"enrollment":426,"conditions":8087,"interventions":8088},"NCT02459977","The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea",[93],[2659],[8069,8089],"No basiliximab",{"intervention":8089,"totalTrials":259,"cells":8091},{"EARLY_PHASE1":8092,"PHASE1":8094,"PHASE2":8096,"PHASE3":8098,"PHASE4":8100,"NA":8102},{"trials":8093,"activeCount":101},[],{"trials":8095,"activeCount":101},[],{"trials":8097,"activeCount":101},[],{"trials":8099,"activeCount":101},[],{"trials":8101,"activeCount":101},[],{"trials":8103,"activeCount":101},[8104],{"nctId":8084,"briefTitle":8085,"status":127,"phases":8105,"primaryCompletion":3097,"start":5154,"enrollment":426,"conditions":8106,"interventions":8107},[93],[2659],[8069,8089],{"intervention":8109,"totalTrials":259,"cells":8110},"Antithrombin III",{"EARLY_PHASE1":8111,"PHASE1":8113,"PHASE2":8115,"PHASE3":8117,"PHASE4":8119,"NA":8121},{"trials":8112,"activeCount":101},[],{"trials":8114,"activeCount":101},[],{"trials":8116,"activeCount":101},[],{"trials":8118,"activeCount":101},[],{"trials":8120,"activeCount":101},[],{"trials":8122,"activeCount":101},[8123],{"nctId":8124,"briefTitle":8125,"status":232,"phases":8126,"primaryCompletion":8127,"completion":8128,"start":8129,"enrollment":8130,"conditions":8131,"interventions":8133},"NCT04912193","Antithrombin III and Post-liver Transplantation Acute Kidney Injury",[],"2019-01-31","2019-12-31","2010-01-04",2395,[8132],"Liver Transplantation and Antithrombin",[8109],{"intervention":8135,"totalTrials":259,"cells":8136},"Ferric Carboxymaltose 50Mg\u002FMl Inj 20Ml",{"EARLY_PHASE1":8137,"PHASE1":8139,"PHASE2":8141,"PHASE3":8143,"PHASE4":8145,"NA":8147},{"trials":8138,"activeCount":101},[],{"trials":8140,"activeCount":101},[],{"trials":8142,"activeCount":101},[],{"trials":8144,"activeCount":101},[],{"trials":8146,"activeCount":101},[],{"trials":8148,"activeCount":101},[8149],{"nctId":8150,"briefTitle":8151,"status":127,"phases":8152,"primaryCompletion":8153,"completion":7312,"start":8154,"enrollment":8155,"conditions":8156,"interventions":8157},"NCT05669872","Patient Blood Mangement (PBM) Using IV Iron in Patients With Gynecologic Cancer",[93],"2025-06","2023-02",334,[7995],[8135,8158],"RBC",{"intervention":8158,"totalTrials":259,"cells":8160},{"EARLY_PHASE1":8161,"PHASE1":8163,"PHASE2":8165,"PHASE3":8167,"PHASE4":8169,"NA":8171},{"trials":8162,"activeCount":101},[],{"trials":8164,"activeCount":101},[],{"trials":8166,"activeCount":101},[],{"trials":8168,"activeCount":101},[],{"trials":8170,"activeCount":101},[],{"trials":8172,"activeCount":101},[8173],{"nctId":8150,"briefTitle":8151,"status":127,"phases":8174,"primaryCompletion":8153,"completion":7312,"start":8154,"enrollment":8155,"conditions":8175,"interventions":8176},[93],[7995],[8135,8158],{"intervention":7440,"totalTrials":259,"cells":8178},{"EARLY_PHASE1":8179,"PHASE1":8181,"PHASE2":8183,"PHASE3":8185,"PHASE4":8187,"NA":8189},{"trials":8180,"activeCount":101},[],{"trials":8182,"activeCount":101},[],{"trials":8184,"activeCount":101},[],{"trials":8186,"activeCount":101},[],{"trials":8188,"activeCount":101},[],{"trials":8190,"activeCount":101},[8191],{"nctId":7433,"briefTitle":7434,"status":232,"phases":8192,"primaryCompletion":3390,"completion":3123,"start":7436,"enrollment":933,"conditions":8193,"interventions":8194},[93],[34,4532,4534,972,7438,4536],[908,992,993,994,585,7440],{"intervention":8196,"totalTrials":259,"cells":8197},"Deep NMB using rocuronium",{"EARLY_PHASE1":8198,"PHASE1":8200,"PHASE2":8202,"PHASE3":8204,"PHASE4":8206,"NA":8208},{"trials":8199,"activeCount":101},[],{"trials":8201,"activeCount":101},[],{"trials":8203,"activeCount":101},[],{"trials":8205,"activeCount":101},[],{"trials":8207,"activeCount":101},[],{"trials":8209,"activeCount":101},[8210],{"nctId":8211,"briefTitle":8212,"status":232,"phases":8213,"primaryCompletion":4799,"completion":8214,"start":8215,"enrollment":1598,"conditions":8216,"interventions":8218},"NCT03266419","Effectiveness of Deep Versus Moderate Neuromuscular Blockade",[93],"2018-11-02","2018-03-28",[8217],"Neuromuscular Blockade",[8196,8219],"Moderate NMB using rocuronium",{"intervention":8219,"totalTrials":259,"cells":8221},{"EARLY_PHASE1":8222,"PHASE1":8224,"PHASE2":8226,"PHASE3":8228,"PHASE4":8230,"NA":8232},{"trials":8223,"activeCount":101},[],{"trials":8225,"activeCount":101},[],{"trials":8227,"activeCount":101},[],{"trials":8229,"activeCount":101},[],{"trials":8231,"activeCount":101},[],{"trials":8233,"activeCount":101},[8234],{"nctId":8211,"briefTitle":8212,"status":232,"phases":8235,"primaryCompletion":4799,"completion":8214,"start":8215,"enrollment":1598,"conditions":8236,"interventions":8237},[93],[8217],[8196,8219],{"intervention":8239,"totalTrials":259,"cells":8240},"Mannitol",{"EARLY_PHASE1":8241,"PHASE1":8243,"PHASE2":8245,"PHASE3":8247,"PHASE4":8249,"NA":8251},{"trials":8242,"activeCount":101},[],{"trials":8244,"activeCount":101},[],{"trials":8246,"activeCount":101},[],{"trials":8248,"activeCount":101},[],{"trials":8250,"activeCount":101},[],{"trials":8252,"activeCount":101},[8253],{"nctId":8254,"briefTitle":8255,"status":232,"phases":8256,"primaryCompletion":8257,"completion":8258,"start":8259,"enrollment":6186,"conditions":8260,"interventions":8261},"NCT03214055","Effect of Mannitol on Optic Nerve Sheath Diameter in Patients Undergoing Robotic Prostatectomy",[],"2017-08-14","2017-08-20","2017-07-12",[24],[8239],{"intervention":8263,"totalTrials":259,"cells":8264},"Alprostadil",{"EARLY_PHASE1":8265,"PHASE1":8267,"PHASE2":8269,"PHASE3":8271,"PHASE4":8273,"NA":8275},{"trials":8266,"activeCount":101},[],{"trials":8268,"activeCount":101},[],{"trials":8270,"activeCount":101},[],{"trials":8272,"activeCount":101},[],{"trials":8274,"activeCount":101},[],{"trials":8276,"activeCount":101},[8277],{"nctId":8278,"briefTitle":8279,"status":232,"phases":8280,"primaryCompletion":8214,"completion":8281,"start":8282,"enrollment":4956,"conditions":8283,"interventions":8285},"NCT03027219","Blood Flow Change After Free Flap Surgery in Diabetic Patients",[],"2018-11-29","2017-01-31",[8284],"Diabetes",[8263],{"intervention":8287,"totalTrials":259,"cells":8288},"Stalevo®",{"EARLY_PHASE1":8289,"PHASE1":8291,"PHASE2":8293,"PHASE3":8295,"PHASE4":8297,"NA":8299},{"trials":8290,"activeCount":101},[],{"trials":8292,"activeCount":101},[],{"trials":8294,"activeCount":101},[],{"trials":8296,"activeCount":101},[],{"trials":8298,"activeCount":101},[],{"trials":8300,"activeCount":101},[8301],{"nctId":8302,"briefTitle":8303,"status":127,"phases":8304,"primaryCompletion":1875,"completion":1875,"start":6455,"enrollment":1598,"conditions":8305,"interventions":8307},"NCT02452606","Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa\u002FCarbidopa\u002FEntacapone) on Sleep Disorders in Parkinson's Disease",[93],[7382,8306],"Sleep Disorders",[8287],{"intervention":8309,"totalTrials":259,"cells":8310},"Niraparib",{"EARLY_PHASE1":8311,"PHASE1":8313,"PHASE2":8315,"PHASE3":8317,"PHASE4":8319,"NA":8321},{"trials":8312,"activeCount":101},[],{"trials":8314,"activeCount":101},[],{"trials":8316,"activeCount":101},[],{"trials":8318,"activeCount":101},[],{"trials":8320,"activeCount":101},[],{"trials":8322,"activeCount":101},[8323],{"nctId":8324,"briefTitle":8325,"status":232,"phases":8326,"primaryCompletion":2256,"completion":2256,"start":8327,"enrollment":8328,"conditions":8329,"interventions":8331},"NCT06086665","The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer",[],"2019-12-01",850,[8330],"Epithelial Ovarian Cancer",[8309],{"intervention":8333,"totalTrials":259,"cells":8334},"azithromycin + N-acetylcystein + inhaled corticosteroid",{"EARLY_PHASE1":8335,"PHASE1":8337,"PHASE2":8339,"PHASE3":8341,"PHASE4":8343,"NA":8345},{"trials":8336,"activeCount":101},[],{"trials":8338,"activeCount":101},[],{"trials":8340,"activeCount":101},[],{"trials":8342,"activeCount":101},[],{"trials":8344,"activeCount":101},[],{"trials":8346,"activeCount":101},[8347],{"nctId":8348,"briefTitle":8349,"status":2280,"phases":8350,"primaryCompletion":4286,"completion":4286,"start":1038,"enrollment":1766,"conditions":8351,"interventions":8354},"NCT01327625","Efficacy Study of Azithromycin-based Therapy for Bronchiolitis Obliterans",[93],[8352,8353],"Graft vs Host Disease","Bronchiolitis Obliterans",[8333],{"intervention":8356,"totalTrials":259,"cells":8357},"PPI",{"EARLY_PHASE1":8358,"PHASE1":8360,"PHASE2":8362,"PHASE3":8364,"PHASE4":8366,"NA":8368},{"trials":8359,"activeCount":101},[],{"trials":8361,"activeCount":101},[],{"trials":8363,"activeCount":101},[],{"trials":8365,"activeCount":101},[],{"trials":8367,"activeCount":101},[],{"trials":8369,"activeCount":101},[8370],{"nctId":8371,"briefTitle":8372,"status":232,"phases":8373,"primaryCompletion":130,"completion":130,"start":916,"enrollment":933,"conditions":8374,"interventions":8376},"NCT02449941","Helicobacter Pylori and Proton Pump Inhibitor",[],[8375],"Helicobacter Infections",[8356],{"intervention":8378,"totalTrials":259,"cells":8379},"CJ anastrozole 1 mg",{"EARLY_PHASE1":8380,"PHASE1":8382,"PHASE2":8384,"PHASE3":8386,"PHASE4":8388,"NA":8390},{"trials":8381,"activeCount":101},[],{"trials":8383,"activeCount":101},[],{"trials":8385,"activeCount":101},[],{"trials":8387,"activeCount":101},[],{"trials":8389,"activeCount":101},[],{"trials":8391,"activeCount":101},[8392],{"nctId":8393,"briefTitle":8394,"status":232,"phases":8395,"primaryCompletion":3300,"completion":3300,"start":234,"enrollment":6855,"conditions":8396,"interventions":8397},"NCT01105299","Bioequivalence Study of Anastrozole 1 mg Tablet",[93],[30],[8378],{"intervention":8399,"totalTrials":259,"cells":8400},"voriconazole",{"EARLY_PHASE1":8401,"PHASE1":8403,"PHASE2":8405,"PHASE3":8407,"PHASE4":8409,"NA":8411},{"trials":8402,"activeCount":101},[],{"trials":8404,"activeCount":101},[],{"trials":8406,"activeCount":101},[],{"trials":8408,"activeCount":101},[],{"trials":8410,"activeCount":101},[],{"trials":8412,"activeCount":101},[8413],{"nctId":8414,"briefTitle":8415,"status":2280,"phases":8416,"primaryCompletion":5084,"completion":5084,"start":4913,"enrollment":25,"conditions":8417,"interventions":8419},"NCT01148160","Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy",[],[8418],"Invasive Fungal Infection",[8399],{"intervention":8421,"totalTrials":259,"cells":8422},"Ultrasound guided popliteal sciatic nerve block with 0.2% ropivcaine",{"EARLY_PHASE1":8423,"PHASE1":8425,"PHASE2":8427,"PHASE3":8429,"PHASE4":8431,"NA":8433},{"trials":8424,"activeCount":101},[],{"trials":8426,"activeCount":101},[],{"trials":8428,"activeCount":101},[],{"trials":8430,"activeCount":101},[],{"trials":8432,"activeCount":101},[],{"trials":8434,"activeCount":101},[8435],{"nctId":8436,"briefTitle":8437,"status":127,"phases":8438,"primaryCompletion":8439,"completion":8439,"start":2011,"enrollment":1079,"conditions":8440,"interventions":8441},"NCT03414593","Preemptive Analgesic Effects of Popliteal Sciatic Nerve Block in Patients With Bilateral Hallux Valgus Surgery",[93],"2018-12-31",[7589,7588,7590],[8421],{"intervention":8443,"totalTrials":259,"cells":8444},"Plasma citrulline",{"EARLY_PHASE1":8445,"PHASE1":8447,"PHASE2":8449,"PHASE3":8451,"PHASE4":8453,"NA":8455},{"trials":8446,"activeCount":101},[],{"trials":8448,"activeCount":101},[],{"trials":8450,"activeCount":101},[],{"trials":8452,"activeCount":101},[],{"trials":8454,"activeCount":101},[],{"trials":8456,"activeCount":101},[8457],{"nctId":8458,"briefTitle":8459,"status":232,"phases":8460,"primaryCompletion":915,"completion":978,"start":8461,"enrollment":945,"conditions":8462,"interventions":8464},"NCT01849107","Plasma Citrulline: A Marker for Monitoring & Quantifying Radiation-Induced Small Bowel Toxicity",[93],"2013-04",[4314,8463,2422],"Anorexia",[8443],{"intervention":7592,"totalTrials":259,"cells":8466},{"EARLY_PHASE1":8467,"PHASE1":8469,"PHASE2":8471,"PHASE3":8473,"PHASE4":8475,"NA":8477},{"trials":8468,"activeCount":101},[],{"trials":8470,"activeCount":101},[],{"trials":8472,"activeCount":101},[],{"trials":8474,"activeCount":101},[],{"trials":8476,"activeCount":101},[],{"trials":8478,"activeCount":101},[8479],{"nctId":7581,"briefTitle":7582,"status":232,"phases":8480,"primaryCompletion":7584,"completion":7585,"start":7586,"enrollment":7313,"conditions":8481,"interventions":8482},[93],[7588,7589,7590],[7555,7592],{"intervention":8484,"totalTrials":259,"cells":8485},"Nilotinib",{"EARLY_PHASE1":8486,"PHASE1":8488,"PHASE2":8490,"PHASE3":8492,"PHASE4":8494,"NA":8496},{"trials":8487,"activeCount":101},[],{"trials":8489,"activeCount":101},[],{"trials":8491,"activeCount":101},[],{"trials":8493,"activeCount":101},[],{"trials":8495,"activeCount":101},[],{"trials":8497,"activeCount":101},[8498],{"nctId":8499,"briefTitle":8500,"status":232,"phases":8501,"primaryCompletion":4772,"completion":2071,"start":248,"enrollment":8502,"conditions":8503,"interventions":8504},"NCT00976612","Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK",[],17,[18],[8484],{"intervention":8506,"totalTrials":259,"cells":8507},"Withdrawal of Spironolactone",{"EARLY_PHASE1":8508,"PHASE1":8510,"PHASE2":8512,"PHASE3":8514,"PHASE4":8516,"NA":8518},{"trials":8509,"activeCount":101},[],{"trials":8511,"activeCount":101},[],{"trials":8513,"activeCount":101},[],{"trials":8515,"activeCount":101},[],{"trials":8517,"activeCount":101},[],{"trials":8519,"activeCount":101},[8520],{"nctId":8521,"briefTitle":8522,"status":232,"phases":8523,"primaryCompletion":8524,"completion":4798,"start":8525,"enrollment":1214,"conditions":8526,"interventions":8528},"NCT04367051","Pilot Study on Withdrawal of Spironolactone Among Heart Failure With Improved Ejection Fraction",[93],"2021-12-10","2020-08-13",[8527],"Heart Failure",[8506,8529],"Continuation of spironolactone",{"intervention":8529,"totalTrials":259,"cells":8531},{"EARLY_PHASE1":8532,"PHASE1":8534,"PHASE2":8536,"PHASE3":8538,"PHASE4":8540,"NA":8542},{"trials":8533,"activeCount":101},[],{"trials":8535,"activeCount":101},[],{"trials":8537,"activeCount":101},[],{"trials":8539,"activeCount":101},[],{"trials":8541,"activeCount":101},[],{"trials":8543,"activeCount":101},[8544],{"nctId":8521,"briefTitle":8522,"status":232,"phases":8545,"primaryCompletion":8524,"completion":4798,"start":8525,"enrollment":1214,"conditions":8546,"interventions":8547},[93],[8527],[8506,8529],{"intervention":8549,"totalTrials":259,"cells":8550},"bupropion or lamotrigine",{"EARLY_PHASE1":8551,"PHASE1":8553,"PHASE2":8555,"PHASE3":8557,"PHASE4":8559,"NA":8561},{"trials":8552,"activeCount":101},[],{"trials":8554,"activeCount":101},[],{"trials":8556,"activeCount":101},[],{"trials":8558,"activeCount":101},[],{"trials":8560,"activeCount":101},[],{"trials":8562,"activeCount":101},[8563],{"nctId":8564,"briefTitle":8565,"status":127,"phases":8566,"primaryCompletion":8128,"completion":2420,"start":4659,"enrollment":8,"conditions":8567,"interventions":8569},"NCT02428439","Identification of Genetic Markers and Predictors of Antidepressant-induced Suicidality in Youth Depression",[],[3219,8568],"Suicidal Ideation",[8549],{"intervention":8571,"totalTrials":259,"cells":8572},"Steroid use during stellate ganglion block",{"EARLY_PHASE1":8573,"PHASE1":8575,"PHASE2":8577,"PHASE3":8579,"PHASE4":8581,"NA":8583},{"trials":8574,"activeCount":101},[],{"trials":8576,"activeCount":101},[],{"trials":8578,"activeCount":101},[],{"trials":8580,"activeCount":101},[],{"trials":8582,"activeCount":101},[],{"trials":8584,"activeCount":101},[8585],{"nctId":8586,"briefTitle":8587,"status":232,"phases":8588,"primaryCompletion":8589,"completion":8589,"start":8590,"enrollment":1866,"conditions":8591,"interventions":8593},"NCT07476235","Predictors of Treatment Response to Stellate Ganglion Block in Cervical Radicular Pain",[],"2025-09-15","2024-10-08",[8592],"Radiculopathy, Cervical Region",[8571],{"intervention":8595,"totalTrials":259,"cells":8596},"Preoperative Statin Use",{"EARLY_PHASE1":8597,"PHASE1":8599,"PHASE2":8601,"PHASE3":8603,"PHASE4":8605,"NA":8607},{"trials":8598,"activeCount":101},[],{"trials":8600,"activeCount":101},[],{"trials":8602,"activeCount":101},[],{"trials":8604,"activeCount":101},[],{"trials":8606,"activeCount":101},[],{"trials":8608,"activeCount":101},[8609],{"nctId":8610,"briefTitle":8611,"status":232,"phases":8612,"primaryCompletion":8613,"completion":8614,"start":8615,"enrollment":8616,"conditions":8617,"interventions":8619},"NCT07089589","Preoperative Statin Use and Major Adverse Cardiovascular Events in Liver Transplant Recipients",[],"2026-01-25","2026-03-22","2008-01-02",6898,[8618,5583],"Major Adverse Cardiovascular Events",[8595],{"intervention":8621,"totalTrials":259,"cells":8622},"tamsulosin 0.4mg",{"EARLY_PHASE1":8623,"PHASE1":8625,"PHASE2":8627,"PHASE3":8629,"PHASE4":8631,"NA":8633},{"trials":8624,"activeCount":101},[],{"trials":8626,"activeCount":101},[],{"trials":8628,"activeCount":101},[],{"trials":8630,"activeCount":101},[],{"trials":8632,"activeCount":101},[],{"trials":8634,"activeCount":101},[8635],{"nctId":8636,"briefTitle":8637,"status":127,"phases":8638,"primaryCompletion":2071,"completion":2071,"start":2206,"enrollment":8639,"conditions":8640,"interventions":8642},"NCT01209988","Impact of Tamsulosin on Voiding Patterns Following Early Catheter Removal After Robot-assisted Laparoscopic Radical Prostatectomy",[93],220,[8641],"Prostatic Neoplasms, Prostatectomy",[8621]]